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ALA - Aminolevulinic Acid
AM - Adrenomedullin
AVM - Arterio-venous malformation
DUB - Dysfunctional Uterine Bleeding
EA- Endometrial Ablation
ELA - Endometrial Laser Ablation
ELITT - Endometrial Laser Interstitial Thermotherapy
FEAT - First Generation Endometrial Ablative Technology
GNRHa - Gonadotrophin Releasing Hormone analogues
HADS - Hospital Anxiety and Depression Score
HNPCC - Hereditary Non Polyposis Colonic Carcinoma
LAVH - Laparoscopically Assisted Vaginal Hysterectomy
LNG - IUS - Levonorgestrel Intrauterine System
MBL - Measured Blood Loss
MEA - Microwave Endometrial Ablation
MMP - Matrix Metalloproteases
MRI -Magnetic Resonance Imaging
NO - Nitric Oxide
NHS - National Health Service
PBLAC - Pictorial Bleeding Assessment Chart
PGF2a - Prostaglandin F 2 Alpha
QOL - Quality of Life
QUALY - Quality Adjusted Life Years
RCOG - Royal College of Obstetricians and Gynaecologists
RCR - Royal College of Radiologists
REA - Rollerball Endometrial Ablation
RCT- Randomised Controlled Trial
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SEAT - Second Generation Endometrial Ablative Technology
SPRM - Selective Progestrone Receptor Modulators
TBEA - Thermal Balloon Endometrial Ablation
TCRE- Trans Cervical Resection of the Endometrium
TAH - Total Abdominal Hysterectomy
TV USS - Trans-vaginal Ultrasound Scan
UFAE - Uterine Fibroid Arterial Embolisation
VEGF - Vascular Endothelial Growth Factor
VH - Vaginal Hysterectomy
Definitions used in this thesis
1. Dysfunctional Uterine Bleeding - Abnormal uterine blood loss either regular or
irregular, occurring from a uterus of up to a ten weeks sized pregnancy on
clinical examination with a normal endometrial pathology
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Referrals to gynaecology from primary care of women with excessive uterine bleeding
are common, with up to 30% ofwomen reporting their menses as abnormal.
It is a condition which has a significant adverse effect on quality of life. The cost to the
Health Service is significant. In the United Kingdom 57,000 hysterectomies alone are
performed per annum for menorrhagia. The 7 million pounds spent per annum in the UK
on prescriptions for medical treatments is similar to the amount expended on surgery. A
majority of hysterectomies performed will be for dysfunctional uterine bleeding, on
anatomically normal uteri, uteri that are eminently suitable to ablation. Despite advances
in medical treatment, hysterectomy remains an effective procedure, releasing women
from the burden of excessive menses, but at a cost. The operation is successful, with the
highest recorded levels of satisfaction of any treatment option. The financial
implications are not insignificant with a cost to the health service and a physical cost to
the patient. Up to 1 in 30 will have a significant complication. Furthermore patients take
6-12 weeks to fully recover. New modes of hysterectomy - laparoscopic assisted
vaginal hysterectomy, total laparoscopic hysterectomy and laparoscopic supra-cervical
hysterectomy promised shorter hospital stays but have associated increased technical
demands on the surgeon, possibly increased complications and would certainly not
appear to be a technique that all could master.
Medical treatments can be effective but prescribing can be misguided with ineffective
regimes deployed in a vacuum of evidence.
Endometrial Ablation, a conservative alternative to hysterectomy offers comparable but
lower levels of satisfaction. Endometrial ablation is established as an alternative surgical
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treatment to hysterectomy. The procedures offer rapid treatment, short hospital stays and
quick recovery at a lower economic cost than hysterectomy. Traditionally Endometrial
Ablation has been offered once a trial of medical treatment has failed although there is
good evidence to show that ablation should be offered to eligible patients early.
The trials reported in this thesis aim to explore the evidence base for the treatment of
excessive menstrual loss, and establish a hierarchy of treatment for excessive menstrual
bleeding from medical treatment, through first generation ablative techniques and ending
with second generation ablative techniques. The traditional rational of ablation only
being offered after a failed trial of medical treatment is explored. The possibility of
moving endometrial ablation, a traditionally theatre based treatment into an outpatient
setting is explored. The incidence of individual surgical procedures for menorrhagia is
explored comparing recently published figure for England and Wales with Scottish
national and regional Grampian Figures. Finally the evidence base is concluded and
summarised with suggestions for future research.
Abstract
This thesis is based on work performed in the Department of Gynaecology ofAberdeen
Royal Infirmary. This is a regional referral centre with an established reputation in
menstrual research, focusing on surgical trials. The work of this thesis continues and
expands on this.
Chapter 1 outlines and reviews the current literature on the treatment of menstrual
disorders. The aetiology, epidemiology and options both surgical and medical are
reviewed. A detailed review of the development, scientific and technical aspects of
Microwave Endometrial Ablation is made. The evidence base is reviewed and discussed
with a focus on randomised trials.
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Chapter 2 describes the 5 year follow up of an original trial comparing women initially
referred to a gynaecologist with excessive menses who were randomised to either
standard medical treatment or endometrial ablation in the form of Transcervical
Resection of the Endometrium (TCRE). This represents the longest follow up ofwomen
randomised to medical treatment for menorrhagia. Those allocated to ablation were
significantly more likely to report themselves as totally satisfied at 5 years as those
allocated medical treatment. Acceptability was high for both arms but only 20% of
women treated medically would recommend this to a friend compared to 79% of the
ablation arm. Amenorrhoea rates were significantly higher in the ablation arm versus the
medical arm (88% versus 66%). Quality of life measures using the generic tool SF 36
revealed that scores for the women in the ablation arm were restored to normative levels
in all 8 subsets, whilst this was improved in only 4 for the medical arm. During the
follow up period 77% of those in the medical arm underwent ablative surgery. The
impact of offering ablative surgery early did not result in an increase in the incidence of
recourse to hysterectomy with similar numbers in each arm (17% versus 18%) being
hysterectomised at 5 years.
Chapter 3 describes a multi-centre international randomised controlled trial comparing
the first generation technique ofRollerball Endometrial Ablation (RBEA) with the
second generation technique of Microwave Endometrial Ablation (MEA). This trial had
8 centres, both academic and private, in the United States, Canada and the United
Kingdom. The trial randomised 322 women to MEA or RBEA in a 2:1 ratio. Menstrual
Loss (PBLAC) diaries were used in the recruitment, follow up and definition of success
(PBLAC score < 75). When comparing women allocated to MEA versus those allocated
to RBEA they reported similar success rates and satisfaction. Higher post operative
amenorrhoea rates were reported in the MEA arm but the result was not significant. In
the subgroup ofwomen with BMI's of over 30kg/m2 MEA was significantly more likely
to be associated with success. The presence or absence of non-obstructing fibroids (<
3cm) did not affect success rates or amenorrhoea rates between MEA and RBEA. MEA
9
treatment was significantly more often performed under local anaesthesia. This trial
established MEA as being comparable in the majority of outcome measures to RJBEA.
Chapter 4 describes a randomised controlled trial ofMEA performed in an outpatient
setting in the early post menstrual phase to standard treatment performed in a day case
theatre after endometrial preparation. All procedures were performed under local
anaesthesia plus or minus sedation. 210 women were randomised in a 1:1 ratio to the
treatment arms. Significantly more women found treatment post menses acceptable
(89.5% versus 76%). Similar numbers were totally or generally satisfied (92.5% versus
84%). Amenorrhoea rates were similar (55.9% versus 61.9%). A significant difference
in direct cost was seen with treatment as an outpatient in the post menses arm costing
£124 less than treatment in day case theatre after endometrial preparation.
Chapter 5 reviews the rates of surgery for excessive menstrual bleeding in Scotland and
the Grampian region from 1998 - 2004. A 43% reduction in the hysterectomy rate is
seen in Scotland over the time scale. A smaller reduction (34%) is seen in the figure for
Grampian. This may be a reflection ofAberdeens pro-ablation stance and early general
uptake of the procedure .A 25% reduction is seen in the total number of procedures in
Scotland. The ratios of hysterectomy to ablation alter over time with a reduction from
5:1 to 1.7:1 seen. The ratio is Aberdeen is more marked with a ratio of 0.5 to 1, twice as
many ablations being done as hysterectomy. The low uptake of vaginal hysterectomy
and decline in minimally invasive technologies of Laparoscopic Assisted Vaginal
Hysterectomy are outlined. Overall an increase of 65% in ablation rates in Scotland is
seen with a shift from first generation to second generation techniques (11% reduction in
1st versus a 65% increase in 2nd generation technologies).
Chapter 6 reviews the conclusions made form the work described in this thesis and there
relevance to medical practice. Suggestions are made for areas of future research.
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Chapter 1 Literature Review
1.1 Heavy menstrual loss - aetiology, epidemiology and options for
management.
1.1.1 Introduction
Menstrual bleeding is a natural biological event caused by the shedding of the functional
layer of the endometrium in response to the withdrawal of progesterone in the absence
of a conception. Despite this event being a biological process, familiar to over half the
population, it is surrounded in mystique and seldom openly talked about.
Cultural attitudes vary enormously with the majority featuring on an unclean and impure
attitude towards women whilst they are menstruating.1 This does nothing to encourage
any openness or understanding of menstruation in society. The prejudices of a
historically male dominated society may be reflected in these attitudes. Many religions
ban menstruating women from Holy places or participation in prayer whilst
menstruating.1 Not all cultures however take such a negative attitude towards the onset
of menstruation. In Australia certain Aboriginal tribes' people celebrate the onset of the
menarche as a sign of reproductive maturity and a rite of passage into the adult world. 1
Modern women will have many more menstmal periods than their ancestors. The
combination of lactation and gestation induced amenorrhoea resulted in Victorian
women probably only having 40 periods in a life time, whilst prehistoric women would
have had only a handful of menses.2 In contrast the modern woman with small family
size and a limited time spent breast feeding can expect to menstruate on average 400
times during her life time.2 Women's attitudes towards menstruation would appear to
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change with time and present day attitudes may have created a new concept of
'Menstrual Intolerance'. Modem women have an expanded role in society; they are
mothers, partners, home economists, and careerists. The addition of menstmation with
its attendant symptoms to their multifactorial roles is seen by many as unnecessary and
undesirable, especially once their reproductive aspirations have been met.
1.1.2 Epidemiology
Menorrhagia is commonly defined as the loss of greater than 80 mis per cycle a
definition derived from the 90th percentile from the mean of 40 mis per cycle in a
Swedish population study . The 80 mis definition of menorrhagia has been validated for
a UK population. 4 Many would argue against the clinical relevance of this statistically
derived value. In reality a significant number of women on a Western diet will become
anaemic when losses exceed the 50 - 60 mis mark.
The 80 mis definition has been explored in a Scottish Population. Two sister papers
published simultaneously by the same group looked at this definition. They assessed
firstly the clinical factors that would predict a menorrhagic blood loss 5 (using the
greater than 80 mis measured blood loss definition) and secondly they looked at the
clinical usefulness of the 80 mis definition6.
They surveyed just under a thousand women (n= 952) with a menstrual complaint
recruited from 3 clinics from Edinburgh and Glasgow 5. Of the subset of women
complaining of subjectively heavy periods (n= 865) they assessed the measured blood
loss on standardised sanitary wear as per Hallberg and Nilsson for 226 women collectors
(26%). Only 34% of those with subjective heavy loss fitted the definition. They reported
that the clinical features that were more strongly associated with menorrhagia were the
rate of change of sanitary wear, the total number of products used, the need to change
protection in the night, the size of clots (> 50 pence piece) and poor iron status. They
suggested that a model based on these features predict reasonably well the presence of
genuine menorrhagia blood losses. They reported strong associations with the
subjective reporting of very heavy period and excessive loss when compared to the
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remainder of the women, which goes against the general clinical perception that women
are poor judges of their loss.
The sister paper published by the group looked at the usefulness of the 80 mis definition
of menorrhagia 6. In the paper the women reported a range of problems with their
periods, but absolute volume (31.2%) was less prevalent than period pain (37.5%), mood
change (35.7%), and change in the amount (volume) of the period (33.8%). Although
there were associations with volume, these associations were due to the heaviest and
lightest of the loss groups, whereas the 2 groups with loss either side of 80 ml were
virtually indistinguishable. They concluded that the 80 ml criterion for menorrhagia is of
limited clinical usefulness because it is prognostic neither for problems nor iron status
and apparently does not guide management.
As a cause of iron deficiency anaemia when looking at the world- wide perspective,
menorrhagia is a trivial cause compared to the chronic anaemia of parasitic disease
burden. It is, however, the number one cause of anaemia in the developed world. 7
Haematological indices in the vast majority of women complaining of menorrhagia will
reveal a normal haemoglobin. Only 15 - 29% will display anaemia, with many more
displaying a depletion of iron stores as revealed by a low serum Ferritin.3'4
The concept of tightly regulated regular menstrual losses with an entirely predictable
almost regimented pattern is a falsehood. Enormous variation between individuals and
over time within individuals is observed. A United Kingdom epidemiological survey of
women's menstrual loss in the community revealed how common menstrual symptoms
are. They used cumulative incidence rates over a twelve month period and revealed 25%
reporting menorrhagia, 21% reporting heavier periods, 29% reporting changes in their
cycle, 21% reporting a short cycle , 15% reporting a long cycle , 17% reporting inter¬
menstrual bleeding, 6% reporting post coital bleeding and 9% reporting prolonged
periods. 8 For a woman the greatest cycle regularity is seen in the mid 20's, with the
greatest irregularity seen at the extremes of reproductive life - the peri-menarche and
peri-menopause. 9;10 The majority (90%) of ovulating women range between two and
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nine days most commonly four to five days. Ninety percent will lose the majority of
their loss during the first 3 days with days 1-2 being the heaviest. 9;11
When analysing data from different studies it is interesting to note that a fairly constant
figure of around 30% ofwomen report their menses to be excessive and often interfering
with their lives. 12;13 This is in dispute with the figures from population studies by
Hallberg14 and Cole 4 where you would expect 10% of patients to be suffering from
excessive menstruation (> 80 mis/ cycle).
Menorrhagia or excessive menstrual loss has associated health implications. As a
condition it is very rarely life threatening, rather it affects patients! working and family
life and is associated with a measurable reduction in quality of life.15 The economic
costs to women in terms of costs for sanitary protection and to the country in days lost to
work represent an often unseen and unmeasured cost.
The subjective nature of the complaint of menorrhagia or excessive menstrual bleeding
is seen in the work by Hallberg et al.14 40% of women with objectively heavy periods (
> 80 mis per cycle) thought their periods to be moderate or light and 26% of those with
losses(< 60 mis per cycle) felt their periods to be excessive.
Clinical markers taken in a history such as length of cycle or number of pads used have
limited reliability. Cycle length has been compared to menstrual blood loss in a study by
Rybo. 16 The study revealed only 45% of women who bleed for more than 7 days
having objective menorrhagia, with 78% of the menstrual loss occurring in the first two
days and 91% by day three. The frequency of sanitary wear changes is highly
influenced by the patient's personal hygiene habits.17 There is a significant variation
between and within different methods of sanitary wear. 18 Grimes reviewed 15
commercially available sanitary products and discovered that mean absorptions ranged
from 1.32 to 94.86 ml for different products. 17 A substantial variation in absorbency
within specific products was also observed. A history of clot passage is more suggestive
of a pathological amount of bleeding as the uterine fibrinolytic system is by definition
overwhelmed.
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The subjective nature of the complaint has led to attempts to objectify or semi- objectify
the menstrual losses of patients. Assessment methods for menstrual loss have been
developed. The most commonly used method is the alkaline haematin method devised
by Hallberg et al in 1964 14 or modifications thereof (as described by Gannon et al 19 and
Newton et al 20). These methods are seen as the gold standard and require women to
collect their sanitary wear over a cycle (taking care to include all losses - e.g. clots or
flooding episodes). Standardised sanitary wear is required. The pads are immersed in a
dilute alkali (5% sodium hydroxide). The haemoglobin reacts with the alkali to form
alkaline haematin. The haemoglobin content is then assessed by estimation of the
absorption of light at 564 nanometres wavelength by the alkaline haematin measured
using the technique of light spectrophotometry. The reliability of the test is greatest if
completed over two cycles. Limitations exist with this test. It is laborious, unpleasant
and time consuming and it relies on the woman collecting all menstrual loss which can
be both unacceptable and impracticable. As a result its use remains generally restricted
to clinical trial settings. Furthermore it only allows measurement of the haemoglobin
content as a surrogate marker of menstrual loss. Fraser et al established that up to 50 -
60% of menstrual loss is not accounted for by whole blood but made up from
endometrial transudates. 21 Thus quantification of haemoglobin may not accurately
reflect the true losses and underestimate the symptoms. Also the technique does not take
into account extraneous losses such as clots falling into the toilet or flooding episodes. It
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has been suggested that up to 12% of menstrual losses may be extraneous. From a
practical point of view when using the alkaline haematin method only certain sanitary
wear can be used as modem sanitary wear contains a highly absorbent gel that 'locks
away' the menstrual fluid and cause underestimates with the alkaline haematin method.
Pictorial Blood Loss Assessment Charts (PBLAC) have been developed.23 They attempt
to semi-objectify the losses and they are more user friendly than the alkaline haematin
method. Patients are required to record on a chart the appearance of their pads or
tampons and the number used for each day of their cycle. Episodes of clots and or
flooding are recorded. From these charts a score can be calculated with different scores
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for pads and tampons. For tampons a score of 1 is given for light soiling, 5 for moderate
and 10 if the tampon is saturated. For pads the score is 1 for light soiling, 5 for moderate
and 20 for saturation. Clots are scored on a scale 1 (small) or 5 (large). Standardised
pads or tampons are required. PBLAC scores over 75 correlate with pathological blood
losses giving high sensitivity (86%) and specificity (88%). 23 The weak points of the
PBLAC is in the estimation of extraneous losses into the toilet at ablutions, a tendency
to underestimate large volume losses and the fact that the sanitary wear on which the
data is based is no longer available. The reliability of the assessment has been
questioned in a validation study.24 (See Fig 1)
Fig 1. Pictorial Blood Loss Assessment Chart (Adapted from Higham et al
1990).
Name: ESN
Day start« 5 Nov 89
4 Score 283
Towel 1 2 3 4 5 0 7 8









Tampon 1 2 3 4 5 8 7 8








A 'Menstrual Pictogram' has been developed. This is similar to the PBLAC method but
asks women to estimate extraneous losses (e.g. losses whilst changing protection /
during ablutions) and to estimate the absorbency of their sanitary wear. This attempts to
correct for extraneous losses ( which in high volume losses can be extensive ) and the
variation in absorbency in sanitary wear.25 (see Fig 2.) Compared to the PBLAC system
there are two additional icons for towels and one additional for tampons. Towels are
separated into day and night towels and tampons into regular, super and super plus
tampons. In addition there are icons to estimate loss into the toilet and three icons to
estimate clots. The score is calculated in millilitres that are equivalent to the actual
amount of blood lost. A validation study by Wyatt et al 25 to assess the Menstrual
Pictogram verses the gold standard Alkaline Haematin test has been performed .It
concluded that there was a significant positive correlation between a women's ability to
estimate her blood loss on sanitary wear using the menstrual pictogram and her actual
loss as estimated by the alkaline haematin test. In its ability to estimate extraneous losses
it proved superior to the alkaline haematin method by allowing the inclusion of these
losses. The inclusion increased the objective diagnosis of menorrhagia from 36% of a
group presenting with subjective menorrhagia to 74% of this group when extraneous
losses were included. It has yet to be validated as a tool used retrospectively and requires
standardised sanitary wear.
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Figure 2. Menstrual Pictogram.
Weighing all sanitary wear can be used as a method of estimating blood loss but again
requires collection of sanitary wear and its associated limitations. Also as Fraser et al 21
reported there is a wide variation in the proportion of menstrual fluid that is made up by
whole blood from 1.6% to 81.0% (average 36.1%). Thus weight estimates are an
inaccurate method of estimation of menstrual blood loss.
Menstrual fluid containment devices such as the Gynaeseal and Menses Cup have been
devised .This obviates the need for sanitary wear by collecting all menstrual fluid.
Gynaeseal was devised by a Melbourne physician Dr John Cattanach and consisted of a
vaginally placed latex device that fitted over the cervix by gentle suction and created a
menstrual seal for up to 24 hours. It was assessed by Gleeson et al 26 in 12 women with
normal menses and 10 with menorrhagia. Twenty-one of the 22 women found the device
easy to insert, but 16 found removing it to be messy. All women with menorrhagia and 4
of 12 women with normal menstrual losses were dissatisfied with the menstrual seal
provided by Gynaeseal. The device is not commercially available and has no research
role.
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A variety of menstrual cups, which fit under the cervix and collect menstrual fluids
rather than absorb them, have been manufactured since the 1930s. After insertion the
cup molds itself to the individual woman's internal shape, creating a seal that protected
against leakage. Acceptability is moderate with 62% at a year reporting it as acceptable
in a study by Cheng et al.27
The majority of patients will present because their symptoms interfere with aspects of
their life (home / work / social / sexual).28 The fact that the symptom's exhaust their
coping strategies is often a precipitant for seeking advice. It is also of note that perceived
heavy bleeding and psychological disturbance are weaker predictors of initiation of
• • 98 •
consultation in primary care. It is also of note that women who present to primary care
complaining of heavy vaginal bleeding are more likely to have a psychological
disturbance than matched controls28 and psychological distress increases the likelihood
of future reporting ofmenstrual disorders including menorrhagia.29
In summary the complaint of excessive menstrual loss is subjective with often a poor
correlation between objective and subjective losses. The objective measurement is
restricted to scientific studies and medical or surgical trials and has very little to add in
the clinical setting. The objective measurement of a loss less than 80 mis to a patient
may reassure a minority but treatments will still be sought by many whatever the
quantification revealed.
The primary aims of all treatment is to restore quality of life and alleviate symptoms in a
patient centred evidence based approach where the patient makes decisions for treatment
based on a knowledge of the relevant options and their pros and cons.
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1.1.3 Physiology
The endometrium is divided into a persisting basal layer and a more superficial
functional layer. The superficial functional layer is composed of a surface epithelium
and complex vascular tree embedded in a connective tissue stroma. The superficial
functional layer is destined to become the maternal component of the placenta and its
role in the short term is to provide a suitable environment for the implanting blastocyst.
If implantation does not occur the falling levels of progesterone trigger the shedding
of this functional layer.31
The complex nature of the uterine / endometrial vasculature was outlined by Rogers. 32
Within the myometrium the uterine and ovarian arteries form the arcuate arteries which
give rise to the radial arteries. The radial arteries on passing the endo-myometrial
junction branch into the basal arterioles and the spiral arterioles which supply the basal
and superficial functional layers respectively. The spiral arterioles branch extensively in
the superficial layer and just below the surface of the superficial layer they form a sub¬
epithelial plexus that drains into venous sinuses. As the functional layer develops the
spiral arterioles become coiled around mid-cycle and span the basal and functional
layers. The spiral arterioles are unusual amongst resistance arterioles, in that they lack
significant elastin within the internal lamina. Each spiral arteriole provides a blood
supply to a uterine luminal surface area estimated at 4-9mm2.34
Compared to the other vascular beds found in the human body the endometrial vascular
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bed has features that make it unique amongst the vascular beds. No other vascular bed
demonstrates growth and regression cycles. The changes in endometrial vasculature at
both a macroscopic and microscopic level have been described. The seminal work on
angiogenesis in endometrium transplanted into the anterior chamber of a female rhesus
monkey allowed direct visualisation of the changes taking place in the endometrium
through a cycle. 36 Further work using electron microscopy on timed endometrial
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biopsies has revealed an extraordinary array of often well timed changes in the
endometrial vascular, cellular and extra cellular components. 37
Steroid hormones have a key role in the regulatory mechanism of angiogenesis in the
endometrium, mediated through their sequential exposure through the menstrual cycle.35
The endometrium expresses both oestrogen (ER) and progesterone receptors (PR) in
both the epithelial and stromal cells. 38;39 Two subtypes of oestrogen receptors {ERa
(alpha) and ERp (beta)} are seen. Two subtypes of progesterone receptor are seen PR A
and PR B. 40The expression of the PR receptor is controlled via the presence of
progesterone and oestrogen. In the oestrogen predominant follicular phase the
endometrial PR expression is up regulated by the effect of oestrogen on mRNA and
protein production. 41 Down regulation occurs through the interaction with progesterone.
Progesterone antagonises the oestrogen mediated proliferation of the endometrium
through a reduction in ER mRNA synthesis. 33 Membrane actions for both progesterone
42 and oestrogen43 have been reported. The proportions and concentrations of both PR
receptors vary through the menstrual cycle. The total quantity of both types of PR
receptor increases in the glandular epithelium during the proliferative phase under the
influence of oestrogen and declines in the follicular phase under the influence of
progesterone. 44-46
Oestrogen receptors have been localised using immunohistochemical studies, ERa has
been identified in the nuclei of glandular and stromal components. Oestrogen action is
dependent upon the presence of specific ligand-activated receptors in target tissues. The
expression ofERa increases during the proliferative phase.
Angiogenesis in non endometrial tissue has typically a predictable pattern of endothelial
cell activation, degradation and breakdown of the basal lamina, migration and
proliferation of the endothelial cells, fusion of sprouts and tube formation.
32;35;47Angiogenesis in human endometrium appears to differ from this mechanism with
proliferating endometrial cells appearing inside existing vessels. Alternative mechanisms
for this form of angiogenesis have been proposed. 32;35;48 Critchley et al studied the
spatial and temporal pattern of expression of oestrogen receptor beta (ERP) with that of
oestrogen receptor alpha (ERa) in full thickness endometrial samples obtained from both
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women and rhesus monkeys. ERa and ERp were both expressed in nuclei of the glands
and stroma. ERa expression declined in the glands and stroma of the functionalis during
the secretory phase. The luminal epithelium also displayed positive immunoreactivity
for ERp. Expression of ERp declined in glandular cell nuclei, but not stroma, within the
functionalis during the late secretory phase. Levels of expression of ERa and ERp in all
cellular compartments remained unchanged in the basalis layer when studying the
vascular endothelium and the peri-vascular cells surrounding endometrial blood vessels
only ERp was present in the endothelial cell population, although both forms of ER were
expressed in peri-vascular cells. They concluded that the action of oestrogen within the
vascular endothelium in the endometrium may be mediated via direct binding to the ERp
isoform. 49 The same team also assessed expression of the ERp variant isoform (ERPcx
/p2). This newly identified receptor lacks the ability to bind steroids. ERpi and ERPcx
/p2 proteins were identified within multiple cell types within the endometrium. The
immuno-expression of ERPcx /p2 appeared less intense than that of ERpi in endometrial
glandular epithelium and endothelial cells. Immuno-expression of ERpi appeared
unchanged throughout the menstrual cycle. In contrast, levels of ERpcx/p2-specific
immunoreactivity were specifically reduced in gland cells within the functional layer,
but not in those of the basal layer, in the mid-secretory phase. They concluded it is
possible that co-expression of ERPcx/p2 in cells containing ERpi and/or ERa may
modulate the effects of estrogens on the endometrium.50
The mechanism of menstruation is triggered by the fall in progesterone levels, in the
absence of a pregnancy, on an oestrogen and progesterone primed endometrium. The use
of the anti progesterone Mifepristone (RU 486) has been used to model progesterone
withdrawal in menstruation, break through bleeding and early pregnancy loss. 51 The
haemostatic response to menstruation differs from the normal tissue responses to a
haemostatic challenge. The normal stages of haemostasis characterised by platelet
adhesion, aggregation into a platelet plug followed by platelet activation and
degranulation combining with fibrin to form a haemostatic plug ultimately progressing
to fibrinolysis and clot dissolution is not seen. Instead, the start of menstruation is
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characterised by an observed period of intense vasospasm thought to be mediated at least
in part by prostaglandin F 2a. Vessel lesions are observed without any of the normal
attendant platelet mediated haemostatic reaction. 52 The first 20 hours of menstruation is
characterised by the shedding of the superficial functional layer including the vessels
and small thrombi. The thrombi are of interest as they are responsible for the majority of
haemostasis in the first 24 hours and are usually too small to completely occlude the
vessels and achieve an effective platelet plug. They are thus ineffective in reducing the
loss ofmenstrual blood. The fact that the tissues levels of tissue plasminogen activating
factor are elevated in women with objective menorrhagia further impacts on the
haemostatic challenge. 53
Prostacyclin has potent platelet adhesion and aggregation inhibition effects that may be
responsible for the small and ineffectual platelet plugs seen in the early phase of
menstruation.54The actual mechanism for the shedding of the functional layer is though
to involve the induction ofmatrix-metalloproteinase (MMP) as summarised by Smith et
al.55 MMP 1,2 and 9 are involved in the up regulation of transforming growth factors P (
TGF P) . This results in a denuding of the vessel support and rupturing of the spiral
arterioles and venules at the junction between the functional and basal layers. Whilst the
spiral arterioles can vaso-constrict their muscularis coat the venules, lacking a
muscularis, have to rely on platelet plug and regeneration for haemostasis.
Nitric Oxide (NO) has a number or roles in the endometrium. 56 It exists in two forms
endothelial NO and inducible NO.57 In the menstrual phase the levels of inducible NO
rise to six times the levels seen in proliferative or late secretory phase endometrium
whereas the levels of endothelial NO remain unchanged.57 It is an important mediator of
vascular paracrine interactions, a powerful inhibitor of platelet aggregation and a potent
vasodilator. The over expression of NO in its inducible form may be implicated in
menorrhagia. NO is also a neurotransmitter and has a role in apoptosis, a significant
process in angiogenesis cycle seen in menstrual endometrium. NO has been implicated
in the initiation and control of menstrual bleeding. It also may have a role to play in
dysmenorrhoea as it has been seen to suppress myometrial contractility in both the non
pregnant and pregnant uterus.56
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The central haemostatic function after 24 hours is though to be vasoconstriction which
reduces the blood loss until ultimately the endometrium regenerates under the
proliferative effects of oestrogen. This healing of the endometrial mucosa is not
associated with a scar formation and thus is more akin to foetal healing than adult
healing.
Prostacyclin may again have a role in menorrhagia as it causes intense vasodilatation.
Women with excessive menstrual bleeding attributed to dysfunctional uterine bleeding
have demonstrably higher levels of prostacyclin in their menstrual endometrium than
controls with normal menstrual blood losses.58
Disordered angiogenesis may also have a role. It is observed that the proliferative index
of endothelial cell in women with objective menorrhagia is twice that of women with
normal menstruation.55
1.1.4 Aetiology of Excessive Menstrual Loss
The aetiology of menorrhagia is diverse. The vast majority of women (80%) with this
condition have no organic disease and have the label of dysfunctional uterine bleeding.
Dysfunctional uterine bleeding may be subdivided into objective, when the loss reaches
the 80 mis per cycle threshold, and subjective where the patient complains of heavy
bleeding and the loss does not reach the 80 ml threshold.
The aetiology is felt to lie at a cellular level with a complex interplay of the coagulation
pathways, prostaglandin, uterine fibrinolytics, vaso-active substances and the uterine
vasculature. To date much basic science work remains to be done.
Dysmenorrhoea or painful periods is a common complaint that often coexists with
menorrhagia. 79% of patients in a study by Warner et al 59 referred with severe
dysmenorrhoea had coexisting menorrhagia. 30 - 50% of the female population are
affected.60;6lThe negative effects on a patients quality of life, the impact on health care
resources and an impact on the economy through high levels of absenteeism are
considerable 60,61. The main conditions are as follows.
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1.1.5 Uterine Fibroids
Uterine fibroids are the commonest tumours affecting women of reproductive age.62 Up
to 1 in 5 women over the age of 30 will have a fibroid.63 A racial predominance is seen,
a higher incidence, earlier onset and greater severity of disease is seen in black women.64
The exact mechanism whereby fibroids are associated with menorrhagia remains
unclear. Theories focus on a change in uterine vascularity, impaired venous drainage,
increased endometrial surface area affect and increased expression of prostacyclin. The
reason why fibroids are asymptomatic in the majority ofwomen is unclear. What is clear
however is that the most common presenting complaint of fibroids is menorrhagia.65 It is
also of interest to note that fibroids are more common in the group of patients with
objective menorrhagia. In a study by Rybo et al 43% ofwomen with an MBL of greater
than 200mls had fibroids compared to only 10% having fibroids in the group with MBL
between 80 and a 100 mis.
A recent paper assessed the effect of size and location of fibroids on menstrual blood
loss. 66 This Scottish data analysed 50 women over a three year period whose fibroids
were assessed on MRI (all but one) and were on the waiting list for Uterine Artery
Fibroid Embolisation.
MBL was calculated using the gold standard alkaline haematin technique.3
Fibroid position and volume was assessed on MRI by an experienced radiologist
unaware of the MBL results. The majority, 33 (66%) had objective menorrhagia. Of the
42 women complaining of menorrhagia the majority, 33 (79%) also had objective
menorrhagia.
With regards to location of fibroids some interesting results emerged. Intramural fibroids
were the commonest. The common dictum that menorrhagia is secondary to cavity
distortion was challenged as all but two of the women had distorted cavities but 17 had
MBL less than 80mls. Of clinical interest all the women with sub- mucosal fibroids had
MBL greater than 80 mis. This would be in keeping with the theory that the
fn
endometrium overlying sub-mucosal fibroids either functions abnormally or that the
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increased endometrial surface area is created by the effect of the sub-mucosal fibroid.
The only associated factor to correlate with MBL was the diameter of the largest fibroid.
1.1.6 Adenomyosis
Adenomyosis is a pathological condition characterised by the ectopic location of
endometrium in the superficial and / or deep myometrium. The associated heavy menses
and secondary dysmenorrhoea may be difficult to distinguish from endometriosis.
Clinical diagnosis by the classical globular, tender uterus is unreliable. High false
positive rates with ultrasound and to a lesser extent with magnetic resonance imaging
means that the condition is often only diagnosed at hysterectomy.69 Occasional cases
are diagnosed at TCRE, on the endometrial chippings and indeed TCRE is a treatment
for superficial adenomyosis, but has no benefit for deep adenomyosis.70'71
1.1.7 Endometritis
Endometritis is characterised by the presence of a chronic infective or inflammatory
process of the endometrium. This is usually polymicrobial in nature and secondary to
either ascending pelvic infection or intrauterine manipulation and can result in irregular
and excessive menses.
Greenwood reviewed 99 women with chronic endometritis. 72 Clinically 94% presented
with vaginal bleeding problems. Histological features were of superficial stromal
oedema, increased stromal density, a pleomorphic stromal inflammatory infiltrate (with
leucocytes predominating) and the presence of a plasma cell infiltrate in the absence of
premenstrual histological changes or other significant pathological lesions. Risk factors
were recent uterine instrumentation (curettage or biopsy) and submucous fibroids. The





Actinomyces infection of an IUCD can also present with menstrual problems. A
review of 1500 IUCD / IUS users revealed an average of 11.4 % of IUCD users
colonised with Actinomyces and an increased incidence with prolonged use.74
Tubercular endometritis is rarely seen now in the developing world but may present with
menstrual problems and infertility. A review of 120 cases of genital tuberculosis proved
by histopathology revealed 19.0% complaining of menorrhagia. Hypomenorrhoea or
oligomenorrhoea were the commonest menstrual symptom in 54.0% of cases whilst
amenorrhoea was present in 14.3% cases.75
1.1.8 Endometrial Hyperplasia / Neoplasia
Abnormality of endometrial proliferation has been associated with excessive
menstruation. Hyperplasia and neoplasia may be associated with abnormal menstrual
bleeding and either excessive or irregular loss.
The risk of associated malignancy is very low with simple hyperplasia and complex
hyperplasia without nuclear atypia.71 This has a high spontaneous regression rate in the
order of 90% with only 1-3% progressing to invasive disease. 71 Atypical hyperplasia
has a regression rate of 60% and a progression to adenocarcinoma of 25%. 20% of
• • • • 7f\
atypical hyperplasia has co-existent endometrial adenocarcinoma.
1.1.9 Vascular Anomalies
Arterio-venous malformations (AVM) may occur any where in the body. Uterine AVM
can be congenital, acquired through trauma or surgery 77'78or associated with gestational
trophoblastic disease 79and to date there are less than one hundred case reports in the
English language literature. AVM can be associated with severe and life threatening
haemorrhages and traditionally has required hysterectomy as a life saving procedure.
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The diagnosis can be made through a combination of cautious hysteroscopy, doppler
ultrasound and pelvic angiography. In view of the risk of precipitating severe
haemorrhage dilatation and curettage are contraindicated where ever AVM is suspected.
Successful treatment with selective embolisation of the feeding vessels is the desired
treatment 80 and offers a uterus preserving option that is very important as many women
will have unresolved fertility desires at the time of diagnosis.
1.1.10 Hypothyroidism
Under activity of the thyroid gland can be associated with excessive menstrual bleeding
81 that responds to thyroid replacement and restoration of a euthyroid state.82 It is
interesting to note however that the most common menstrual effects of thyroid
dysfunction is amenorrhoea or oligomenorrhoea.83 When questioning a cohort of 50
hypothyroid women 56% reported menstrual cycle abnormalities, the commonest being
the complaint of menorrhagia.84 It is recommended in the RCOG Guidelines 85;86 that
thyroid function tests are only performed where hypothyroid symptoms exist. It is not
cost effective to routinely screen for thyroid disease.
The mechanism is thought to lie in either an effect on LH / FSH ratios and ovulation or
possibly a haemostatic defect with a temporary acquired Von Williebrands disease
which is reversible on institution of thyroxine treatment.87;88
1.1.11 Coagulation Defects
Coagulation disorders can present to the gynaecologist with excessive menstruation
often of a dramatic kind, and to the obstetrician with post partum haemorrhage. A study
looking at 15 women with known coagulation disorders identified blood losses in the
rather dramatic range of 750 - 1000 mis per cycle.89
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The commonest disorders of coagulation include Von Williebrands, Haemophilia A,
deficiency of Prothrombin and Factor deficiencies (V, VII, IX, X, XI)
Anticoagulant therapy can result in an acquired defect of coagulation. Van Eijkeren et al
reported on a series of 11 women on oral anticoagulants .90 The mean menstrual blood
loss for the eleven was 98 ml (range, 9 to 239 ml). Six had eumenorrhoea and five
women had menorrhagia. Of the six women with normal menstrual blood losses, two
had losses in the high normal range (60 to 80 ml). There was no correlation between
anticoagulant state and menstrual blood loss. The group suggested that oral
anticoagulants increase the trend towards excessive menstrual blood loss.85
Severe uraemia may cause altered platelet function and severe liver disease with
resultant defects in coagulation factors are also causes of menorrhagia related to
coagulation defects in those that are not amenorrhoeic.
The possibility of a inherited coagulation disorder or platelet disorder should be always
be considered in those young, often adolescent women referred from their general
practitioner with a history of heavy menstrual bleeding from menarche unresponsive to
medical treatments. They may give a family history of the condition or allude to other
symptoms such as easy bruising and dental bleeding. There is some debate as to the true
incidence of coagulation disorders in young women and adolescents complaining of
menorrhagia. The often quoted paper by Classen and Cowel 91 from the 1980's
retrospectively reviewed all admissions to a children's hospital for acute menorrhagia,
where genital tract pathology had been excluded. 59 patients were identified over a nine
year period. A primary coagulation disorder was found in almost 20% of these. One
quarter of those had severe menorrhagia, one third of those required transfusion, and one
half of those presenting at menarche had a coagulation disorder (most commonly
thrombocytopenia and Von Williebrands). They concluded that proper screening and
therapy are essential in all young women with menorrhagia. A later paper by Falcone et
al in 1994 reported, however, a much lower incidence of coagulation / platelet disorder
in their retrospective, multi-centre analysis. All adolescents admitted to three paediatric
hospitals in Montreal, Quebec, Canada, over a 10-year period (1981-1991) with a
primary diagnosis of dysfunctional uterine bleeding were assessed. Sixty-one patients in
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total were identified. Only two patients (3%) had an identifiable condition (one with
immune thrombocytopenic purpura and one with acute pro-myelocytic leukemia). In
contrast to Classen's work all patients who were evaluated had normal factor VIII levels,
partial thromboplastin times and prothrombin times. The mean age at presentation was
13.8 +/- 2.1 (SD) years. More than 50% of the patients had a history of irregular
bleeding. Most patients (93.4%) responded to medical management with only five
(8.2%) requiring therapeutic dilation and curettage. Given the close proximity to the
menarche, the preponderance of irregular cycles and the lack of demonstrable
coagulation / platelet disorder they concluded that the etiology of dysfunctional uterine
bleeding in adolescence is most likely related to the immaturity of the hypothalamic-
pituitary-ovarian axis. Of note the vast majority responded to medical therapy which was
highly effective in controlling such bleeding. Surgical measures such as therapeutic
dilation and curettage were rarely required.
1.1.12 Platelet Disorders
Normal platelet function is an essential part of the haemostatic mechanism in
menstruation. It is particularly important after the first 24 hours where platelet plugs in
the spiral arterioles and venules are the main mechanism. Platelet disorders in the form
of thrombocytopenia, Glazmann's thromboasthenia, Bernard -Soulier Syndrome,
Aplastic Anaemia and Leukaemias may present with menorrhagia.88
Whether the primary pathology is reduced adhesiveness (Bernard -Soulier Syndrome - a
hereditary disease), reduced production (bone marrow failure, infiltration) or increased
destruction (hypersplenism, auto immune thrombocytopenia, congenital
thrombocytopenia) the end result is a failure of the haemostatic mechanism to the
challenge ofmenstruation.92
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1.1.13 Intra-uterine Contraceptive Devices
Copper bearing intrauterine contraceptives are effective methods of contraception. They
do however have certain negative effects on a patient's menstrual cycle. Inter-menstrual
bleeding, an increase in reported dysmenorrhoea and menorrhagia are reported. The
foreign body reaction essential to the contraceptive function of the device is implicated
in the mechanism of IUCD related menstrual problems. Although the copper IUCD
devices have no effect on ovulation they are associated with reduced luteal phase 93 and
an earlier onset of menses.93,94 Menstrual problems from light irregular bleeding /
spotting through to heavy and / or prolonged bleeding are commonly reported in the first
3-6 month of use of an IUCD but the majority will settle over time.95 Menstrual
bleeding problems and bleeding with pain are the commonest reasons for IUCD
removal.95,96 The incidence of removal for bleeding problems is no greater with the
classic versus frameless IUCD.97 Dysmenorrhoea can be treated with NSAIDS and the
heavy bleeding responds to Tranexamic Acid.85;86
Ongoing menstrual problems in someone who otherwise prefers an intrauterine device
can be remedied by conversion to a hormonal impregnated device such as the Mirena
IUS (Schering).
Others Associations
1. Increasing weight, age and number of intrauterine pregnancies have been all
associated with increasing menstrual blood volume.98 The mechanism for
increased blood loss with higher parity is thought to be a reflection of the
increased uterine size (increased endometrial surface area).The increased loss
with age may reflect higher parity and increased BMI.
2.. Body Mass Index. The mechanism postulated is one of higher circulating
peripherally produced oestrogens resulting in disturbances of the
hypothalamic- pituitary- ovarian axis and anovulation.99
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1.1.14 Investigations
Patients are assessed clinically with a full medical and gynaecological history. An
assessment should be made of the effects of the condition on the patient's quality of life.
85;86 Symptoms of bleeding diathesis (easy bruising / excessive bleeding at dental
extraction or in response to minimal trauma) ; hypothyroidism ( lethargy / cold
intolerance / weigh gain / constipation); and anaemia ( fatigue / poor exercise tolerance
/ breathlessness) should be sought. Clinical examination should include an assessment
for features of iron deficiency anaemia, hypothyroidism and liver disease. Abdominal,
pelvic examination and a speculum are required to assess the size and shape of the
uterus. For the purposes of the RCOG guideline the uterus requires to be less than 10
oz
weeks in size. Trans-vaginal Ultrasound Scanning (TV USS) is not indicated with a
normal clinical examination and regular bleeding pattern. However, TV USS is useful in
the assessment of the endometrium in those with irregular bleeding and in the
identification, dimensions and location of any associated submucous fibroids and should
be used as the first line investigation of the endometrial cavity.86
Patients should all have a full blood count checked to exclude anaemia and
thrombocytopenia. Thyroid function tests and coagulation screens should be performed
only if clinically indicated. Endometrial sampling can be performed where clinically
indicated. The routine histological assessment ofwomen under the age of 40 years is not
recommended. 100 The incidence of serious pathology is very low ( less than one case
per 100000) in the under forty years of age group - such that 3000- 4000 samples would
be required to detect one case. 101 Women over the age of forty years, those not
responding to first line medical treatment and those at increased risk of endometrial
pathology as estimated by risk factors and clinical history can and should be assessed.
Women on Tamoxifen therapy; unopposed oestrogen therapy; those who are obese,
diabetic, hypertensive; women suffering from anovulatory infertility [especially
polycystic ovary syndrome] and those with family history of HNPCC (Hereditary Non
Polypoid Colonic Carcinoma) are at a greater than average risk of both pre-malignant
conditions such as hyperplasia and of endometrial cancer itself.
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The evidence does not support the routine use of dilatation and curettage. The technique
is blind, requires general anaesthesia and theatre time. The technique samples between
30 and 50% of the endometrial cavity and whilst this is adequate for global endometrial
pathological processes it is poor at detecting focal pathology.95 Gimpleson et al 102
compared the diagnostic information received from dilatation and curettage following
panoramic hysteroscopy in 51 women. For the majority of cases the two procedures
agreed with each other however hysteroscopy provided more information in 16 cases
whilst curettage provided more information in 2 cases. The procedure has no
therapeutic merit ( menses return to previous levels or greater after 1-2 cycles ) 103 and
the fact that it misses significant amount of intrauterine pathology especially localised
disease processes such as endometrial polyps and more worryingly early focal
endometrial neoplasia is a concern. 100
Current practice for outpatient endometrial sampling involves the use of endometrial
samplers. In the United Kingdom the most commonly used is the Pipelle (Pipelle de
Cornier ®, Laboratoire C.C.D, France), a 3 mm manual suction aspiration device. It is
well tolerated, cost effective and has a high acceptability and diagnostic accuracy. The
RCOG guideline development group felt it was on balance the optimal sampling
device.86 Others do exist and offer benefits but often offset by larger diameter
instruments and greater patient discomfort for example the Vacurette Aspirator which
has been compared in a RCT to the Pipelle aspirator. 104
The cavity can also be assessed by transvaginal ultrasound. This is a highly acceptable
and versatile tool.105The high-resolution images give accurate information about the
endometrial cavity. An endometrial thickness of less than 12mm can be used as a screen
prior to considering endometrial sampling.106"109 The current guidelines on Heavy
Menstrual Bleeding of the New Zealand College of Obstetricians and Gynaecologists
recommends TV USS as the initial screening tool prior to endometrial sampling in those
at low risk of endometrial cancer.110 The diagnostic accuracy of TVUSS can be
enhanced by the use of saline infusion hysterography111"113 . This technique would
appear to be especially useful in the differentiation of endometrial polyps and sub¬
mucous fibroids. Ultimately the gold standard assessment of the endometrial cavity is
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hysteroscopy and directed biopsy. The procedure has been shown to be superior to
dilation and curettage.102'114'115
Hysteroscopy is traditionally performed as an inpatient procedure under general
anaesthesia. The technological advancement in fibre-optics, solid state cameras and
general miniaturisation of hysteroscopy has allowed the procedure to be performed
under local / no anaesthesia as an outpatient procedure.116 These rigid or flexible micro-
hysteroscopes have the ability to provide high resolution, diagnostic images without the
requirement of general anaesthesia. As a procedure it compares well with inpatient
hysteroscopy, with a very similar failure rate ( 4% for outpatient hysteroscopy versus
3% at inpatient hysteroscopy)117 , with women describing the pain as tolerable and less
than menstruation.118 Clark et al assessed the diagnostic accuracy of the investigation in
a meta-analysis.119 A positive hysteroscopy raised the prevalence of endometrial cancer
from a pre-test probability of 4% to a post test probability of 72%. A negative result
reduces the post-test probability to 0.6%. Hysteroscopy, in particular outpatient
hysteroscopy is a growing area of interest. Twenty eight percent of UK gynaecologists
when surveyed in 2001 were either performing outpatient hysteroscopy or in the process
of setting up an outpatient hysteroscopy service. The British Society of Gynaecological
Endoscopists is currently running an outpatient hysteroscopy training course for nurses
in a development likely to mirror the evolution of nurse colposcopists. However, there is
a note of caution. A randomised trial comparing endometrial biopsy versus endometrial
biopsy and hysteroscopy by Bain et al 120 found that the routine use of hysteroscopy did
not change clinical decision making, especially with respect to hysterectomy rate. Whilst
there were additional pathologies detected they were uniformly benign and detection did
not change clinical management. They concluded that hysteroscopy may be useful in
selected cases, but when performed in a non-selective manner, it had little influence on
clinical management and increased costs.
This finding goes against the rapid expansion and liberal use of outpatient hysteroscopy
as a diagnostic tool in the initial, unselected assessment of women with excessive
menstrual bleeding. The wide spread use of endometrial sampling in the such women
has also recently been questioned.121
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1.2 MEDICAL TREATMENT
Treatment of the woman complaining of excessive menstrual loss can range from simple
reassurance of normality through to major surgery at hysterectomy. A woman's fertility
wishes will determine the options open and closed to her. Many treatments will have a
contraceptive effect (e.g. COCP), require the use of barrier methods (e.g. Danazol /
GnRHa), and require the use of contraception during the reproductive years (e.g.
Ablation) or render the patient relatively or completely infertile (Ablation and
Hysterectomy).
For many women medical treatments are either desirable (if future pregnancies are being
contemplated) or the only treatment option, for example if surgery is either not desired
or contraindicated.
In the United Kingdom substantial expenditure is made every year on medical treatment
for menorrhagia with up to seven million pounds spent annually, a figure that rivals the
expenditure on surgical treatments. 100 There is evidence that the treatments prescribed
in the community are often less than evidenced based and this may lead to an increase in
recourse to surgery as patients become disheartened by ineffectual medical treatments.
100
1.2.1 Reassurance
The relative social taboos surrounding menstruation do nothing to objectify menstrual
loss. The trigger for many women to seek medical advice is when they reach a point
where they can no longer cope or when they notice that their menses have changed
relative to what they perceive as normality i.e. greater than previous or indeed less than
previous experience - an experience that is unique to them.
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The significant subjective element combined with the inability to readily compare blood
loss between women results in a relative ignorance of what is defined as normal. Some
women seek medical advice in an attempt to objectify their loss and are happy to be told
that they are normal. These numbers are relatively small but an important group in that
once normality is established no other treatment is required.
Rees described a pilot study where they assessed the effect of a normal measured
menstrual blood loss. 122 17 women with normal MBL (range 15 -60mls) were advised
on the normality of their bleeding, their health status and discharged from clinic. At 3
years follow up 14 had accepted the advice and had not received any treatment.
The medical treatments treatment options will now be reviewed.
1.2.2 Non Steroid Anti Inflammatory Drugs
The commonest non-steroidal anti-inflammatory drug Mefenamic Acid ( Ponstan,
Chemidex, Surrey, England) is taken 500 mg orally three times a day on heaviest days
and is a first line treatment for menorrhagia commonly prescribed in primary care.123
NSAIDS inhibit prostaglandin synthesis and are also thought to alter favourably the
balance between vasoconstrictor and vasodilatory prostaglandins.
Mefenamic Acid is an effective drug with a 25% reduction in menstrual loss by 75% of
women. It is well tolerated in healthy individuals with a good safety profile.
Interestingly in a paper by Fraser et al which demonstrated between a 20% and 39%
reduction in menstrual blood loss, some women exhibited an increase in their MBL on
Mefenamic Acid.124 Why this group of women experienced an increased blood loss is
unclear but an adverse effect on platelet aggregation is postulated.
Its use is restricted in those with a hypersensitivity to NSAIDS (a minority of
asthmatics), women with active or previous peptic ulcer disease and severe renal
disease. It relieves coexisting dysmenorrhoea in 75% of women, is non-hormonal and
non contraceptive. As its usejs limited to days of heaviest bleeding this reduces adverse
effects and enhances compliance. Mefenamic Acid can be taken in conjunction with
Tranexamic Acid. It is also useful in the reduction ofmenorrhagia associated with non-
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medicated intrauterine contraceptive devices. The main adverse effects are
gastrointestinal effects, rash, renal impairment and exacerbation of asthma in
predisposed NSAID-intolerant asthmatics.
A Cochrane review of NSAID in the management of menorrhagia by Lethaby et al has
been reported. 125 Sixteen RCT were involved in the meta-analysis of individual
NSAID with each other, placebo or other medical treatments in women with regular
dysfunctional uterine bleeding. Weighted mean differences for continuous outcomes
were estimated from the data of comparable nine trials. NSAID were more effective than
placebo at reducing heavy menstrual bleeding but less effective than either tranexamic
acid or danazol. There was a non significant trend towards greater efficacy of NSAID
compared to oral progestogen (luteal phase) and ethamsylate but no differences were
demonstrated between NSAID and the progesterone releasing intra-uterine system (IUS)
and the oral contraceptive pill, although these results were based on very small studies.
There was no evidence of a difference between the individual NSAID (naproxen and
mefenamic acid) in reducing HMB. NSAID reduce heavy menstrual bleeding when
compared with placebo but are less effective than either tranexamic acid or danazol.
There were no significant differences in efficacy demonstrated between NSAID and
other medical treatments such as oral progestogen given in the luteal phase, ethamsylate,
oral contraceptive pill and the progesterone releasing IUS. 125
The majority of evidence for the role of Mefenamic Acid in menorrhagia comes from




Tranexamic Acid (Cyclokapron, Pharmacia and Upjohn, UK) is one of the most
effective medical treatments for menorrhagia. Despite being known of for over thirty
years the drug has been reported as the least prescribed medical treatment for
menorrhagia in the UK 123'126 making up only 5% of GP's prescriptions. These figures
from the mid 1990's have been improved upon by UK evidence from the end of that
decade showing that specific evidence based educational packages increased prescribing
rates from 32% to 57%. 127 The treatment has been used for many years in Scandinavian
countries but has achieved less favour in the UK. Possible explanations lie in the
theoretical concerns that a medication that inhibits clot dissolution may promote venous
and arterial thrombo-embolism in patients. The concern regarding thrombo-embolism
has prevented its licensing in the United States. Long term epidemiological data from
Sweden is reassuring on this point revealing that the incidence of thrombosis in women
treated with tranexamic acid is comparable with the spontaneous frequency of
thrombosis in women not taking tranexamic.128 The drug is prescribed in the dose of 1
gram orally three times a day for the heaviest days. Tranexamic Acid is a plasminogen
activator inhibitor (antifibrinolytic) that has affinity for the five lysine binding sites of
plasminogen preventing activation of plasminogen to plasmin thus promoting
coagulation in the endometrial vessels. As a treatment it reduces menstrual blood loss by
up to 50%.
Women with menorrhagia have been shown to have increased levels of plasminogen
activator enzymes [Tissue plasminogen activator enzymes(t-PA) ] in their endometrium
when compared to women with normal menstrual loss129"131. Plasminogen activator
enzymes encourage clot dissolution, thus promoting menstrual bleeding. 132:133
A previous personal history of a thrombo-embolic event is a contraindication to
treatment. The treatment is non-hormonal and non contraceptive and can be used by
women who are trying to concieve. As use is limited to days of heaviest bleeding this
reduces adverse effects and enhances compliance. Tranexamic Acid is also effective in
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the reduction of menorrhagia associated with non-medicated intrauterine contraceptive
devices. 132
Randomised controlled trials comparing Tranexamic Acid ( or its pro drugs ) to placebo
133;'34, luteal phase progesterone 135, Mefenamic Acid 53, Flubriprofen and Ethamsylate
53have been published. These trials whilst differing in methodology are generally small
trials (participants vary between 20 and 103), are short term (2-3 months of active
treatment) and only included women with objectively defined menorrhagia (> 80mls
blood loss). They all revealed a significant reduction in menstmal blood loss by
Tranexamic Acid varying between a 36 to a 53% reduction. It is interesting that many of
the trials reported no significant difference between treatments in terms of subjective
reduction in menstrual loss.
The Cochrane Database of Systematic Review entitled 'Antifibrinolytics for heavy
menstrual bleeding' assessed the available evidence for the use of Tranexamic Acid 136
and performed a meta-analysis on the suitable trials. The most recent reassessment in
April 2004 revealed no new trials of note. Of the 15 trials assessed they concluded that 4
were suitable for meta-analysis. They concluded that antifibrinolytic therapy causes a
greater reduction in objective measurements of heavy menstrual bleeding when
compared to alternative oral treatments (placebo, NSAIDS, oral luteal phase
progestogens and ethamsylate). However they note that although there was a trend
towards a greater perceived reduction in menstrual blood loss in the Tranexamic Acid
treated groups that this was not significant. Tranexamic Acid uses was not associated
with greater reported sided effects when compared to luteal phase progesterone 135 or a
greater reported discontinuation rate than with ethamsylate or mefenamic acid. 53
Symptoms of flooding, leakage and sex life were significantly improved after
tranexamic acid therapy when compared with oral luteal progestogens. 136
Of note there is a definite lack of data on the continuation rates and outcomes with long
term tranexamic acid treatment, limited quality of life data beyond the work of Preston
et al 135, a lack of data on the clinical effects on women without objective menorrhagia
( a significant clinical entity ) especially as Preston et al reported the most significant
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clinical effects with MBL of 80 -200mls and a lack of data comparing Tranexamic Acid
with Mirena.
1.2.5 Combined Oral Contraceptive Pill
The use of the combined oral contraceptive pill (COCP) as a treatment for menorrhagia
is well established. The use is especially valid where a patient also requires effective
contraception. The COCP suppresses, via a feedback loop, the pituitary production of
gonadotrophins. The main effect in menorrhagia is through endometrial suppression
with a reduction in mean blood loss of approximately 50%. l24' 137 Lighter withdrawal
bleeds, reduced dysmenorrhoea and good cycle control are benefits. The COCP can also
be tri-cycled (three packets run together) to limit patient to five or six bleeds a year.
Epidemiologically the COCP demonstrates a protective effect for endometrial and
ovarian cancer and also reduces benign breast disease. Previous concerns regarding use
in older women have been allayed and women aged over 40 years in absence of venous
or arterial risk factors can continue or commence the COCP. The evidence for the
beneficial effect ofCOCP on menorrhagia is restricted to 30 microgramme pills.
The main contraindications to treatment are risk factors for arterial or venous
thrombosis: obesity; hypertension; severe varicose veins; familial thrombophillias and
severe or focal migraine.
In general treatment is well tolerated by the majority. Adverse effects include migraine,
hypertension, venous thrombosis (greatest with the third generation progestogens
desogestrel and gestodene), arterial thrombosis (risk increased by smoking, age and
obesity), bloating, weight gain, breast enlargement, breakthrough bleeding and nausea.
The evidence for the use of COCP in the treatment ofmenorrhagia has been the subject
of a Cochrane Review 138. Iyer et al reviewed the literature originally in October 1996
and most recently in June 2004. They identified only one trial by Fraser and McCarron
who randomised 45 women with ovulatory menorrhagia to 3 treatments - Mefenamic
Acid, COCP, low dose Danazol and Naproxen. They received therapy with mefenamic
acid in 2 cycles and 1 of 3 other agents in 2 cycles (allocated by random). The treatment
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was not blinded nor was it placebo controlled. Menstrual blood loss was measured in 2-4
control cycles and during therapy. There was a 43% reduction (p< 0.001) reduction in
menstrual blood loss in the COCP arm, a 49 % (p = 0.006) reduction in low dose
danazol arm, a 38% reduction in the pooled Mefenamic Acid arm (p<0.001) and a 12%
reduction in the Naproxen Arm. There was no significant difference in blood loss
reduction observed between the four treatments. Interestingly some in the Mefenamic
Acid group had an increased loss and patients who failed to respond to treatment had
low pre treatment measured blood losses.
The small numbers of patients in the trial combined with the 15% (7/45) drop out
hamper the interpretation of the trial. Ideally an arm with Tranexamic Acid would have
enhanced the findings. The data for the COCP in this trial is based on only 6 individuals.
To date an adequate RCT comparison of the COCP is required to establish the role of
the COCP in heavy menstrual bleeding.
1.2.6 Oral Progesterone
Oral progesterone in the form of the C19 nortestosterone derived progesterone
norethisterone ( NET) [ Primulot N, Schering Health, UK / Utovlan, Pharmacia, Pfizer
Ltd, UK], the C21 groups ofmedroxyprogesterone acetate ( MPA) [Provera, Pharmacia,
Pfizer Ltd, UK] and are commonly used medical treatments for menorrhagia. In general
they are well tolerated and have an acceptable side effect profile.
Progesterone and norethisterone in particular, are the most commonly prescribed oral
medication for menorrhagia in the UK. In 1995, norethisterone accounted for 55% of all
prescriptions for heavy menstrual bleeding 126. The management of menorrhagia
guidance produced by the NHS Centre for Review and Dissemination published in
Effective Health Care Bulletin highlighted the significant lack of evidence based
prescribing.100
The commonly used dosage regimes are norethisterone 5 mg two to three times a day
orally, days 5-25 of cycle and medroxyprogesterone acetate 5-1Omg twice a day orally.
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The mechanism of action is to stabilise the endometrium in a pseudo-decidualised form.
Withdrawal of progesterone from an oestrogen primed endometrium triggers predictable
bleed, whereas continuous use causes endometrial atrophy.
There are few contraindications to progesterone therapy but these include severe liver
and renal disease.
The main benefits are a reduction in menstrual blood loss (if used in long cycle regime),
regulation of a disordered cycle and the balancing of the oestrogenic effect in those who
are anovulatory (endometrial protective effect).
The chief side effects are either premenstrual symptoms or androgenic symptoms.
Fatigue, mood changes, weight gain, acne, nausea, bloating oedema, headaches,
depression, loss of libido, irregular bleeding and, on long-term therapy atherogenic
changes in the lipid profile.
It is of note that luteal-phase support, short-cycle regimens; for example, from day 15 to
day 26 or day 19 to day 26 are ineffective in the treatment of menorrhagia and, in fact,
have been shown to increase menstrual loss. 110
1.2.7 Levonorgestrel Intra Uterine Device ( LNG-IUS)
The LNG-IUS or levonorgestrel intrauterine device (Mirena, Schering Health, UK) is
without doubt the most significant advance in the non-surgical treatment of menorrhagia
in recent times. The device itself is a T shaped plastic frame onto the long arm ofwhich
is a mix of Levonorgestrel (54 milligrams) with polydimethylsiloxane which releases 20
micrograms of the 19-nortestosterone-derived progestin levonorgestrel per day through a
rate limiting membrane. The initial rational behind the progesterone releasing device
was to add progesterone to an intrauterine contraceptive device (IUD) to reduce the rate
of expulsions. The device itselfwas initially licensed in 1995 in the United Kingdom as
a contraceptive, in 2002 it gained a licence to be used in the treatment for idiopathic
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menorrhagia and in more recently in 2005 it gained a license for the endometrial
protection with systemic oestrogen replacement therapy in peri-menopausal and post¬
menopausal women. As a contraceptive it is currently used by around 1% of 16-49 year
olds using contraception in the UK.139 Initial studies comparing the LNG-IUS to copper
bearing IUCD reported a decreased menstrual blood loss and decreased dysmenorrhoea
in women in the LNG-IUS arms. 140;141 The device is suitable for the majority ofwomen
who present with menorrhagia and after appropriate counselling and pre - fitting
investigations can be fitted and utilised. The device last for 5 years and after that can be
refitted. It is contraindicated in : thrombo-embolic disease (in the scenario of current
deep venous thrombosis or current pulmonary embolus) , ischaemic heart disease; active
viral hepatitis; severe decompensated cirrhosis, benign liver tumours and malignant
hepatomas; current breast cancer, current endometrial cancer, current cervical cancer,
current trophoblastic tumour and current pelvic infection. 142
The local delivery of the androgenic progesterone levonorgestrel to the endometrium
results in high local levels of progesterone and low systemic levels. The intrauterine
levels of levonorgestrel are 1000 times that seen with systemically delivered sub dermal
progestogen implant devices.143 The device is as effective a contraceptive as modern
IUD's with a failure rate of less than 1 per 100 woman- years (Pearl Index of 0.18 per
100 women-years). 144
The high local levels of levonorgestrel result in a variety of observable physiological
and histological changes. The predominant histological effect is endometrial atrophy
which appears to increase from an initially patchy effect to a more global effect with
time. 145 There is also observed an increase in local inflammatory cells seen with IUD in
general. 146 Pakarinen et al 147 reported a change in the composition of the endometrial
stroma. The stroma of nine fertile women was analysed using scanning electron
microscopy over a 6 month exposure to LNG IUS. The glandular epithelial cells became
lower; the junctional complexes between epithelial cells remained unchanged, whereas
the lateral microvillus inter-digitations became more prominent. The basal lamina under
the epithelium became wavy but remained uniform and the stromal cells were largely
decidualised. They concluded that in parallel with the generally known cellular effects,
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the use of the LNG IUS results in distinct changes in the basal lamina between the
endometrial epithelial and stromal cells and that these changes may be involved in the
mechanism of the LNG IUS-induced endometrial suppression.
A reduction in the numbers of spiral arterioles is also reported. 148 At a receptor level
both the oestrogen and progesterone receptors are down regulated. 149 The hyopathalimc
- pituatry - ovarian axis is relatively unaffected with over three quarters of women
continuing to ovulate. 150
The effects of LNG-IUS with respect to menstrual loss reveal a significant effect. The
LNG -IUS is the most effective medical treatment currently available. There is over a
90% reduction in menstrual blood loss with approximately one in ten reporting
amenorrhoea at one year.151'152 Side effect of the device reported include hormonal
related side effects such as bloating, breast tenderness, acne, headache and menstrual
irregularities. The incidence of hormonally related side effects with long-term usage of
the LNG-IUS has been compared to standard copper containing IUD and they showed
no difference in a randomised controlled trial at 5 years. 153
Irregular bleeding is cited as a common reason for discontinuation where LNG- IUS is
used for menorrhagia. The mechanism for irregular bleeding is not conclusively
explained and remains a common cause for discontinuation. Discontinuation rates with
LNG-IUS have been compared to IUD in the contraceptive use of the device, this is a
different population of users than those complaining of menorrhagia but some
interesting features are noted. LNG-IUS users were more likely than other IUD users to
discontinue because of hormonal side-effects or menstrual disturbance. No other
significant differences in reasons for discontinuation were observed. 153
Irregular bleeding with the LNG-IUS is common especially in the first three months of
use. Proposed mechanisms for irregular bleeding include : endometrial atrophy with
patchy atrophy commonly seen in the first three months and more complete atrophy
thereafter ; decreased expression of VEGF( vascular endothelial growth factor) and
increased expression of Adrenomedullin (AM) in the endometrial glands and
44
stroma.154 Results obtained suggest that the increase in AM expression in the
endometrium may be responsible for the frequent occurrence of irregular bleeding
during the initial 3 months of LNG-IUS.155 Rogers et al 154 assessed VEGF expression
and BVD ( Blood Vessel Density) in women complaining of break through bleeding
using various hormonal regimes and the Mirena IUS. They concluded that unopposed
progestogens reduce endometrial BVD and that there was no link between VEGF
immunostaining and BVD or break through bleeding.
Critchley et al reported a study examining endometrial tissue in 14 normal women from
insertion of a Mirena IUS through to 12 months post-insertion. ER and PR (A+B) and
PR subtype B were significantly down-regulated in glands and stroma in the presence of
continuous intrauterine LNG delivery. There was an apparent increase in PR (A)
immunoreactivity in endometrial glands between 6 and 12 months post-insertion. The
significant suppression of PR (B) implies that the PR (A) receptor is responsible for the
long term effect on the endometrium. They concluded that alterations to normal sex
steroid receptor expression, following exposure to high concentrations of local LNG,
may play a role in the aetiology ofbleeding disorders associated with the LNG-IUS.149
Matrix Metalloproteinase have important functions in the endometrium.
Metalloproteinase-9 (MMP-9) has been implicated in the irregular bleeding seen in some
LNG-IUS users. MMP-9 protein is present throughout the cycle with highest expression
in glandular cells during the mid-secretory phase. In women with a levonorgestrel
intrauterine system (LNG-IUS) MMP-9 is highly expressed in endometrial glandular
cells, stromal cells, endothelial and peri-vascular cells. It can be concluded that MMP-9
is stimulated directly or indirectly by progesterone. The increased expression ofMMP -
9 and its role in the remodeling of the endometrium during the menstrual cycle may,
through associated morphological changes, have a role in the breakthrough bleeding
associated with long-term progestogen administration via a LNG-IUS. 156
The menstrual benefits of the LNG-IUS were first seen in the Scandinavian countries
where it was first used as a contraceptive. Andersson et al 151 in a Swedish study of 20
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women with confirmed objective menorrhagia and no demonstrable gynaecological
pathology who received a LNG-IUS. Menstrual blood loss (MBL) was measured in two
consecutive cycles prior to device insertion, and at 3, 6 and 12 months of use. MBL was
significantly reduced after 3 months (86%) and after 12 months the reduction was 97%.
A significant increase in serum ferritin during the first year of LNG-IUS use was also
seen. In a Scottish study Irvine et al 152 used a randomised comparative parallel group
study to comparing LNG-IUS to high dose Norethisterone ( 5 mg / tds) day 5-day 26 in
women with objective menorrhagia of a dysfunctional type. The main outcome measure
was the change in objectively assessed menstrual blood loss after three months of
treatment. The levonorgestrel intrauterine system reduced menstrual blood loss by 94%
(expressed as a percentage of the original loss) and oral norethisterone by 87%. There
were high rates of continuation with 76% of the women in the levonorgestrel intrauterine
system group wished to continue with the treatment, compared with only 22% of the
norethisterone group.
A comparison between LNG-IUS and endometrial ablative technologies will be made in
the Chapter on surgical management ofmenorrhagia.
1.2.8 Danazol
Danazol (Danol, Sanofi-Synthelabo, UK) in a dose of 200 mg orally 1-3 times a day can
be used successfully in the treatment ofmenorrhagia as a second line agent. Reductions
in measured blood loss by between 30% and 70% are seen with amenorrhoea usually
157 •
seen in doses of 400 mg/day and above. It was introduced as a medical treatment for
endometriosis and commonly used in the treatment of menstrual pain and excessive
menses in the 1980's but its popularity has waned.157"159
Pharmacologically danazol is an isoxazole derivative of 17 alpha-ethinyl testosterone
and as such is a weak synthetic androgen. A complex combination of effects is seen
with suppression of GnRH pulse frequency thereby reducing pituitary gonadotrophin
production, inhibition of ovarian steroidogenisis and a direct endometrial suppressive
effect.160 The androgenic effects are mediated by the affinity of danazol for the androgen
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receptors, its ability to increase the free androgen index by displacing testosterone from
sex hormone binding globulin and its ability to reduce the levels of sex hormone binding
globulin itself. Anti-androgenic, androgenic, anti-oestrogenic, oestrogenic, anti-
progestogenic and progestogenic effects are observed in different tissues. It has multiple
uses beyond menorrhagia including in the treatment of endometriosis related
dysmenorrhoea, cyclical mastalgia and also as an endometrial thinning agent prior to
endometrial ablation / resection. The main contraindications are thrombo-embolic
disease, severe cardiac, renal and liver disease, porphyria and uncontrolled hypertension.
It is diabetogenic through a reduction in insulin resistance and should be avoided in
diabetics.
Prolonged treatment with danazol is limited by the presence of significant adverse
effects in women when given in high doses and in prolonged (over 6 months) courses.
Androgenic effects predominate. Weight gain, acne, bloating, skin rashes, an
atherosclerotic lipid profile, hirsuitism, voice changes and in prolonged use virilisation
has been reported. The risk of virilisation of a female foetus necessitates the use of
barrier methods of contraception. Despite its significant efficacy many patients are
unable to tolerate any more than short term use with high numbers discontinuing
treatment due to side effects. It is currently only licensed as a second line therapy.
1.2.9 Gonadotrophin Releasing Hormone Agonist Analogues
Gonadotrophin-releasing hormone analogues (GnRHa) are a useful second line
treatment utilised in the medical treatment of menorrhagia. Following an initial
stimulatory (agonist) phase lasting 7-10 days, there follows a down regulation of the
pituitary GnRH receptors, LH and FSH production reduces and a pseudo-menopausal
state created with suppression of ovarian steroid hormone production and thus
suppression of the endometrium. The initial agonist phase is associated with often an
increase in menstrual symptoms of bleeding and, or pain which abate thereafter. It has
been used as a short term measure to relieve menstrual symptoms, as a means of down
sizing fibroids pre-operatively, as diagnostic tool in the evaluation of chronic pelvic pain
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and as an endometrial thinning agent prior to ablation or resection. In those whom
surgery is contraindicated it may be useful in the medium to long term.
The main contraindications are osteoporosis and barrier contraception must be utilised to
prevent pregnancy. As these are implants or depot injections there are no tablets to
remember and this allows enhanced compliance although short term discomfort or
bruising at injection sites is common. Treatments are usually monthly to 5 weekly. High
levels of amenorrhoea are achieved by second to third injections with a significant
reduction in dysmenorrhoea seen.
Complete resolution of associated dysmenorrhoea and pelvic pain gives a good
indication of the therapeutic effect of hysterectomy in cases where these symptoms
coexist or predominate.
Menopausal symptoms secondary to the induced hypo- estrogenic state are common
with vasomotor-type symptoms and vaginal dryness described. An irreversible
osteoporotic effect is seen if treatment is continued for longer than 6 months. Add back
hormone replacement therapy in the form of combined preparations or the
gonadomimetic Livial (Organon, Cambridge, UK) may be used if treatment past 6
months is required or if menopausal effects become a problem.161"163
The problems of loss of bone density and high costs of GnRH analogues limit its long
term use.
1.2.10 Conclusion
Significant amounts of NHS expenditure are made on medical treatments for
menorrhagia. There is a lack of evidence based prescribing in primary care.123
Educational packages can improve the incidence of evidence based prescribing and
reduce referrals to secondary care with its possible knock on effect on the incidence of
surgery. 127 The data pertaining to medical treatments varies in quality. Many of the
trials of oral therapy are based on small numbers, relate to only 3-6 cycles using a cross
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over design to allow different arms to become their own control. Many of the trials, as
part of the inclusion criteria, include only those with objective menorrhagia. This has its
merits but does increase the difficulty of recommending evidence based therapy to the
majority of women who complain of subjective menorrhagia. There is little research
evidence from where we can advise this significant clinical group of women. This was
bome out in Fraser et al whose randomised crossover trial revealed women with
objective menorrhagia having better outcomes compared to those without. 124
The importance of effective medical treatments cannot be over estimated. The
prescribing of ineffective regimens will lead to patients despair and a possible
unnecessary resort to surgical treatment. The increased use of tranexamic acid, the most
effective oral medication, and of the LNG-IUS, the most effective medical treatment,
has to be encouraged. The LNG-IUS is currently the single most important breakthrough
in the medical treatment ofmenorrhagia.
Looking to the future there requires being a greater emphasis on the basic science of
menorrhagia especially at the level of gene expression. Preliminary work on
proteonomics reveals a potential window to the mechanism.164 Proteomics is the study
of proteins in order to understand cell behaviour. It studies the translation process of
RNA into proteins as well as the overall process of DNA into proteins. Proteonomics
analysis involves running samples through a 2-D gel electrophoresis. Proteins are then
separated by their characteristics of molecular weight, shape, and charge, and expression
levels are determined by the resulting patterns on the gels. The expression of different
proteins in health and disease states can then be determined and compared. It is
suspected by many experts in the field that the central process at the heart of the
majority of menstrual disorders is abnormal gene expression.165 Currently the majority
of investment and research is channelled into evermore methods of destroying the
endometrium primarily through endometrial ablation. This represents the necessity of
commerce driven research to generate income. More funding is required in the less
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commercially desirable area of investigating the genetic basis of excessive menstrual
loss with a view to targeted gene therapy.
1. 3 SURGICAL MANAGEMENT OF MENORRHAGHIA
The first description of surgery to remove the uterus was described over 2000 years ago
in Greek manuscripts.166 The first and usually fatal attempts at vaginal hysterectomy are
recorded from the 16th century.167 The first description of abdominal hysterectomy
comes from Charles Clay of Manchester in 1843 who performed a subtotal procedure,
unfortunately the diagnosis was wrong and the patient died.167 The total abdominal
hysterectomy as we know it today was introduced in 1929 by the American surgeon
Richardson.167
Until the introduction of the first generation, hysteroscopic methods of endometrial laser
ablation (ELA) and trans-cervical resection of the endometrium (TCRE) in the late
1980s a hysterectomy by the abdominal or vaginal route was the only definitive surgical
treatment for dysfunctional uterine bleeding (DUB). Despite hysterectomy being the
mainstay of gynaecology surgery (becoming ever more common with a doubling of the
hysterectomy rate in Scotland between 1961 and 1984 ') there was little evidence from
randomised control trials regarding its role, patient acceptability and long term
implications. Some evidence regarding the effectiveness of hysterectomy was already
available. Observational studies had shown that though patient satisfaction following
hysterectomy was high but not the 100% that many gynaecologists assumed.
The endometrial ablative methods gave the promise of replacing hysterectomy with a
minor, quick and safe technique. The endometrial ablative techniques all shared a
common aim, to destroy or remove the basal endometrial glands thereby creating a
therapeutic Ashermann's Syndrome. In pharmacologically prepared endometrium the
basal glands lie at a depth of 4mm and thermal injury or resection requires penetration to
this depth 168;169. The resulting eumenorrhoea (normal periods), hypomenorrhoea
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(reduced periods) or amenorrhoea (absence ofperiods) is the clinical effect. The
restoration of normal menses is ultimately the goal.
Historically ablative techniques began in the 1980's with work by Goldrath in the United
States ( US) on Endometrial Laser Ablation (ELA) 170. Davis introduced ELA into
Britain with the neodymium-YAG laser 171. In the late 1980's Magos introduced
Transcervical Resection of the Endometrium (TCRE) to the British system 172. A rapid
expansion ofTCRE in Britain followed. The equipment was initially a modified
urological resectoscope, which was easily available in most hospitals. The lack of capital
expenditure and general availability of necessary accessories such as bipolar
electrosurgical generators and urological glycine enhanced the development of the
technique in the UK.
These first generation ablative techniques comprise TCRE, ELA and Rollerball
Endometrial Ablation (RBEA). TCRE is the commonest first generation technique in the
UK 173, whereas in the US, RBEA is the most common. The expansion ofELA was
probably limited by both the significant expense of the laser generator and the specialist
training required for the theatre staff.
The early 1990s was a time when the concept of evidence based medicine was becoming
established. This meant that the newly introduced endometrial ablative methods were
rigorously assessed with randomised controlled trials comparing them to hysterectomy,
medical treatment and the differing methods of ablation. Evidence regarding all the
surgical methods including hysterectomy began to accme.
At the same time national audits of endometrial ablation, and recently hysterectomy
gave robust data regarding safety.
Despite the increasing acceptance of the role of randomised trials and the concept of
grading evidence as used by the Scottish Intercollegiate Guidelines Network (SIGN) it is
unfortunate that even to this day the majority of publications in this area are
uncontrolled observational studies. Furthermore only the minority of studies have used
power calculations to determine the size of the population studied.
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A problem with studies on surgery for DUB is the question of outcome measures. Of
the patient centred outcomes patient satisfaction is the most useful and important
measure and this allows for valid comparison between ablation and hysterectomy.
Acceptability is similarly an important patient centred outcome, a procedure can be
highly effective but if patients find it totally unacceptable it is of little use. Hysterectomy
rates in women treated by conservative surgical methods allow for important
comparisons between ablative techniques. Hysterectomy rates are meaningless when
comparing ablative techniques with hysterectomy. Amenorrhoea rates are useful when
comparing one ablative method with another, but again meaningless when comparing
ablation to hysterectomy. Surrogate measures of menstrual loss have their limitations as
even the PBLAC score has been shown to be potentially unreliable in women with DUB
24. Economic outcomes secure data on both direct and indirect costs. Economic analysis,
increasingly reported in clinical papers, gives important information for the health
service especially if taken over the long-term.
Patient selection for trials and studies is an area where bias is possible. Certain
prognostic factors for the success or failure of endometrial ablation have been
recognised. Success is more likely in women who are older, have genuinely heavy
periods and who have less dysmenorrhoea. 174 Studies can therefore be biased if the trial
population is not representative of the population to which the technology will be
applied. Care must therefore be taken when interpreting results of studies, especially
those that are not randomised. Inclusion and exclusion criteria based on PBLAC scores
and the demonstration of genuine menorrhagia, where only women with small regular
cavities are included, will give over optimistic results when compared to trials that take a
more pragmatic approach with limited inclusion and exclusion criteria that more
accurately reflect clinical practise.
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1.3.1 Morphological and Cytological Effects
The effects of endometrial ablation have been studied. The evolution of the histological
and morphological changes may explain the clinical evolution of treatments post
ablation.
Hawe et al175 describe the immediate post ablation changes using an enzyme
histochemical staining technique for respiratory enzymes. They assessed the effect of
varying ablation times with the Cavatherm Endometrial Ablation System and the effect
on the immediate zone of thermal necrosis (ZTN) and serosal temperature. The
temperature was measured with thermocouples at the serosa. The serosal temperature
sensors did not demonstrate any rise in temperature above 44.1 degrees C. The
maximum ZTN was greatest for the 15-min treatment time (3.1 mm, SD 1.5) compared
to the 10- and 7-min treatment times (3.0 mm, SD 1.4 and 2.2 mm, SD 0.7,
respectively). The maximum ZTN recorded was 5.6 mm. No full thickness injuries were
demonstrated.
Colgan et al describe the histopathological features of the endometruim post
electrosurgery in a group of 19 women at three to sixteen months post rollerball
endometrial ablation.176 Of the patient studied at three months or less (n = 6) all
displayed necrotic myometrium, and in five of these cases, a foreign body and
granulomatous reaction to the necrotic myometrium was seen. Acute inflammation was
evident in all six cases but seen exclusively in one case. Examination at three to sixteen
months or more post treatment revealed the necrotic reaction had been replaced by a
granulomatous reaction and or foreign-body reaction in 5 of 12 cases. In most cases (9
of 12), there was very obvious endometrial scarring. They commented on the similarity
between the morphologic response of the endometrium to electrosurgical endometrial
and that reported previously for both resection and laser ablation.
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Jarvela et al 177 displayed a rise in uterine artery impedance measured with colour flow
doppler at 6 months post ablation. Jarvela suggested post operative cavity fibrosis as the
mechanism for the change in impedance. The same group also described the ultrasound
changes displayed post ablation with a clear and limited hyperechogenic zone
surrounding the uterine cavity with or without an area of fluid.178
Mishra et al 179 describe and compared the early cytomorphological and
histomorphological changes post thermal ablation. They compared three groups - non
ablated hysterectomies as a control, hysterectomy specimen's ablation in vitro and
hysterectomy specimens ablated in vivo. They describe a characteristic post ablation
cytomorphology consisting of fragmented glands, single cells with fuzzy cytoplasm and
giant cells. When assessing oxidative enzymes over 90% of endometrial cells from
uteruses ablated in vivo compared to 100% of those ablated in the control group.
MRI features post ablation have been described by Olson et al ,180 They performed T1
and T2 sequences on the uteruses of 15 women undergoing MEA. The women were
scanned pre-operatively, on the 1 st post operative day and at 4 months. On the first post
operative day a low signal intensity band was seen subjacent to the treated area of the
endometrial cavity on T2 images. At 4 months there was no change in the myometrial or
uterine dimensions and significant amounts of endometrial tissue were seen in 11
patients. This included the patients who were amenorrhoeic. The MRI data puts paid to
the suggestion by some that unopposed oestrogen HRT is safe in those who are
amenorrhoeic.
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1.3.2 When to offer surgical treatment for DUB
When hysterectomy was the only surgical option for the treatment of DUB it was
seldom employed as a first line treatment. It was standard practice for patients to "earn"
their operation by being treated with multiple medical treatments and uterine curettages.
Only after these had failed was a hysterectomy employed. This was sensible as
hysterectomy is a major procedure not without risks. As the endometrial ablative
methods were thought of as an alternative to hysterectomy the same view was held.
Surgical methods, hysterectomy and ablation should only be offered to women who have
completed their family, because the absolute sterility caused by hysterectomy and the
relative sterility and possible risks of pregnancy following ablation. In couples not using
a permanent method of contraception female sterilisation can be offered at the same time
as conservative surgical measures.
Data regarding the place of medical versus primary surgical treatment for DUB comes
from the original and follow-up papers of a randomised trial comparing oral medical
treatment with TCRE15'181'182 and from trials of Mirena compared to Thermal Balloon183,
hysterectomy184 and TCRE.185'186
Cooper at al randomised patients to either medical (oral) treatment or TCRE.15 The
study was pragmatic in design, methodologically sound and adequately powered.
Follow up data at 4 months15, 2 years181 and 5 years182 is available ( the data from the
five year follow-up will be presented later in this thesis).
At 4 months women allocated transcervical resection were significantly more likely to
be totally or generally satisfied, to find the treatment acceptable, and willing to have the
treatment again. Pain and bleeding scores were significantly reduced by medical
treatment but this reduction was modest in comparison with that seen after transcervical
resection. Quality of life scores improved in both arms, although only transcervical
resection returned them to normal values. The parallel partially randomised patient
preference trial yielded some interesting data.187 Overall, more women participated in
the partially randomised patient preference design. There was no difference in the
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numbers who agreed to be randomised. Women who expressed a treatment preference
exhibited certain characteristics. Those wishing medical management tended to have
better general health, to be less restricted by their menstrual problems, with fewer having
been previously treated by their general practitioner. Those with a preference for
transcervical resection of the endometrium had all tried medical management and had
higher bleeding scores. Follow up satisfactions and acceptability rates, and Short Form
36 scores were highest after transcervical resection of the endometrium, whether chosen
or randomised. Acceptability and a desire to continue the same treatment was greater
among those who chose medical management than those randomly allocated it.
At two years women allocated medical treatment were significantly less likely to be
totally or generally satisfied, to find their management acceptable or to recommend their
allocated treatment. By two years 59% of the women in the medical arm had undergone
TCRE, hysterectomy or both, whereas 17% in the TCRE cohort had undergone further
surgery. Bleeding and pain scores were similar in the groups. A greater improvement in
Short Form-36 health survey scores was seen in the TCRE arm. They concluded a policy
of early TCRE to be effective, and does not result in an increase in hysterectomies at two
years.
A small number ofRCT exist comparing Mirena to surgical management.
Crosignani et al 186 randomised 70 women referred for hysterectomy in a 1:1 ratio to
either insertion of a Mirena or TCRE in the early proliferative phase. Follow up was to
a year. 65% of women using a Mirena reporting amenorrhoea or hypomenorrhoea at 1
year compared to 71% in the TCRE arm. Satisfaction was high for both procedures -
85% in the Mirena arm and 94% in the TCRE arm. Health Related Quality (SF 36) was
not significantly different. . Whilst these figures are encouraging the generalisability of
the results are significantly reduced by a number of factors. These factors are the small
numbers, the invalidation of the power study, and the restriction of recruitment to
women over 38 years who were referred for hysterectomy. These all reduce the ability to
apply the findings to the general population. The use of PBLAC menstrual diaries in the
recruitment and follow-up (see earlier comments on PBLAC) has its own problems.
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1.3.3 Hysterectomy or Endometrial Ablation- Results and Safety.
When TCRE and ELA were introduced into the United Kingdom a number of
randomised trials were carried out comparing these new techniques to hysterectomy.
As the complaint of DUB is rather subjective, and selection criteria for surgery vary it
was essential to perform randomised controlled trials to compare endometrial ablation to
hysterectomy.
Randomised controlled trials (RCT) have compared the procedures to hysterectomy. To
date there are five RCT which have varied in methodological soundness.
The first, by Gannon et al l88, randomised 51 women on a waiting list for hysterectomy
to either abdominal hysterectomy or TCRE (1:1 ratio). There was no power calculation
or intention to treat analysis. The patients in the ablation group received oral
progesterone as endometrial preparation. The patients were followed up to nine months.
The second trial by Dwyer et al randomised two hundred women to TCRE or abdominal
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hysterectomy . A sample size calculation was made and the trial adequately powered.
The uteri were not prepared pharmacologically. Patients were followed up clinically for
4 months in the initial report, and to two years in a follow-up paper by Sculpher at al 190.
The level of satisfaction recorded at 4 months for hysterectomy was 94% versus 85% for
TCRE (just statistically higher). It also showed TCRE to have a significantly shorter
hospital stay and a significantly faster time of return to work and daily activities.
Economic analysis revealed TCRE as 53% of the cost of a hysterectomy (mean total
costs) at 4 months, and 71% of the costs at an average follow-up of 2.2 years 190 .
The third trial by Pinion et al in Aberdeen randomised 204 women to hysterectomy or a
conservative ablative technique (ELA or TCRE sub-randomised in a 1:1 ratio) 191. The
trial was adequately powered to detect a 20% difference in satisfaction between
hysterectomy and ablation. The trial was not powered to detect a difference in
satisfaction between the two ablative techniques although the results were very similar.
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At twelve months, 89% in the hysterectomy group and 78% in the conservative surgery
group recorded themselves as very satisfied with the results of their procedure.
Significantly less early morbidity, faster operative times and shorter post-operative stays
were recorded by the conservative groups. The 5 year follow-up revealed 76% of the
conservative group avoiding hysterectomy. 192
The multi-centre RCT Medical Research Council trial reported by O'Connor et al,
randomised 202 women to TCRE or hysterectomy in a 2:1 basis. 193 Primary end points
were women's satisfaction and the numbers requiring subsequent surgery. The trial was
powered to detect up to a 15% difference in the proportions of women dissatisfied with
their treatment at three years. The multi-centre (9 UK centres) nature of the trial
enhances the ability to generalise the results, however, of the approximately 800 eligible
patients, approximately 600 refused randomisation. Endometrial preparation prior to
TCRE was at the discretion of the operator. At a median follow-up of 2 years, 96% in
the hysterectomy group and 85% in the TCRE group recorded satisfaction with their
results (statistically non-significant). Further surgery was seen in 22% of the TCRE arm
at 3 year follow-up and 9% in the hysterectomy arm. The prolonged recruitment time,
low number of eligible women recruited (this may be an effect of private practice), and
the fact that the hysterectomy findings are based on the 28 women in the hysterectomy
group affecting the trials external validity.
The fifth trial was a randomised comparison of endometrial resection (TCRE) with
vaginal hysterectomy (VH). 194 Some may argue that the comparison with vaginal
hysterectomy is a more valid comparison than the comparison to abdominal
hysterectomy. The preferred route for hysterectomy of a normal sized uterus with
associated dysfunctional uterine bleeding is vaginal. The vaginal route with its
associated lower morbidity, shorter hospital stay and faster recovery would be a more
valid comparison to ablation
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The study by Crosignani in Milan recruited menorrhagic women, less than 50 years,
with uteri 12 week size or less. 194 85 women were randomised (44 VH / 41 TCRE).
They assessed satisfaction at two years (very satisfied or satisfied) in the 77 followed up.
87% of the resection arm and 95% of the hysterectomy arm reported satisfaction.
Quality of life scores, social functioning and vitality scores were significantly higher for
hysterectomy and anxiety and depression scores were significantly lower. There were no
significant differences in sexual function (Sabbatsberg Sexual Rating Score) and
improvements were seen in both groups.
These Randomised Control Trials established the validity of the ablative procedures,
securing its evidence base and legitimising many of the claims made in earlier non-
randomised observational studies. The studies, whilst differing in methodology, shared
many common features. The uteri were all 10 - 12 week size and the procedures
performed to similar techniques. The similarity in outcome is striking, with TCRE / ELA
recording comparable (although lower) levels of satisfaction to hysterectomy
(hysterectomy however, never achieving 100%). The common finding of shorter
operating times, rapid recovery, lower morbidity and faster return to normal activity is
noticeable. The ability of ablative techniques to reduce dysmenorrhoea and pre¬
menstrual symptoms was noted as was the improvement, where measured, in the quality
of life and psychological scores. The rates of further surgery were similar.
Importantly these studies were pragmatic in design and included women with uterine
enlargement up to the size of a 10 or 12 week pregnancy. Twenty percent had fibroids
identifiable at hysteroscopy. In Pinions study (hysterectomy group) endometriosis was
found in 8% and adenomyosis in 17% of the women so it can be assumed that the
women in the TCRE group contained had similar pathology. This meant that the women
in these studies were not carefully selected to only include women with no pathology
and regular uterine cavities.195
Long term follow up of the Pinion study from Aberdeen has been published 192. The
follow up period was a median of 5.1 years (range 4-6 years). Hysterectomy was
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avoided in 76% of the hysteroscopic surgery group. There was no significant difference
between the two groups as 89% of patients were totally or generally satisfied after
hysterectomy and 80% after hysteroscopic surgery. Life table analysis showed that
hysterectomy was only seldom needed once women were beyond 36 months after their
hysteroscopic surgery. This result is reassuring as it shows that in this group of women
hysterectomy was avoided in three-quarters of them. This is despite the fact that these
women were expecting a hysterectomy and its associated amenorrhoea. In the
hysterectomy group 7% were dissatisfied with the results of the procedure compared to
9% in the hysteroscopic surgery group showing that satisfaction is not universal
following hysterectomy for DUB.
Persistence of pelvic pain following endometrial ablation is a common reason for
apparent failure of the technique and the cause for a subsequent hysterectomy. In that
study 15% of women continued to suffer from pelvic pain four to six years after
hysterectomy compared to 18% after hysteroscopic surgery. If abdominal or pelvic
pain continues following endometrial ablation pain it is investigated and managed, often
by hysterectomy, whilst after hysterectomy it is either ignored or thought to be not a
gynaecological problem.
The above study also gave some evidence as to the relative effects of hysterectomy and
endometrial ablation on sexual function. Both groups reported either no change or an
improvement in sexual interest and satisfaction.
Further work was done on this study population to compare the psychological effects of
hysterectomy and hysteroscopic surgery. There was a similar beneficial effect on
anxiety, depression and sexual function between both groups at six and twelve month's
post operatively. When re-assessed between four and six years post operatively there
was no difference between the groups. The improvement over the pre-treatment score in
the Hospital Anxiety and Depression Scale for both anxiety and depression were
maintained 192;195_
McPherson et al reported on the effect on psychosexual health of ablation and
hysterectomy at five years.196 They compared three groups TCRE, hysterectomy (sub-
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total and total) with oophorectomy and hysterectomy (sub- total and total) without
oophorectomy. The groups were comparable except the oophorectomised group was
older. They looked at self reported psychosexual health in a unselected population of
11,325 women based on groups derived from the MISTLETOE173 and VALUE197
studies. They asked to rank how much they were bothered with regards to their loss of
interest in sex, difficulties in becoming sexually excited and vaginal dryness using a
four point Likert Scale. They revealed (adjusting for age and HRT) that crude and
adjusted prevalence of psychosexual problems was higher after hysterectomy than
TCRE especially if accompanied by bilateral oopherectomy.
In a similar fashion to the psychosexual health study, and using the same cohorts of
TCRE, hysterectomy and hysterectomy with oopherectomy McPherson reported a
separate paper on self reported bladder symptoms at five years derived from the
MISTLETOE and VALUE studies populations. 198 The findings were that the odds of
severe urinary incontinence, urinary frequency and nocturia were increased with
hysterectomy.
The relative symptomatic results of the two treatment approaches are best assessed by
the use of randomised controlled trials as shown above. These are large enough to give
an indication of the relative frequency of common complications, but for the study of
uncommon complications large prospective series are needed. Fortunately two such
audits of the hysteroscopic methods have been carried out in the U.K. and recently (and
perhaps belatedly) one on the complications of hysterectomy.
1.3.4 Complications of Endometrial Resection and Ablation
The introduction of these new surgical techniques elicited concerns over safety. The
move from the dedicated proponents into the hands of the generalist is a delicate one.
Initial high success rates and low complication rates may be misleading. Over time new
complications became evident. Cases of uterine perforation, cervical laceration, false
61
passage creation, haemorrhage, sepsis and bowel injury were reported. Complications of
fluid overload, seen previously by the Urologists in Post Transurethral Resection of the
Prostate Syndrome (Post TURP Syndrome), were reported. The use of 1.5% Urological
Glycine (non ionic) irrigation fluid in TCRE and RBEA was reported to be associated
with serious and occasionally fatal consequences. This fluid is non-miscible with blood
(hence improving vision) and non-ionic (allowing intrauterine electrosurgery). However
the potential to cause significant hyponatraemia if absorbed (via open uterine vessels or
transperitoneally) was present. The resulting hyponatraemia caused cerebral oedema
(confusion, agitation, coma), pulmonary oedema and metabolic acidosis from ammonia
metabolites. Cases of death from respiratory arrest with compression of the respiratory
centres due to cerebral tonsillar herniation were reported l99'2()0. Current
recommendations limit total fluid absorption to 1500 mis, with the advice to abandon the
procedure if this limit is exceeded.
Whilst minor complications such as post operative endometritis, prolonged bleeding and
transient pelvic pain are relatively common, more major, potentially life threatening
complications do occur, albeit infrequently. Transient bacteraemia has been shown to be
relatively common post ablation with low grade endometritis being seen in
approximately 1% of cases 20', and a death secondary to overwhelming sepsis has been
909 ... . . •
reported . Antibiotic prophylaxis is recommended by many as good practice although
its does not have a solid evidence basis 203.
Post-tubal sterilisation syndrome 204"206 is a late complication associated with
endometrial ablations. This occurs when cervical stenosis prevents menstrual loss
draining transcervically and tubal sterilisation prevents retrograde menstruation. The
resulting haematometra causes dilation of the proximal portion of the fallopian tube
resulting in a history of post ablation cyclical pelvic pain, occasionally an adnexal mass,
raised CA 125 and tenderness. Many mimic ovarian pathologies such as ovarian cancer
62
or cyst accidents. Ruptures have been reported. Previous sterilisation is an independent
risk factor for hysterectomy 207;208.
Pregnancies have been reported following ablation. Many advise offering women
sterilisation as a permanent method of contraception at the time of ablation, with
significant numbers already using female or male sterilisation prior to ablation. The
concerns over the safety for the mother and the pregnancy are significant. The risks are
miscarriage, preterm labour, intrauterine growth retardation, placental implantation
abnormalities (placenta accreta, increta, percreta) and abruption. Occasional normal
outcomes have been recorded but such are the concerns over the risks to the mother and
unborn child that therapeutic abortion is to be recommended. Up to June 2002, Cook et
al reviewed the reported pregnancies post ablation 209. They reported only 17
pregnancies progressing beyond 20 weeks and a single successful term pregnancy.
The incidence of complications following the hysteroscopic methods of TCRE and ELA
has been determined firstly by the Scottish Audit of Hysteroscopic Surgery 210 then by
the MISTLETOE study in England and Wales 173 which between them give the results
from over 11 000 patients. In both audits it was estimated that over 90% of procedures
were reported and that there was no difference in the complication rate in the unreported
group. In the MISTLETOE study of over 10 000 cases the rate of bowel damage due to
TCRE was 0.7/1000 173. The Scottish Audit of Hysteroscopy Surgery of just under
1,000 cases reported no cases of bowel damage. One case which was reported to the
audit as a uterine perforation and laparoscopy following TCRE, was actually a case of
small bowel damage. The patient subsequently required a laparotomy after the
registration form was returned. This gives a rate of 1/1000 for bowel damage due to
TCRE. Endometrial Laser Ablation (ELA) is felt to be safer than TCRE with no case of
bowel damage in 1764 cases in MISTLETOE and 314 in the Scottish Audit but there
was a case of small bowel damage in the Aberdeen randomised study 191.
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Rollerball endometrial ablation (RBEA) is a first generation method derived from
TCRE and felt to be a safer method as the surface of the uterine cavity is coagulated
rather than resected. No visceral damage was reported with this method in
MISTLETOE, but there were only 650 cases 173. There have been a number of case
reports of large and small bowel damage after REA 211;212. In the MISTLETOE study the
rate of emergency hysterectomy was 6/1000 overall, but 11/1000 when TCRE was
performed using a loop for the whole procedure. In the Scottish audit the emergency
hysterectomy rate was 2/1000, considerably lower than the English audit. Uterine
perforation is reported in 15/1000 cases in the MISTELTOE and 10/1000 in the Scottish
audit 173;21°. This is of little consequence if the perforation is recognised and does not
involve the use of electro-diathermy or laser energy.
As all the hysteroscopic methods use fluid to distend and irrigate the uterine cavity,
excessive absorption of irrigation fluid is a potential risk. During TCRE using Glycine,
changes in electrolytes especially serum sodium can be avoided if the procedure is
abandoned when absorption is noted to be reaching 1500ml. In MISTLETOE there was
a 1% rate of fluid absorption of greater than 2000ml and 1% in the Scottish Audit. Both
audits and a RCT comparing TCRE to ELA have shown a greater rate of fluid
absorption following ELA as compared to TCRE 173;210;213. The increased fluid
absorption post ELA however is not as much of a concern as that seen with TCRE as
saline is used with ELA. Combining the two audit studies the mortality from the
hysteroscopic methods of endometrial resection and ablation was 0.27/1000 173;210.
In conclusion the two studies reported on over 11,000 cases. ELA and RBEA were
revealed as the safest techniques (albeit with a smaller number of procedures
performed), with higher rates of perforation and emergency hysterectomy seen in the
TCRE cases.
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1.3.5 Complications of Hysterectomy
The complications of hysterectomy are often underestimated. Minor pyrexial morbidity
was found in 47% ofwomen after abdominal hysterectomy in the Pinion study with 11%
having a vaginal vault haematoma and 5% requiring a blood transfusion 191. There were
also three major complications in that series.
The VALUE study in England , Wales and Northern Ireland is the most recent
assessment of complications197. Unfortunately, unlike its sister publication the
MISTLETOE study, the numbers included were a minority of the total number of
procedures and there is a strong suspicion of a general under reporting of cases and their
complications.
The Value study assessed serious operative and post-operative complications (to six
weeks) of hysterectomy in a prospective cohort of women undergoing hysterectomies
for benign indications. A total of 37,512 women from 276 NHS and 145 private
hospitals were studied. This group was originally recruited to compare the outcomes of
endometrial destruction with those of hysterectomy. Severe operative complications
occurred in 3%. The risk decreased with age and increased with greater parity and
history of serious illness. Women with symptomatic fibroids experienced more
complications than women with dysfunctional uterine bleeding [adjusted odds ratio =
1.3, (95% CI 1.1-1.6)]. Laparoscopic procedures doubled the risk of operative
complications of abdominal hysterectomy [adjusted odds ratio = 1.9, 95% CI 1.5-2.5)].
Post-operative complications occurred in around 1% of women, with a slight decrease
with increasing age, and the strongest risk factor was a history of operative
complications. Hysterectomies by the vaginal and laparoscopic route had significantly
higher adjusted risks than abdominal operations (0.9%), RR =1.4 (95% CI 1.0-1.9) and
RR =1.6 (95% CI 1.0-2.7).No intra- operative deaths were recorded. 14 women died
within the six-week post surgery giving a crude mortality rate of 3.8/1000, ( range 2.5-
6.4).
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There is a large retrospective study from the United States of 1851 pre-menopausal
women undergoing hysterectomy.214 The hysterectomy were performed by the
abdominal route in 1283 and vaginally in 568 women. The rate of fever after abdominal
hysterectomy was 30% and 15% needed a blood transfusion. Vaginal hysterectomy had
a lower rate of febrile morbidity of 15%. Bowel injury occurred in 3/1000 women
following abdominal hysterectomy and 6/1000 after vaginal hysterectomy. The urinary
tract was damaged in 3/1000 after abdominal hysterectomy but 14/1000 with the vaginal
route. The mortality was 1/1000. A similar rate of bowel damage has been found in
another large American study where the rate of bowel damage in abdominal
gynaecological surgery has been reported as 8.4/1000 and 7.3/1000 for vaginal surgery
14. Though the Dicker study advocated vaginal hysterectomy because of a 70% higher
rate of complications after abdominal hysterectomy the difference was mainly caused by
relatively minor febrile problems. There was however more damage to the bowel or
urinary tract during vaginal hysterectomy 13.
1.3.6 Patient Selection for Ablation
Whilst some selection criteria are fairly obvious, others have become clearer as the
evidence has accrued. From the beginning the ablative procedures have only been
offered to women whose family is complete because of the probable sub-fertility and the
potential risks to both to mother and foetus of a pregnancy following endometrial
ablation. As it became obvious that pregnancies could occur after ablation, women had
to continue adequate contraception after the procedure.
It was also obvious that ablation would not deal with a very large fibroid uterus.
There is now evidence as to the prognostic factors for successful ablation based on
randomised trials and the large audit studies. Women whose menstrual blood loss is
genuinely excessive have a better outcome after TCRE than those with normal menstrual
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blood loss. Gannon showed that if menstrual blood loss was above 80 ml per cycle the
subjective failure rate was 9% compared to 18% if periods were perceived to be heavy
but who had normal menstrual loss.19 Patient age may be important with younger
women having a lower satisfaction than older women. Studies in different medical fields
and interventions have shown that expression of satisfaction is affected with age, with
older people in general expressing higher levels of satisfaction.215 The Scottish Audit of
Hysteroscopic Surgery showed a lower satisfaction in women less than 40 years of age,
though this was still 79% as compared to 88% in women aged more than 40.210
The presence of irregular periods or menstrual dysmenorrhoea is not a predictor of a
poor outcome. In the trial comparing TCRE and ELA there was no difference in
satisfaction using either of these criteria.213
Whether endometrial ablation of the endometrium succeeds or fails is probably
dependant on a number of variables, with genuine and perceived severity of symptoms,
patient expectation and uterine pathology all playing their part. In addition there is the
individual variation in efficacy and performance of the procedure as well as the
pathological healing processes in the uterus.
One method of determining reasons for the failure of endometrial ablation is to look at
the pathology of the uterus in women who have a hysterectomy for failure. The draw
back is that it tells us nothing about the women who have had a successful ablation.
Davis et al have studied the histopathological status of the removed uterus following
hysterectomy for failure of REA to control symptoms. 216. In women still complaining
of bleeding excessively they found that endometrium was present focally but not
diffusely in the uterine cavity. Fibroids were found in 30% and adenomyosis in 27%.
As already stated in the Pinion study, where the women had a clinical diagnosis of
dysfunctional uterine bleeding, those randomised to hysterectomy were found to have
endometriosis in 8 %, adenomyosis in 17 % and fibroids in 20%. 191 Presumably as it
was a randomised study the same uterine pathology would be present in those women
undergoing TCRE or ELA. Despite this the hysterectomy rate 4-6 years after treatment
is only 22%. It is probable that even in women with this range of pathology, many will
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have a satisfactory result from endometrial ablation if the indication for endometrial
ablation is DUB rather than pain.
1.3.7 Which Method of Endometrial Ablation
1.3.7.1 First Generation Techniques
A large number uncontrolled series of TCRE and ELA have been published as well as
randomised studies comparing them to each other and to medical treatment. The two
uncontrolled studies that give the best estimate as to the long-term outcome are the long
term follow up of TCRE from the Magos group2'7 and ELA from Garry's group218.
Magos followed up 525 women for up to five years. Despite the apparent long term
nature of this study the mean follow up was actually 31 months and only 43 women
were followed up for the full five years. The hysterectomy rate was only 9% and 80%
avoided further surgery. The Middlesbrough group (Garry) have reported long term
follow up of 1000 ELA procedures, with 746 women followed up for up to 6 years. The
rate of repeat surgery was 15% during the period of follow up, but by using life table
analysis they predicted a hysterectomy rate of 21% at 6.5. years.218 Despite the size of
these studies they are less useful than the long term follow up of randomised controlled
trials because the duration of follow up is not uniform for all women in these studies.
They therefore rely on statistical estimation of the final hysterectomy rate. The other
drawback is the fact that in an uncontrolled series the degree of symptomatology of
these women at the start of treatment is unknown. These studies along with long-term
follow up of the Aberdeen randomised trial show that the great majority of women will
avoid a hysterectomy following first generation endometrial ablation.
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TCRE has been compared to ELA in a randomised trial of 372 patients. This study
showed that TCRE had a shorter operating time than ELA. There was less mean fluid
absorption following TCRE and fewer patients had large volume absorption during
TCRE than with ELA. Clinically this difference is irrelevant as ELA utilises normal
saline and therefore doesn't pose the same risks as the glycine utilised in TCRE. There
were no differences in complications between the two methods and the only major
complication was a case of small bowel damage after ELA. There was no difference in
outcome as measured by satisfaction (90%), amenorrhoea rate (45%), or hysterectomy
rate (20%) between the two methods 213 •
Rollerball Endometrial Ablation (REA) is a widely used method especially outside the
United Kingdom. Uncontrolled results give this method a similar success rate to the
other hysteroscopic methods219.
1.3.7.2 Second Generation Techniques
Second generation ablative techniques represent a rapidly expanding area of medical
technology. The majority use tissue heating as the method of endometrial destruction
using electrical energy (Vesta System - multielectrode), microwave energy (Microwave
Endometrial Ablation), laser (ELITT), heated saline / glycine irrigating the uterus
(Hydrotherm Ablator and Circulating Hot Saline) or heated saline / dextrose contained
within a balloon device (Thermachoice and Cavatherm Systems). Second generation
techniques are mostly blind in nature (no hysteroscopy), and most avoid the need for
fluid distension media and its risks. They are quicker and much simpler to leam and
perform than first generation techniques, which many gynaecologists found difficult or
impossible to master. Some also offer the benefits of local anaesthesia (Microwave
Endometrial Ablation and Thermachoice).
These new procedures all post date the earlier national safety audits l73;21°. The new
techniques must prove equal efficacy but also safety before they can become widely
accepted. Their efficacy should be compared in randomised trials of adequate power to
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the now established gold standard of TCRE. Adequate training is vital to reduce the
potential for serious complications with the second generation techniques.
The methods which have been subject to adequate assessment to date are Thermachoice
(Gynaecare UK Ltd) 2I0;219"221, Microwave Endometrial Ablation (MEA - Microsulis
UK Ltd) 222;223, Vesta system 224, Novasure device (Novacept Inc) 225, Heroption
(Cryogen Inc) 226 and the Hydrothermablator (Boston Scientific Corp) 227.
1.3.7.3 Thermal Balloon Therapy
Thermal balloon therapy has been compared in an RCT to Rollerball Ablation (RBEA)
which, although a first generation technique, has not been validated against
hysterectomy or TCRE and as such is therefore not seen as a gold standard.
Thermachoice Thermal Balloon utilises a 16 cm long, 3.1 mm diameter catheter. Three
cables link the device to the control unit. One is the electrical connection, the second the
fluid line and the third supplies the impeller. The distensible silicone balloon is filled
with 5% dextrose solution at a working temperature of 87 degrees Celsius and a
distending wall pressure of 160 -180 mmHg. Treatments are completed in 8 minutes. A
predictable 5mm endometrial thermal destruction is achieved when utilising these
parameters.
Thermachoice III, the currently marketed version, contains an impeller which circulates
the dextrose solution to ensure an even thermal effect (previous models were troubled by
uneven heating). The technique is blind and after sounding of the cavity dilatation is
rarely required. The device requires a minimum of 150 mmHg pressure before the
heating element is activated. Failure to maintain this pressure will result in an automatic
cut of if pressures exceed 200mmHg or less than 45mmHg. Prior to treatment the
catheter requires priming with 5% dextrose to establish the balloon is intact and it is then
inserted into the cavity and filled with between 10 mis and 30 mis of dextrose to
stabilise the pressure at 160 -180 mmHg. Extra dextrose can be introduced during
70
treatment if a small pressure fall (as a result of uterine relaxation) is encountered, a
larger drop however should raise concerns of a leaking balloon or a uterine wall defect.
A multicentre North American trial randomised 275 women to thermal uterine balloon
therapy (Thermachoice) or RBEA to study efficacy and safety 221. The study was
powered to detect 20% lower efficacy for RBEA versus balloon. The study was
restricted to women with small, regular uterine cavities and with high PBLAC scores
and therefore the results are less generalisable to an unselected population than the trials
of first generation methods. No pre-treatment endometrial hormonal preparation was
used in either arm, instead the endometrium was prepared with a five minute suction
aspiration. At 1 year both techniques significantly reduced the PBLAC score, 68.4% in
the RBEA arm and 61.6% in the Balloon arm had a reduction of over 90% from their
pre-operative baselines scores. This difference was not significant. Quality of life scores,
satisfaction and improvement in dysmenorrhoea / PMS were also similar. The balloon
treatment was significantly quicker with no complications, compared to a complication
rate of 3.2% of the RBEA group. The amenorrhoea rate was significantly lower after
Thermachoice (15%) compared to (27%) after RBEA, despite the fact the amenorrhoea
rate after RBEA was considerably less than expected with a first generation method.
9 1 Q-990-99R
This study was re analysed at 2, 3 and 5 years of follow up ' ' . At two years follow
up it was found that in total 15 hysterectomies had been performed, 11 in the RBEA arm
and 4 in the balloon arm. Of the 214 who were followed for 3 years, the results of
uterine balloon therapy and Rollerball Endometrial ablation remained similar, with little
difference at 3 years compared with results at 1 year. There was a suggestion of an
increase in hysterectomies in the RBEA group (n= 14) compared with the uterine balloon
therapy group (n=8) at 3 years 220.
The conclusion was that both methods were highly successful at avoiding hysterectomy
and relieving symptoms and that patient satisfaction remained high.
A European RCT by van Zon-Rabelink et al 229 from Holland recorded similar results to
Loffer in their 2 year study of women randomised to Thermachoice or Rollerball.
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Thermachoice was significantly more successful at reducing menstrual blood loss with
equivalent success rates (as defined by a PBLAC scores) measured at 24 months post¬
operatively. Satisfaction rates were not significantly different (respective 75% for roller
ball and 80% for uterine balloon).
Data regarding the use of Thermachoice III in an outpatient setting has been published.
230 In a prospective observational study trained non-specialists (General Practitioners)
performed outpatient treatments in a community hospital under the indirect supervision
of a consultant gynaecologist. Patients were screened with a normal endometrial biopsy,
cavity length and ultrasound by a radiologist with a special interest in gynaecological
transvaginal ultrasound scan. Of the 166 referred 87 women treated. There were no
complications and all procedures were well tolerated. They commented on the suitability
of the technique as an outpatient technique possibly even as a procedure for primary
care. The findings are interesting. Its validity is affected by the high numbers found
unsuitable (n = 79, nearly 50%) and the highly selected group who were operated on.
Also the subjects were not randomised and bias will have entered the selection of cases.
There are the wider issues ofperforming the procedures without direct specialist input.
A randomised comparison with the second generation ablative technique of the Thermal
Balloon is published. 183 The study was based on 50 women in a district general hospital
who were randomised to either surgical treatment using thermal ablation
(Thermachoice) or medical treatment using a LNG-IUS. PBLAC diaries were used at
recruitment and 6 month post procedure. Follow-up was possible in 23 women in the
Thermachoice group and 21 women in the Mirena group. Median post-insertion
/operative menstrual scores were 27 for the Thermachoice group and 19 for the Mirena
group ((P=0.689). It is notable that at entry the median menstrual scores were higher in
the Thermachoice arm. The study concluded that both Thermachoice endometrial
ablation and a Mirena LNG-IUS are equally effective in the management of
menorrhagia and treatment choices should be tailored to the woman's needs and
preferences. The small numbers, short term follow-up and lack of a power study limit
the interpretation of these results
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Cavatherm a thermal balloon endometrial ablation device is similar to Thermachoice in
that it utilises a heated dextrose solution filled silicone balloon. Similarly it uses an
impeller to circulate the heated solution and takes 10 minutes to complete therapy. The
main difference is that the Cavatherm balloon has an adjustable balloon length to allow
treatment of cavities from 5 to 10 cm in length.
Cavatherm has been compared to the gold standard of TCRE. Pellicano et al have
-jit
reported an Italian RCT of Cavatherm versus TCRE with 2 years follow up. 82
patients were randomised in a 1:1 ratio to TCRE or Cavatherm with patient satisfaction
as the main outcome measure. All women had failed medical treatment with uteri less
than 12 weeks gestation in size. There were 23 post randomisation, pre-treatment drop
outs. The inclusion criteria were restrictive with all women undergoing a hysteroscopy,
TVUSS and haematological work up. The TCRE arm was pre-treated with GNRH
analogues whilst those in the Cavatherm arm were not. All procedures were undertaken
under spinal anaesthesia. Follow up to two years was achieved in 75.3% in the TCRE
arm and 87.5% of the Cavatherm arm. The satisfaction rate was significantly higher in
the thermal destruction group. Operative time was significantly shorter in the thermal
destruction group. Intra-operative blood loss was significantly lower in the thermal
destruction group. Re-intervention rates were higher in the transcervical hysteroscopic
endometrial resection group at two years (15.1% vs. 5.7%). Discharge time,
complication rate, and resumption of normal activity were not significantly different
between the two groups. They concluded that Cavatherm thermal destruction of the
endometrium for the treatment of menorrhagia should be considered an effective
therapeutic option.
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1.3.7.4 Microwave Endometrial Ablation
This will be discussed fully in Section 1.4.
1.3.7.5 Multi-electrode Systems
The Vesta System - a disposable distensible multi-electrode carrying balloon utilising
mono-polar diathermy has been compared in an RCT to combined resection /
coagulation technique (TCRE). Women with menorrhagia as defined by PBLAC scoring
(>150), with normal cavities and who had failed medical treatment were randomised.224
Out of the 557 women assessed as menorrhagic only 244 were randomised, as
approximately half proved unsuitable for the procedure by the other inclusion
parameters. PBLAC's were used in selection and definition of outcome success (a score
PBLAC < 75 defined success). Success was achieved in 86.9% of the Vesta arm and
83% in TCRE at one year. Amenorrhoea rates were 31% in the Vesta arm and 34% in
the TCRE arm. No significant complications were reported. 87% of the Vesta
procedures were performed on an outpatient basis, under local anaesthesia +/- sedation.
Of note there were 18 (10.6%) technical failures in the Vesta arm and one Vesta
procedure had to be abandoned as the device had entered a weakened caesarean scar.
The benefits of avoiding fluid overload and local anaesthesia were present. The
allocation of the procedure to local anaesthesia was at patient and physicians discretion
and thus as a non randomised outcome the findings lack generalisabilty. They concluded
the Vesta method to be equally effective and safe as TCRE. The Vesta system is
however not currently being commercially marketed.
1.3.7.6 Hydro Thermablator Procedure
Hydro-thermablator, unlike the rest of the second generation techniques, requires
hysteroscopy and gives a view of the cavity during active treatment. No manipulation of
the device once placed in the uterine cavity is required. The technique relies upon
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circulating heated saline within the endometrial cavity. The saline is heated externally
prior to being introduced into the hysteroscope and achieves an intrauterine temperature
of 90 degrees Celsius. The fluid is constantly re-circulated at a rate of 300 mis / min.
This method is suitable for cavity lengths from 4 cm and for irregular and fibroid
cavities unlike the balloon methods. Intrauterine temperature can be maintained with
cavities up to a volume of 60 ml although this size of cavity is unlikely to be selected for
ablation (10 - 30 ml is the average). The device is 7.8mm in diameter and takes 10
minutes of active treatment, with a post treatment cool down of 1 minute prior to device
removal. A pre-treatment test run using saline at room temperature is carried out to
ensure the circuit is intact; a loss of only 10 mis from the system will trigger an
automatic shut down. The intrauterine pressure is maintained at a net pressure of 50 - 55
mm Hg, thus preventing spillage from the fallopian tubes which is only apparent at
70mm Hg or above 232,233. An adequate seal at the cervix is imperative and care must be
taken not to over dilate the cervix. The pressure is maintained by the balance between
the hydrostatic mechanism and the pump evacuating the saline from the cavity. The
saline is suspended from a dedicated intravenous pole 115 cm above the patient's uterus.
The main advantages of the technique are the pre-operative hysteroscopic view of the
cavity (to exclude false passage / perforation formation) with saline at room temperature
the fact that the device can accommodate any hysteroscope up to 3mm or smaller, and
the ability of the technique to treat irregular cavities. A pharmacological endometrial
preparation is essential which is expensive, cause side effects and increases cervical
resistance.
A multi-centre RCT study comparing Hydro ThermAblator (HTA) to Rollerball (RBEA)
is published. 234 Nine centres in North America were included. The trial was part of a
Food and Drug Administration Phase III clinical trial seeking approval for the device in
the United States. 276 patients with menorrhagia were randomised using computer
generated randomised blocks, in a two to one ratio, to HTA (n = 187) or Rollerball (n =
89). PBLAC diaries were used for inclusion criteria and follow-up. Women between 30
and 50 years were included. Uterine cavities between 4 and 10.5cm were included. The
inclusion of irregular cavities is of note for this second-generation technique. Intramural
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fibroids / polyps less than 4 cms, sub-mucous fibroids and anatomical variants up to
partial sub-septated were included. Success was defined as a PBLAC score of < 75.
Success rates as defined were 77% after HTA and 82% for RBEA. Amenorrhoea rates
were 40% after HTA and 51% after RBEA at one year (percentages were of the
evaluable population). They concluded that HTA was safe and effective; it offers safety
benefits with the associated use of hysteroscopy and the potential to be performed as an
outpatient procedure. As with many new technologies technical problems may arise, and
seven HTA procedures were only partially completed secondary to technical failures.
Medium term data on the multicentre Hydro Thermablator Trial (3 year) have recently
been published. 235 276 women were randomised to HTA or RBEA. The amenorrhoea
rate at three years was 53% in the HTA group and 46% in the RBEA group. Reduction
to normal bleeding or less was reported by 94% in the HTA group and 91% in the
RBEA group. Patient satisfaction was reported by 98% in the HTA group and 97% in
the RBEA group. 16 (9%) in the HTA group and 5 (6%) in the REA group required
hysterectomy. Repeat ablation was performed in 3 (2%) of the HTA and 3 (4%) of the
RBEA. A conclusion of equivalent efficacy between HTA and RBEA was made.
Although not a primary outcome measure, 45% of the HTA procedures were performed
under local anaesthesia +/- sedation. These claims, whilst encouraging, do not support a
conclusion in an unselected population. The initial safety problems with 2 external bums
to leg / buttock in the HTA group were an initial, now rectified, design fault, with bums
secondary to contact with the then un-insulated hot saline tubing in anaesthetised
patients. Worldwide, over 10,000 HTA treatments have been reported to date.
1.3.7.7 Novasure Procedure
Novasure is a second generation device that utilises a conformable, three dimensional
bipolar gold plated mesh mounted on an expandable frame to deliver bipolar energy to
the cavity 236. The device has a disposable hand held instrument 7.2 mm in diameter that
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is suitable for cavities up to 12 cm in length. The instrument incorporates an intra-
comual measuring device retracted into a protective sheath that allows the uterine cavity
width to be measured. An adjustable sheath accommodates and protects the cervix
during active treatment preventing endo-cervical burns that can lead to haematometra
formation. Energy delivery is regulated by two factors, firstly the cavity length and
width measurements that are input to the control unit by the operator, and secondly by
the measurement of tissue impedance. The progressive vaporisation and desiccation of
the tissues caused by the electrical energy increases tissue impedance as tissue water
content diminishes. The endometrium is vaporised and evacuated by the constant suction
applied to the cavity during the procedure. The myometrium desiccates and once the
tissue impedance reaches 50 Ohms the device automatically terminates the procedure.
This tissue impedance factor allows the device to be used on unprepared uteri and even
during active menstruation by regulating energy delivery, only terminating treatment
once the tissue impedance reaches the set 50 Ohms that represents adequate treatment.
Average active treatment times are 90 seconds, representing the fastest second
generation technique. The suction applied to the cavity is constantly maintained
removing endometrial ablation by-products and ensures the endometrial tissue is well
applied to the bipolar mesh. Perforation and inadvertent energy delivery to pelvic /
abdominal contents is always a concern with blind techniques and as part of its process
prior to activation the device has a cavity integrity assessment feature. This feature
utilises carbon dioxide to insufflate the cavity to a set pressure (50 mm Hg), cavity
integrity is confirmed if the pressure is maintained for 4 seconds. A poor seal around the
uterine cervix may causes a leakage of carbon dioxide and false positive cavity integrity
check such that the machine cannot be activated. Neither pre-operative pharmacological
preparation nor immediate pre-operative hysteroscopy are required.
The Novasure device has been compared in a randomised control trial to hysteroscopic
wire loop resection plus rollerball with follow up to one year 225. Nine centres were
included in this multi-centre international trial. 265 pre-menopausal women (age 25 - 50
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yrs) were randomised in a 2:1 ratio to Novasure or hysteroscopic surgery. The
procedures were performed on unprepared uteri at any time in the menstrual cycle.
Inclusion was based on PBLAC scores > 150, regular cavity sizes 6-10 cm. Sub
mucous fibroids / polyps < 2cm that did not obstruct the cavity were included. In the
control arm the endometrium was prepared for rollerball ablation by prior loop resection.
No preparation was used in the Novasure arm. The trial was a phase III trial as part of a
submission to the United States Food and Drug Administration. The trial was funded by
the manufacturer and the possibility for bias must be borne in mind. On the plus side the
trial was multi-centre.
The amenorrhoea rate for Novasure treated patients was 41% versus 35% for the
hysteroscopic arm, success as defined as a PBLAC score less than or equal to 75
(eumenorrhoea) was seen in 88.3% and 81.7% respectively. Mean procedure times for
Novasure were 4.2 minutes versus 24.2 minutes in the hysteroscopic group (p < 0.0001).
No perforation was seen in the Novasure group whilst three were reported in the
hysteroscopic arm. Although not a primary or secondary outcome measure, anaesthetic
use (left to individual clinicians / patient preference) was recorded. 73% of the Novasure
procedures were performed under local anaesthesia +/ - sedation versus 18% under
hysteroscopic surgery.
1.3.7.8 Cryosurgical Techniques
Cryosrgical techniques have been developed. Her Option, the endometrial ablative
technique that utilises cryosurgical endometrial ablation to produce the desired effect on
the endo/myometrium. The device uses a mixed gas coolant to generate temperatures of
-90 to -100 degrees Celsius. Irreversible tissue death is seen at temperature below - 20
degrees Celsius. The device utilises a 5.5 mm probe that incorporates an electric heater,
a thermocouple and a saline flush port. Intra-operative ultrasound is required. Treatment
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is monitored with ultrasound that reveals the extent of ice ball formation and by the
thermocouple display. The leading edge of the ice front corresponds to -1 to -2 degrees
Celsius and the ultrasound image corresponds to within 1 mm of the actual depth of the
cryo-lesion 237. Instillation of 3 - 400 mis of warm saline into the bladder facilitates
ultrasound scanning. The probe is inserted in to the cavity, its fundal position confirmed
by ultrasound, and 5 mis of saline is instilled into the cavity to couple the probe to the
endometrial tissues. Treatment begins with the probe angled to the first cornue to be
treated. On average three ice balls are required, with the probe tip thawed (via the
electric heater) to allow disengagement and repositioning of the device.
Work on extirpated and pre-hysterectomy uteri confirmed ice balls seen in the range of
24 - 34 mm in the first cornue treated to 28 - 37 mm in the second, and a depth of tissue
necrosis of 9 - 12mm 238, the largest range reported by any device. This is greater than
the 6 mm required to incorporate the basal layer of the endometrium and of slight
concern as the thinnest comual region may be only 7mm in thickness.
A randomised control trial ofHer Option cryoabaltion versus rollerball ablation has been
reported. The trial was multi-centre with 279 women recruited and randomised in a 2:1
ratio to Her Option or Rollerball. Pre-recruitment PBLAC and FSH of less than 40 iu/1
were part of the inclusion criteria. Anaesthesia was at the discretion of the clinician /
patient. Success, defined as a PBLAC score less than 75 (corresponding to
eumenorrhoea), was seen in 77.3% after cryoablation and 83.8% after rollerball. 92% of
cryoablations were performed under local anaesthesia versus 46% of rollerballs. The use
of a freezing effect rather than a thermal effect as used in the other treatment options is
seen as the reason behind the large number of procedures being performed without




The use of photosensitising drugs delivered to the endometrium and then used to destroy
the sensitised tissue has been described.
5-Aminolevulinic acid (ALA) when added to many tissues, results in the accumulation
of sufficient quantities of the endogenous photosensitizer protoporphyrin IX (PpIX).
When exposed to activating light this results in destruction of the tissue. Topical ALA
application, followed by exposure to activating light (ALA PDT), has been used in a
number of dermatologic diseases. 239 Local internal application of ALA has also been
used for selective endometrial ablation in animal model systems 240 and in human
clinical studies.241
Currently there is no commercially available technology and evaluation has not
progressed past the initial case reports.
1.3.7.9 ELITT
The ELITT device utilises an intrauterine diode laser that scatters a laser beam around
the endometrial cavity. It is a non-hysteroscopic method. It is a non-contact procedure
and purports the benefit of treating irregular cavities and difficult to access areas (e.g.
the cornua) equally well. 242'243 A RCT comparison of TCRE to ELITT has been
reported. 244: Fifty-eight patients were treated with the ELITT procedure and 58 patients
with TCRE. No power study was performed and method of randomization was not
described. Endometrial preparation in both arms was with GnRH agonists. At 12 months
follow-up, 56% in the ELITT group and 23% in the TCRE group were amenorrhoeic. At
36 months, the figures were 61% for ELITT and 24% for TCRE.
The data is encouraging but at present the device is not commercially available.
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1.3.7.10 Review
The extensive evidence of the efficacy of endometrial ablative techniques is testimony to
the culture of evidence based medicine. Endometrial ablation offers high patient
satisfaction and relief of menstrual symptoms but is still inferior to hysterectomy in
these outcome measures. Ablative techniques offer rapid recovery and are more
economical than hysterectomy.
With the exception of the trials on MEA, all the above trials on second generation
methods were initiated as Phase III trials to obtain Food and Drug Administration (
FDA) approval of the device in the USA, and were under the control of the device
manufacturers (albeit with the supervision of the FDA). Trial results must be interpreted
cautiously and with this fact in mind. The FDA trials almost uniformly use highly
restrictive inclusion criteria that reduce the generalisability of the trial results with both
doctors and patients receiving financial remuneration for their involvement. The
restriction of treatment to only those women who had objective menorrhagia, restricting
treatments to only those with small regular cavities (a known positive prognostic factor)
will exaggerate outcomes when compared to treatment outcomes achievable when
treatment is applied to a clinical population. Many claim the ability to be performed
under local anaesthesia but only MEA offers RCT based evidence. The remainder offer
observational series that are inherently biased by practitioner and patient bias. Merely
saying something can be done does nothing to prove patient acceptability, satisfaction
and whether at the end of the day it should be done. To establish the suitability of
endometrial ablative techniques under local anaesthesia requires the use of adequately
powered, independent randomised controlled trials. To date only MEA offers such
evidence.
At present the most thoroughly evaluated second-generation techniques remain MEA
and Thermachoice.
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1.3.8 Uterine Fibroid Arterial Embolisation
The advances in the field of interventional radiology have created novel therapeutic
strategies for the treatment of the symptoms associated with fibroids. Improvements in
menstrual symptoms have been reported with significant reductions in objectively
measured MBL seen, an effect that is independent of the changes in uterine volume.245
Arterial embolisation, a technique that was initially utilised in the treatment of solid
tumors, obstetric haemorrhage and trauma has been developed and refined over time.
Uterine Fibroid Arterial Embolisastion (UFAE) has been demonstrated to have
beneficial effects on the size, menstrual effects and pressure symptoms associated with
uterine fibroids.
The first reported cases of fibroid embolisation as a therapeutic option was reported
from France by Ravina et al.246 It was used prior to this as a pre-operative procedure to
reduce intra-operative bleeding. The first observational series was reported by Ravina's
group in the Lancet in 1995 . 247 They reported on the first series of 16 who were on the
waiting list for open surgery treated with UFAE. With a mean follow-up of 20 months
11 patients reported resolution of their symptoms (with 10 reporting normal menstrual
cycles). Three patients reported partial improvement and two required surgery. A variety
of series has been reported, often with duplication and overlap as papers report differing
aspects of the procedure. The majority of the literature comes from the United Sates,
France and England. Most are uncontrolled series and only one RCT has been published.
The case series are prone to the biases of case selection and follow-up bias. By 2000 it
was estimated that approximately 8,500 procedures have been performed in the United
States248 with the majority of insurance companies reimbursing the procedure. In the UK
approximately 2050 UFAE have been performed by 2004 of which the majorities were
performed in London and the South West. 249 One centre in London is responsible for
1000 of the procedures.
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The technique involves usually a single puncture per-cutaneous trans-catheterisation of
both uterine arteries under fluoroscopic control, the selective identification and
catheterisation of the tortuous uterine arteries with small, steerable ( 4 French) catheters.
The desired effect is to achieve total or near total occlusions of the arteries by using a
combination of contrast agent and the occlusive agent. The most common occlusive
agent used is poly- vinyl alcohol particles (PVA). PVA particle vary in size with 300 -
500 micrometers being most commonly used for UFAE. Gel- foam biodegradable foam
can also be used as an adjunct to assist in the complete embolisation. There is no attempt
to embolise individual fibroids. To minimise radiation dosage to the ovarian tissue
modem pulsed fluoroscopy is advised utilising screening rather than diagnostic imaging.
Patient assessment prior to treatment is important. A major concern with UFAE
treatments is that the technique, unlike surgery, does not yield a pathological diagnosis.
The main concern is that a uterine sarcoma is embolised. The delay in definitive surgery,
diagnosis and the attendant adverse effect on prognosis is obvious. Uterine sarcomas are
rare comprising only 1% of gynaecological malignancies and 2-5% of all uterine
malignancies. 250 Clinically they behave differently from fibroids with their behaviour
characterised by an aggressive history, usually women in their 7th decade and arising as
a solitary tumour. The Ultrasound Image and Magnetic Resonance Image (MRI) can be
useful in making the diagnosis but false negatives occur. Cases of embolised sarcomas
have been reported.251;252> 253
All types of fibroids seem amenable to treatment with the exclusion of pedunculated
sub-serosal fibroids. Reports of bowel obstruction secondary to necrotic subserosal
fibroids 'droping off into the abdomen post UFAE have contraindicated treatment in
these circumstances.254 Infection must be excluded prior to treatment, clinically and
usually with screening swabs. Emergency hysterectomies and deaths from
overwhelming sepsis have been reported. 255"257 Future fertility is a concern with this
technique as the long-term implications are uncertain. Live births have been reported
post UFAE. 258;259 There have also been reports of amenorrhoea post UFAE with the
majority of these settle spontaneously and represent short term endometrial changes;
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however there have also been reports of permanent premature menopause mostly in
women over the age of 40 years (2% [4 of 181] in Spies series260 and 7% [ 26 of 400]
• 961 • • • •
in Walkers series ), possibly related to unintentional embolisation of the ovarian
arteries through anastomotic utero-ovarian channels.
Pregnancy post UFAE is an interesting issue. The problem with interpreting the number
of live births post UFAE is that we have no denominator and no idea how many people
were trying to achieve pregnancy. Ravina et al in their case series published in 2000
reported on 5 miscarriages in 13 subsequent pregnancies in a series of 286 (age range
21-53). 262 McLucas data from a series of four hundred women who underwent uterine
fibroid embolisation over a four year period give us reasonable data on pregnancy with
UFAE. One hundred and thirty nine patients stated a desire for fertility after
embolisation. Of these, 52 were <40 years old and seventeen pregnancies have been
reported in 14 women with five spontaneous abortions were observed. At the time of
writing up ten of the women had normal term deliveries and two women were still
pregnant. Carpenter and Walker report retrospective observational data on pregnancies
in a series of twenty-nine pregnancies in 671 women who had undergone uterine artery
embolisation by one interventional radiologist in a UK district general hospital. 263 Of
the 16 deliveries after 24 weeks, fourteen were delivered by caesarean section. There did
not appear to be any other major excess obstetric associated risk when the demographics
of the population in question is considered
The expulsion of fibroids vaginally has been reported by Park et al 264 and can be a
rather dramatic late complication.
The predictive factors affecting outcome of UFEA has been reviewed in a French
paper.265 Eighty-five women who underwent UFEA for the treatment of uterine fibroids
were followed up. At a median follow-up of 30 months 17.2% were symptomatic, with
15 requiring further treatment (eight hysterectomies, five hysteroscopic resections for
sub-mucous fibroids, one second embolisation and one woman refusing further
treatment). The predictive factors for recurrence of symptoms were fibroid size and
number. Regarding the time frame for symptom recurrence it is notable that recurrences
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occurred after two years. The relevance of late recurrences is that most of the published
observational data has follow-up periods of 12 months at the most and thus will under
report the incidence of failure and the need for further surgery.
The general lack of good quality trial data is a concern. One small RCT of UFAE has
been reported by Pinto et al. 266The vast majority of the data is retrospective and derived
from observational series. The results of REST Study a multi-centre randomised control
trial comparing surgery (myomectomy or hysterectomy) with UFAE coordinated by Dr
John Moss ofGartnavel General Ftospital are eagerly awaited.
Immediate post procedure pain requires a patient controlled analgesia pump and
inpatient care for 24 - 48 hours. Some centre advocate prophylactic antibiotics to reduce
the risk of infection but this is not evidence based. Uterine Fibroid Embolisation
Syndrome ( UFES) typically last 2-7 days post procedure and is characterized by pelvic
pain, malaise, low grade fever, nausea and or vomiting. It may be difficult to distinguish
between infection and UFES and thus many are required to be admitted for antibiotics
and observation.
NICE have issued an Interventional Procedure Guidance ( No. 94) for UFAE of
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Fibroids and systematic review commissioned by NICE was completed in March
2004.249 They comment on the general safety of the treatment in the majority but also
note the lack of data pertaining to long-term prognosis, fertility data and avoidance of
surgery. They recommend a multidisciplinary team approach incorporating the
radiologist and gynaecologist and that all treatments were logged on a database with the
Royal College of Radiologist (RCR).
The RCOG and RCR issued a joint statement in 2000 which recommended that the use
ofUFAE should be viewed as experimental; recruitment should be as part of randomised
controlled trials.
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Adenomyosis had also recently been treated with embolisation and case reports are
encouraging for a condition usually only amenable to non conservative surgery269. Many
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claim MRI is the best imaging tool for the diagnoses of adenomyosis. MRI criteria that
include diffuse or focal widening of the junctional zone as well as bright foci or linear
striations within the myometrium on T2-weighted images. On MRI, a focal
adenomyoma may appear as a localized low-signal myometrial mass with poorly defined
margins that often contain high-signal foci. The sensitivity of MRI and TV ultrasound
for diagnosing adenomyosis are comparable in the best hands. Two prospective blinded
studies using pathology at hysterectomy as the standard report sensitivities of 70 -78%
and specificities of 86 - 93% for MRI with sensitivities of 65 -68% and specificities of
65 - 98% for transvaginal scanning . 69;27°
1.3.8 Laparoscopically Assisted Vaginal Hysterectomy
Minimal access surgical techniques have been developed that allow for Laparoscopic
Assisted Vaginal Hysterectomy (LAVH). The technique allows for varying levels of
laparoscopic surgery from the dissection and securing the uterine artery pedicle to a
complete laparoscopic procedure and allows for the addition of adnexal surgery and
treatment of co-morbidities such as endometriosis. The technique has many exponents
who extol the virtue of rapid recovery and minimal abdominal scarring. Randomised
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trial data exists to expand on the previous observational series. " These trial whilst
methodologically an improvement on the observation series are unfortunately mostly
small trials, most comparing abdominal hysterectomy with LAVH , usually with single
surgeon and thus lack generalisability back to clinical practice. The limited data on
LAVH especially versus vaginal hysterectomy has been addressed in the Evaluate trial.
The Evaluate trial group headed by Professor Garry published the results of the largest
trial of laparoscopic hysterectomy in 2004. In the same edition they published an
economics paper based on the trials work.276 Two parallel multicentre trials were
reported. The first trial comparing LAVH with abdominal hysterectomy in the
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abdominal trial, the second comparing LAVH with vaginal hysterectomy in the vaginal
trial. The trial was based on 28 UK centres and two centres in South Africa looking at
major complication as the primary outcome. Major complication was defined as: major
haemorrhage (requiring transfusion); haematoma (requiring transfusion / surgical
drainage); bowel, bladder, ureteric injury; pulmonary embolism; major anaesthetic
complications; unintended laparotomy and wound dehiscence. A total of 1380 women
were recruited with 1346 receiving surgery and 937 completing follow-up at one year.
Women were eligible if they required hysterectomy, had uteri 12 weeks in size or
smaller and without significant prolapse (greater than first degree). The randomising
surgeon decided which arm - abdominal or vaginal that the patients entered into on
clinical grounds. The laparoscopic procedures were a clinically heterogeneous group
with laparoscopically assisted vaginal hysterectomy, laparoscopic hysterectomy,
laparoscopic supra-cervical hysterectomy and total laparoscopic hysterectomy included.
The abdominal arm of the trial was adequately powered but the vaginal arm was
underpowered. In the abdominal arm significantly more patients in the laparoscopic arm
had a major complication (mean difference 4.5%, 95% CI 0.9%- 9.1%) with a number
needed to treat to harm of 20. In the vaginal arm there was no significant difference in
the incidence of major complications although this arm of the trial was under powered
and the results were not significant with odds ratios spanning the nil effect. There was
no difference in the incidences of minor complications between the study arms. In the
laparoscopic arms there was a greater incidence of additional pathology identified
(fibroids, adhesions, endometriosis) with the lowest incidence in the vaginal arm. Mean
pain scores were significantly less in the laparoscopic arm versus abdominal (adjusted
mean pain score 3.9 versus 3.5, mean difference 0.5 at a p value of 0.01). There was no
difference in pain scores in the vaginal trial. The mean length of hospital stay was
shorter in the laparoscopic versus abdominal trial (3 versus 4 days) and 3 days for each
arm in the laparoscopic versus vaginal trial. Quality of life (Short Form 12) was
measured at baseline and to 12 months. All trial arms showed improvements in the
physical and mental component scores, body image scales, and sexual activity at four
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months which persisted at 12 months. There was a significant difference in body image
scores at 6 weeks in the laparoscopic versus abdominal route but this was a short term
effect with equivalent results at 4 months and no effect seen at 12 months.
The conclusions of the trial were that laparoscopic surgery was associated with a
significantly higher rate of major complications than abdominal surgery, took longer to
perform( mean 84 minutes versus 50 minutes for abdominal and 79 minutes versus 39
minutes when compared to vaginal hysterectomy). Laparoscopic surgery was
associated with faster recovery, less pain and better short term quality of life.
The economic paper published by Sculpher et al 276 in the same journal revealed
interesting features. They utilised cost effectiveness analysis at one year expressing their
results in QALYs based on the results of the health utility score derived from the EQ-5D
at four points from baseline over the year from treatment. Laparoscopic hysterectomy
cost £401 (95% CI £271 to £542) more than vaginal hysterectomy with little difference
in QALYs ( 0.015). Compared to abdominal hysterectomy it cost an average of £186
more ( 95% CI -£26 to £ 375) but this may not be significant. The higher resource use in
the laparoscopic arm when compared to the abdominal and vaginal hysterectomy arm
were related to the longer theatre time and the use of disposables. When compared to
abdominal hysterectomy this was offset by the shorter inpatient stay (mean stay 3.95 vs.
5.11 days).
The incremental cost per additional QUALY for laparoscopic hysterectomy was £267,
333 when compared to vaginal hysterectomy and £26, 571 when compared to abdominal
hysterectomy. They concluded that costs for laparoscopic hysterectomy were higher
than vaginal hysterectomy and closer but still higher than abdominal hysterectomy with
the cost per QUALY. The cost per additional QUALY limit of £30,000 set by the NHS
in other spheres of health care is breached by the comparison between vaginal
hysterectomy and laparoscopic hysterectomy and finely balanced by the comparison
with abdominal hysterectomy. A greater use of reusable equipment would present
laparoscopic hysterectomy in a more favourable light.
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A number of features of this trial deserve closes inspection and certain of these issues
have been addressed in the BJOG editorial by Chen et al.277 Caution must be exercised
before accepting the results of this RCT at face value.
Firstly issues of generalisability arise. The allocation of patients into the abdominal or
vaginal arm was made on clinical grounds. This allows the creation of allocation bias
with the more potentially difficult cases being entered into the abdominal arm, thus
skewing the complication rates in those randomised to laparoscopic hysterectomy.
Secondly is the definition of the primary outcome measure of major complication. The
outcome measures were composite and could not be equally applied to each arm of the
abdominal trial arm. An unintended laparotomy is not possible in the abdominal
hysterectomy arm. The progress to open surgery for the laparoscopic arm may be seen as
judicious surgery rather than a complication and if the complication rate was adjusted
this would cast a much more favourable light over the laparoscopic arms complication
rate. If the complication rates are adjusted to exclude unintended laparotomy then the
corrected incidences were not significantly different between the laparoscopic and
abdominal arms (7.8% versus 6.2% respectively).
Thirdly the individual surgeons in the trial were only required to have experience of 25
laparoscopic hysterectomies prior to inclusion. This does not represent the end of a
learning curve 278 for laparoscopic surgery and this difference in experience may bias the
results. This raises a training issue.
Fourthly is the heterogeneous nature of the four laparoscopic procedures grouped
together under the umbrella of 'laparoscopic hysterectomy'. The range of procedures
varied from procedures that were the most technically challenging with a complete
laparoscopic hysterectomy with all pedicles taken and the vagina opened
laparoscopically to the least invasive procedure of laparoscopic subtotal hysterectomy.
Overall the validity of utilising a RCT to address complication issues is questionable as
a study of this kind will always be underpowered to accurately comment on rates of
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complications. The trial does allow accurate estimation of effectiveness as measured by
differences in QOL scores.
The ACOG recent advice on laparoscopic hysterectomy advises the technique used for
hysterectomy should be dictated by the indication for the surgery, patient characteristics,
and patient preference. Most patients requiring hysterectomy should be offered the
vaginal approach when technically feasible and medically appropriate. If specific
additional procedures that can be completed laparoscopically are anticipated before
surgery, laparoscopically assisted vaginal hysterectomy may be an appropriate
alternative to abdominal hysterectomy. The benefits of laparoscopically assisted vaginal
hysterectomy must be weighed against the potentially increased risk and expense of two
distinct operative procedures, laparoscopy and vaginal hysterectomy.279
1.3.9 Subtotal Hysterectomy
The first recorded hysterectomy was a subtotal procedure performed by Charles Clay in
1843.167 This procedure remained the chosen method of abdominal hysterectomy for
benign indications until the 1950's when the total abdominal hysterectomy
predominated. In the 1980's a resurgence in the interest in subtotal hysterectomies
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occurred fuelled by the work on urinary and sexual function by Kilkku " and the
emerging evidence of the long term efficacy of the cervical screening programme. The
procedure benefits from the reduced operative time and morbidity associated with
preservation of the cervix uteri. A laparoscopic procedure is also possible.283 The
drawbacks of the procedure are the small numbers who will suffer from light bleeding /
spotting from residual endometrial tissue high in the endocervical canal and the fear of
cervical cancer in a cervical stump. Hysterectomy rates vary regionally and nationally,
so to do methods and the ratio of total abdominal hysterectomy to subtotal
hysterectomy.166;284 A significant decrease in total abdominal hysterectomy and an
significant increase in the proportion of subtotal procedure is seen in the US data by Sills
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et al.285 However, 99% still remain total abdominal procedures. Danish data by Gimbel
et al revealed a similar trend to the US data.286 In the Finish data revealed by Vuorma et
al the ratios remained static. 287 Overall looking at national figures the Scandinavian
countries have the highest ratio of subtotal to total procedures with Sweden having
(0.56), the smallest reported ratio is in the UK (0.04).284A postal questionnaire of British
gynaecologists reported in 1998 by Thakar et al revealed subtotal hysterectomy to be an
unpopular procedure in the UK, with seventy eight per cent of female gynaecologists
preferring a total hysterectomy for themselves.
Comparisons between the total and subtotal procedure have been made with respect to a
variety of outcome. Urinary symptoms, bowel symptoms, pelvic organ prolapse and
effects on sex life are assessed.
Urinary incontinence has been assessed in a number of trials.289"291 The trials vary in
size and methodological soundness. The two largest RCT by Thakar and Gimbel give
the best quality of evidence. Thakar et al 289 compared subtotal to total hysterectomy in a
double blinded RCT involving 279 women followed up for one year. There was no
significant difference in urinary frequency between procedures at one year. Both arms
showed a reduction in frequency, nocturia and stress incontinence. The frequency of
bowel symptoms and measures of sexual function did not change significantly in either
group after surgery. The women in the subtotal-hysterectomy group had a significantly
shorter hospital stay and a significantly lower rate of post operative pyrexia. In the
subtotal arm seven percent ofwomen had cyclical bleeding and two percent had cervical
prolapse. They concluded that neither method of hysterectomy adversely affects pelvic
organ function at 12 months with subtotal hysterectomy resulting in shorter recovery and
fewer short-term complications. The largest trial to date, the Danish RCT by Gimbel et
al 292 reported on 349 women randomised to total abdominal hysterectomy (n = 158) or
subtotal abdominal hysterectomy (n = 161). Analysis was by intention to treat. A
significantly smaller proportion of women had urinary incontinence (the primary
outcome) one year after total abdominal hysterectomy compared with subtotal
abdominal hysterectomy (9% vs. 18%) [OR 2.08, 95% CI 1.01-4.29)]. Twenty-seven
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women (20%) from the subtotal abdominal hysterectomy group suffered vaginal
bleeding. Two required removal of the cervix. There was no clinically important
differences found between the two hysterectomy methods with respect to the incidence
of post-operative complications, quality of life scores (SF-36), constipation, prolapse,
satisfaction with sexual life or pelvic pain. This study is the largest to date and
methodologically sound and the results are interesting going against the perception that
subtotal procedures give rise to less bladder symptoms, long term follow up would be
very interesting.
"7Qn,TQ')
Between 5-20% of women with subtotals will have cyclical bleeding. ' whereas all
will be amenorrhoeic after a total procedure. A variety of techniques have been deployed
to reduce this number from simple techniques as diathermy to the canal through to
radical conisation of the cervix but even then up to 11% will still report symptoms of
bleeding.283
The incidence of pelvic pain in the literature shows no significant difference between
techniques with a generalised reduction in pain seen with both techniques, a similar
pattern is seen with respect to quality of life parameters.289'292"295
Intuitively one would think that pelvic organ prolapse would be less common after a
subtotal procedure as the cervix retains the uterosacral and cardinal ligament complexes.
The evidence points to no significant difference but with a trend favoring total
abdominal hysterectomy.284
The postulated role of the cervix uteri in the physiology of the female sexual response
and orgasm in particular has fueled some of the interest in the subtotal procedure. A
number of studies of subtotal versus total hysterectomy have reported on sexual
functions as an outcome. ' Various parameters including frequency of
coitus, dysparunia, orgasm and satisfaction with sexual function have been assessed. The
initial work by Kilkku suggested a beneficial effect of subtotal however further
randomised and observational studies289;296;297 have reported no significant difference
between the two methods has been found with regards to sexual function. The work of
Zobbe et al 296 revealed the predictors for satisfaction with sexual life after hysterectomy
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to be a satisfactory preoperative sex life , a good relationship with partner, physical well-
being and the use of hormone replacement therapy. Many studies on hysterectomy
reveal a reduction in post operative dysparunia with hysterectomy whether total or
subtotal.
Overall it would appear that as a procedure subtotal hysterectomy has a lower blood loss
than total, takes a shorter time to perform and has less peri and post operative
complications (especially pyrexia). On the down side it has a worse effect on bladder
function than a total procedure and is associated with a not insignificant incidence of
stump related problems. There is no significant difference on the sexual function of
patients post total or subtotal hysterectomy.
1.3.11 Conclusion
A number of surgical treatment options are available. Hysterectomy in its various forms
remains a very effective treatment for menorrhagia with the highest recorded levels of
patient satisfaction but it is associated with a number of common minor complications
and a not insignificant number of serious complications. The ever expanding variety of
endometrial ablative techniques offer quick easy to leam procedure with high levels of
patient satisfaction and a high likelihood of avoiding hysterectomy in the long term.
Some offer the ability to be performed under local anaesthesia but few have ever
demonstrated this as a primary outcome measure in an adequately powered RCT.
Uterine Artery Embolisation offers good relief of a number of symptoms of fibroids but
seems particularly good at relieving menstrual symptoms possibly through a local
endometrial effect.
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1.4 MICROWAVE ENDOMETRIAL ABLATION - AN OVERVIEW
Microwave Endometrial Ablation (MEA ™) has evolved from a theoretical technology
into the most evidence based second generation ablative technology available today.
The purpose of this chapter is to review the scientific basis, evidence base, safety and
clinical applications of this ablative technology.
1.4.1 MEA- Scientific Basis and Technical Aspects
Microwaves are part of the electromagnetic spectrum of energy lying between radio
waves and infra-red. Microwaves have a wavelength between 0.3 to 30cms and a range
of frequency between 300 and 300 000 MHz.
On transmission to tissue the microwave energy causes the water molecules to rapidly
change polarity, the resulting oscillations generate thermal energy that results in the
clinical effect.
The effect of any thermal energy on a tissue is dependant on the temperature achieved
with progressive changes seen in proteins through to irreversible cell death.
The depth of penetration of the microwaves thermal effect is determined by the duration
of application, the water content of the tissue and the frequency and wavelength of the
microwaves.
All ablative techniques share the ultimate aim of destroying or removing the basal layer
of the endometrium. This results in a therapeutic Ashermann's syndrome, alleviating
menstrual symptoms. This basal endometrium extends 3-4mm into the myometrium in
pharmacologically prepared uteri.168 The depth of destruction must therefore extend to
4mm, however it must be limited as the total wall thickness in the corneal region may be
as little as 6mm.
Any energy source that causes destruction to a greater depth runs the risk of thermal
energy reaching the serosa and causing injury to intra-abdominal structures, with the
small bowel being most at risk of injury.
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Microwave Endometrial Ablation ( MEA™ ) utilises an 8 mm diameter probe that
delivers microwaves of a set frequency of 9.2GHz.
The microwave frequency and wavelength utilised in MEA was specifically chosen so
that the total depth of thermal effect matched the endometrial thickness but did not
exceed total wall thickness. The power delivered to the tissue is only around 20 watts,
approximately equivalent to the energy used to power one small light bulb.
The selected microwaves result in a predictable 3mm depth of direct microwave
penetration and a further 2mm depth of thermal transmission. Thus in total a reliable
5mm depth of penetration can be achieved. The microwaves radiate from the tip of the
probe in a hemispherical array. The probe itself consists of an aluminium tube which
delivers through a ceramic dielectric wave guide the microwave energy that is generated
in the magnetron (microwave generator). The energy is radiated in a dielectric
hemisphere at the tip of the probe. The probe has two thermocouples, one at the tip to
measure the temperature at the tissue surface and a second 10 cm down the shaft of the
probe to measure any reflected energy and ensure the shaft does not overheat. The
temperature at the tip of the probe is relayed to the microwave unit and displayed as a
continuous visual temperature display. This allows the operator to guide treatment of the
cavity and maintain the temperature within the therapeutic range of 70 to 80 degrees
Celsius that results in endometrial and superficial myometrial cell death. The continuous
temperature monitoring also serves as a safety feature in that if temperatures of above
85 degrees Celsius occur an audible alarm will sound and an automatic shut off of the
generator will occur once the temperature reaches 90 degrees Celsius. The probe itself is
a reusable single piece device that is 338 mm long and 8.5 mm in diameter at the shaft.
The probe is covered in a polymer - FEP (Flurinated Ethylene Propylene). The shaft is
marked with graduations in whole centimetres. For a distance of 35 mm from the tip a
black band extends to indicate the endocervical canal. A yellow band extends for 7mm
below the black band and indicates that the tip of the probe is immanent to prevent
haematometra formation that can arise from inadvertently treating the endocervical
canal. The MEA applicator is attached to the MEA system by two cables. The first is the
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coaxial cable that carries the microwave energy from the microwave generator to the
MEA probe and a second data cable that relays continuous information from the
thermocouples to the consol display and communicates with the chip inside the
applicator that stores treatment data and records the number of treatments (set at a
maximum of 30 treatments)..
Human endometrium has very high water content and in this respect is very similar to
animal liver. A tissues water content is a key factor in the depth of penetration of the
microwaves and animal livers provide an ideal model to simulate the clinical effects of
microwaves. The initial work on animal livers revealed the predictable depth of
penetration of the thermal effect.
In vitro work was progressed to extirpated post -hysterectomy ( non-perfused and
perfused) uteri utilising vital staining techniques to assess depth of penetration of
thermal effect.
A total of 4 non perfused uteri were treated with power settings of 18 watts and
treatment times varying between 360 seconds and 510 seconds.298 Thermocouples
measured the temperature at the endometrial and serosal surface. The specimens were
processed to assess degree of coverage and the depth of cell death measured using a
nitro-blue tetrazolium vital staining technique. From this work it was established that it
was possible to limit the depth of necrosis to 5-6 mm without raising the serosal
temperature.
Work on 8 extirpated perfused uteri to simulate the heat sink effect of uterine blood flow
was performed.298 This time the power level was varied between 12 and 60 watts over
90 - 960 seconds. The vital staining tests confirmed established that there was no effect
on depth of necrosis from blood perfusion. Pre-hysterectomy specimens were utilised
with thermocouple monitoring of serosal temperature to establish safety and efficacy in
vivo before the first clinical trial on patients.298 In total 16 pre-hysterectomy treatments
were performed with power levels varying between 30 and 48 watts and treatment times
varying between 137 and 300 seconds. In these in vivo experiments the bowel was
packed away and thermocouple placed on the serosa. No rise in temperature was
recorded at the serosa and pathological assessment with vital staining was performed. A
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further 3 cases were performed in vivo with the power settings at 30 watts and 40 watts
to confirm adequate treatment depths without serosal heating.298
From this human data and the animal data the optimal frequency and power settings
were selected - 9.2 GHz with an operating power of 42 watts that translates into a tissue
power delivery of around 20 watts.
1.4.2 Endometrial Preparation
Pharmacological endometrial preparation can be used prior to MEA but unlike first
generation technique it is not an essential. Preparation does allow a predictably thin
endometrium, the scheduling of procedures to theatre lists and may improve outcome.
The initial RCT evidence from work by Bain and Cooper299 reported on results using
Goserelin ( Zoladex) as endometrial pre-treatment in both the MEA and TCRE arms.
The centre at Bath reported on utilising suction curettage as a pre-treatment but this is
not to be recommended as it may result in unrecognised uterine wall damage (partial
perforations / full perforation). The reported bowel injuries shortly after the release of
the device into the Australian market is, it is alleged, blamed on a combination of the use
of suction preparation, poor training and supervision. Danazol and Goserelin have been
used in RCT comparison ofMEA under general anaesthesia and local anaesthesia 300
Whilst some ablative techniques such as Novasure can be used at any stage in the
menstrual cycle this does not apply to MEA. Data from Wallage et al301 established that
MEA effectiveness will be reduced if the endometrial thickness is greater than 10 mm.
Post menstrual treatments can be performed in the immediate post menstrual phase when
the endometrium is thin after either natural or hormonally induced menstruation.302
Current practice at Aberdeen Royal Infirmary is to treat patients after 10 days of
medroxypregsterone acetate (Pharmacia, Pfizer Ltd, UK) lOmg twice a day by
mouth.The treatment is stopped 10 days prior to the procedure to time menstruation and
allows predictable endometrial thickness.
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1.4.3 Procedure
Suitable patients are those complaining of excessive menstrual bleeding with a
completed family, histologically assessed normal endometrial pathology and a cavity
length between 5 and 12cm. Previous myomectomy, classical caesarean section,
endometrial malignancy or atypia and active pelvic inflammatory disease are
contraindications to treatment. As no fluid distension media is utilised there is no risk
of fluid overload and the technology is a blind technique.
Endometrial polyps and non-obstructing sub-mucosal fibroids up to 3cm can be
included. Patients require to be fully counselled regarding the nature of the procedure
and the clinical outcomes. As with all ablative techniques patients must accept
eumenorrhoea as the desired outcome. If amenorrhea is the priority then hysterectomy is
to be recommended.
The procedure itself is preceded by an ultrasound scan to measure myometrial wall
thickness. A minimum of 10mm thickness to the anterior uterine wall is required before
the procedure can be considered. There is a safety concern regards women with a
previous lower segment caesarean section having thin anterior uterine walls which
resulted in the requirement of an ultrasound scan to show the anterior wall thickness is
10 mm minimum being made by the manufacturers.
As with all ablative technologies patients must be aware of the risk of future pregnancy
is such that further pregnancy is not advised and reliable contraception is required post
procedure. Concomitant laparoscopic sterilisation can be offered to those undergoing
general anaesthesia.
Patients are pre-medicated with a lOOmgs of Voltarol ( Diclofenac Sodium, Novartis
Pharmaceuticals UK Ltd) suppository per rectum one hour pre-operatively. In those with
contra-indications to NSAIDS 1 gm (P.R.) paracetamol can be used instead. The
technique can be performed under local anaesthesia +/ - conscious sedation or general
anaesthesia. The evidence for this will be discussed later in this chapter. The technique
of local anaesthesia is that of a four quadrant cervical block (2, 4, 8 and 10 o'clock)
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starting posteriorly. 2.2 ml Citanest 3% with felypressin 0.03 unit/mL (Citanest with
Octapressin, Dentsply UK) ampoules are delivered to each quadrant through a dental
syringe and a 35 mm needle.
Midazolam (to a maximum of 4mg) can be titrated pre / intra-operatively to provide
conscious sedation. Intra-operative analgesia 25 - 50 micrograms of Fentanyl (I.V.) can
be used if required to achieve short acting rescue analgesic effect. Heart rate and oxygen
saturation require to be monitored intra-operatively if sedation and or analgesia are
utilised.
The cervix dilated to 9 Hagar, cavity length established and hysteroscopy performed.
The cavity must be confirmed as intact and both tubal ostia should be seen to exclude for
certain the possibility of a false passage. The utility of ultrasound to ensure correct intra¬
cavitary placement is not to be recommended. Whilst USS allow for detection of full
thickness perforation it will not identify false passage formation or partial thickness
perforation. The probe is inserted gently into the cavity and the graduated measurements
on the probe must agree with the measured cavity length before treatment can be
commenced. The foot pedal is activated once the probe tip temperature of 30 degrees is
achieved. The temperature rises is monitored by the control unit and effectively gated by
comparing it to data from thousands of previous uncomplicated treatments. Failure to
achieve a satisfactory thermal gradient or deviation from the gated results in an
automatic shut down and requirement for hysteroscopy to exclude false passage or
perforation. Once the probe reaches 50 degrees Celsius the operator is instructed to
begin a gentle fundal sweeping action and once in the therapeutic band of 70 -80 degrees
Celsius the cavity is then treated, moving the probe from side to side whilst gradually
withdrawing the probe to treat the whole cavity. It is undesirable to treat the uterine
cervix as this may result in cervical stenosis and haematometra formation on those who
continue to menstruate. The tip of the probe is black for a distance of 3.5 cm from its
distal end with a yellow band extending for 7mm proximally. The approach of the
internal os corresponds to a yellow band appearing at the external os. Treatment is
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terminated when this yellow band ends and prior to revealing the black tip of the probe.(
See Fig 1.)
MEAJB1JO_02_STREAMOAD_
Fig 1 Microwave Endometrial Ablation .
Top right applicator in position. Bottom right instrument display. Left schematic
diagram.
1.4.4 Evidence Basis
The initial observational study describing the first 43 women treated with the
experimental probe. These first treatments were reported in a paper by Sharp et al from
the Royal United Hospital, Bath, UK in 1995.303
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All women received endometrial preparation ( Danazol 800mgms per day or a single
Zoladex implant for 4 weeks prior to surgery). The mean treatment time was 2 min 12
sec (range 50-310 sec). 6 months after treatment the quoted success rate was 83%, 13
patients (57%) were amenorrhoeic, and six (26%) were experiencing light menstruation.
They reported the technique as safe and easier and quicker to perform than current
alternatives.
The paper was followed up with a second paper published in 1999 that included clinical
follow up to 3 years. 304 The treatments were performed between October 1994 and
April 1995, all patients had failed to respond to medical treatment. Follow-up
assessment was by a statement of perceived menstrual loss and satisfaction supported by
a menstrual symptoms questionnaire score. The rapid technique (mean treatment time of
141 seconds reported) was much faster than comparable first generation ablative
technologies. Amenorrhea was observed in 37% and very light periods/discharge was
seen in 26 %. Overall satisfaction at three years was reported as 84 %. Significant
reductions in dysmenorrhoea were reported at three years. Three re-treatments and four
hysterectomies had taken place by three years. The technique was also described as
easier to leam with a very short learning curve avoiding the risks of fluid overload,
operative haemorrhage and earthing problems.
In the age of evidence based medicine no matter how promising the results of an initial
study, any claims made based on observational non-randomised data requires to be
backed up with good quality evidence. Ideally this should be from methodologically
sound randomised controlled trials. This evidence will be reviewed.
1.4.5 Comparison to Gold Standard
The 'Gold Standard' for ablation technology is Trans Cervical Resection of the
Endometrium (TCRE). This technique has been validated against hysterectomy in a
number of trials. MEA™ has been compared to TCRE in a randomised control trial by
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Cooper et al.223 Follow-up data at one, two and long-term data to 5 years will be
discussed.
The study randomised 263 women referred for endometrial ablative surgery to MEArM.
The study was powered to give 80% power of demonstrating a 15% difference in
satisfaction with treatment. All procedures were done under general anaesthesia after
endometrial thinning. At 12 months, 89 (77%) women in the MEA group and 93 (75%)
in the TCRE group were totally or generally satisfied with their treatment and 109 (94%)
versus 112 (90%) found it acceptable.
Despite very rapid TCRE procedures the mean operating times were significantly shorter
for MEA™ than for TCRE (11.4 vs. 15.0 min, p=0.001) and the postoperative stay
slightly but not significantly shorter. Quality of life data was assessed using SF-36. Of
the eight health-related quality of life dimensions, all were improved after MEA™ (six
significantly) and seven were improved after TCRE (all significantly). Both techniques
achieved high rates of satisfaction and acceptability and both improved quality of life
after 1 year. However the study was inadequately powered to exclude a difference in
satisfaction between the groups of less than 15%.
Follow-up to 2 years by Bain et al revealed durable results with 249 (95%) of the
original patients returning questionnaires at 2 years. 299 Menstrual status in both groups
was similar, although the amenorrhea rate was higher after microwave endometrial
ablation. Seventy-nine percent of women were either completely or generally satisfied
after microwave ablation compared with 67% after transcervical endometrial resection.
Health-related quality-of-life scores remained higher than at recruitment for both
treatments. Hysterectomy rates were similar at 2 years (11.6% after microwave
endometrial ablation and 12.7% after transcervical endometrial resection), and no repeat
endometrial ablative procedures were required.
Recent long-term data to 5 years was presented initially as a conference proceeding at
the America Association of Gynaecological Laparoscopists in Las Vegas in November
2003 and subsequently published.305 A total of 236 (90%) were followed up to 5 years
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(116 MEA™ arm, 120 TCRE arm). Menstrual status in both groups was similarly and
significantly improved. Amenorrhea was reported by 65% after MEAim versus 69%
after TCRE (p = 0.751). Significantly more women reported themselves totally or
generally satisfied with MEA™ compared to TCRE (86% percent versus 74%, p=
0.017). Significantly more women in the MEA™ arm reported their treatment as
acceptable (97 % vs. 90%, p= 0.03). Health-related quality-of-life scores remained
higher than at recruitment for both treatments. Hysterectomy rates at 5 years were 16%
after microwave endometrial ablation and 25 % after transcervical endometrial resection
(p= 0.09).
They concluded that Microwave endometrial ablation is an effective long-term
alternative to transcervical endometrial resection for dysfunctional uterine bleeding.
1.4.6 Local Anaesthesia versus General Anaesthesia
The evolution of ablative technologies includes the assessment of the technologies under
different anaesthetic regimes. General anaesthesia is the predominant anaesthesia
utilised with first generation technologies of TCRE, Rollerball Endometrial Ablation and
Endometrial Laser Ablation. The rational of moving to a local anaesthesia treatment
includes the benefits to a healthcare system and its recipients of freeing up theatre /
anaesthetic time and staff and the proven safety benefits of local over general
anaesthesia. The move to local anaesthesia if proved possible would be a keystone in the
development of an outpatient treatment. First however the suitability of a technology
under local anaesthesia must be demonstrated on an unselected population in a
adequately powered randomised controlled trial with acceptability as the primary
outcome.
Many ablative technologies can claim that they can be performed under local
anaesthesia but lack robust evidence based on RCT evidence in an unselected non biased
population.
Wallage et al assessed the suitability of MEA ™ with women randomised to local
anaesthesia (L.A.) or general anaesthesia (G.A.).300 The trial included a patient
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preference arm where patients were allocated their anaesthesia of choice. All patients
received pharmacological endometrial thinning (Zoladex or Danazol) and were
performed in the operating theatre. This trial addressed the key questions of whether it
was possible to perform MEA ™ on unselected patients and whether patients found it
acceptable. 180 patients were required to give be randomised to give a 85% power to
detect a 15% reduction in acceptability. The level of acceptability was derived from a
known acceptability of 93% for women under general anaesthesia generated by a
previous RCT. 322 procedures were completed in the trial.
91% of treatments commenced under L.A. were completed under L.A. Women with a
preference for local anaesthesia were especially likely to be completed under local
anaesthesia. In conclusion 69% of women would consider MEA ™ under local
anaesthesia ( either expressing a preference or willing to be randomised to L.A. ), 87%
of patients found MEA ™ under L.A. totally or generally acceptable and post operative
recovery details (time to discharge, nausea, analgesic use, return to work or normal
activity) were similar for both L.A. and G.A. Despite this only 75% of those randomised
to L.A. would have their treatment the same way, significantly less than those
randomised to GA (88%).
When analysing factors that predicted success under local anaesthesia they looked at
baseline hospital anxiety and depression scores, previous vaginal delivery,
dysmenorrhoea scores and previous LLETZ (Large Loop Excision of the
Transformation Zone). None of these factors predicted success under L.A. This study
revealed the potential of the technology to be performed acceptably under local
anaesthesia and opened the door to the possibility of moving the technology out of
theatre into the outpatient department.
1.4.7 Assessment of Outpatient Post Menstrual Treatment.
The author undertook a randomised controlled trial to evaluate outpatient post menstrual
treatment under local anaesthesia which will be discussed in a subsequent chapter.
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1.4.8 Comparison to IUS
As ablative technologies have moved towards treatment under local anesthesia often in
an outpatient setting it becomes increasingly valid to make comparisons to the Mirena
Intrauterine System. A study by Henshaw et al in Southern Australia compared MEA™
with Mirena in the management of heavy menstrual bleeding.306
The conclusions from this study are limited by the study design which was a
retrospective cohort study. Thirty-nine women were treated with MEA ™ and 23
women with Mirena, with the mean duration of follow-up to 14.6 months. Acceptability
of the treatment process and satisfaction with outcomes was very high for both
procedures. Each treatment led to a statistically significant reduction in menstrual
bleeding (p < 0.0001) and dysmenorrhoea scores (p < 0.002). There were no statistical
differences between the two treatments for any of the primary or secondary outcome
measures assessed (Primary measures included acceptability of the treatment process,
effectiveness of the treatment, and satisfaction with outcomes. Secondary measures
included side effects, complications and quality of life [ SF-36]).
They concluded that the treatments seem equally effective in the management of heavy
menstrual loss.
Prospective adequately powered randomised controlled trials are desperately needed to
compare Mirena IUS with MEA ™. Unfortunately they are very difficult to recruit for
and as Rogerson et al discovered in the SMART trial. 307 The SMART trial was multi-
centred and methodologically sound and should have by rights succeeded but for the
unexpected strong preferences expressed by women approached for either IUS or
ablation such that the women would not accept random allocation.
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1.4.9 Safety
The safety of any endometrial ablative technologies is crucial. The safety of first
generation endometrial ablative technologies has been established in two national audits
reported (Mistletoe study and Scottish Hysteroscopy Audit Group 173;210). The second
generation technologies are not yet sufficiently widespread and complications too
infrequent to allow for large national audits and thus safety data must come from smaller
audits, prospective series and case reports. Parkin reported 308 a prospective series of
1400 consecutive cases. The data covered 13 gynaecological units in the UK and
Canada. Out of 1433 cases one major complication of small bowel damage occurred
giving an incidence of 0.7/1000. There were few minor complications and he concluded
that MEA™ appeared at least as safe if not safer than first generation hysteroscopic
methods. A satellite symposia held in conjunction with the American Association of
Gynaecological Laparoscopists 32nd Annual Meeting commented on the safety of second
generation ablative technologies in general and MEA ™ in particular. 309 The MAUDE
database of the United States Food and Drug Administration 310 was analysed in July
2003 and revealed 46 reports of bowel injury associated with the Thermachoice device,
2 associated with the HerOption, 1 with the Hydrothermablator and 9 with Novasure.
The incidence of major adverse events in the over 18,000 MEA ™ treatments to date
was reported as 27 cases (22 bowel injuries). It would appear that no ablative technology
is without risks. The sub-analysis of the 27 adverse events with MEA ™ reported that 4
(15%) of the cases were contra-indicated (e.g. repeat MEA ™ , endometrial pre-
treatment suction aspiration, treatment continued despite discrepancy between measured
cavity length and probe depth), 3(11%) would have been screened out as unsuitable by
ultrasound measurement of uterine wall thickness, 19 ( 70%) could reasonably be
expected to have been picked up by post dilation hysteroscopy and 1 remained
undetermined (salpingitis). The effect of improved operator training and revised
manufactures instructions for use resulted in 6640 treatments without incident between
November 2002 and July 2003.
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1.4.10 Assessment of MEA versus Fluid-filled Thermal Balloon Ablation-
the NICE Report
The National Institute for Clinical Excellence (England and Wales) has recently
published its Technology Appraisal Guidance No 78.311 The guideline was based on the
evidence submitted both by device manufacturers, expert groups/ bodies and the
Assessment Group by the Garside et al of the Peninsular Technology Assessment Group
of the Universities of Exeter and Plymouth, UK.312
This guidance asserts that both fluid filled balloon ablation (Thermachoice / Cavatherm)
and Microwave Endometrial Ablation are recommended as treatment options for heavy
menstrual bleeding when a woman and her clinician decide that surgical treatment is
indicated. The similar abilities of both technologies to restore periods back to a normal
level (eumenorrhoeia) were stated. The versatility ofMEA over a wider range of cavity
types ( 5-12cm cavity lengths / polyps / non-obstructing fibroids up to 3cm) was noted
with Thermal Balloons being restricted to 4-10cm regular cavities. The higher
amenorrhoea rate associated with MEA™ was noted. The individual indications for each
technology were reviewed and it was recommended that the decision as to which
treatment to use was to be made jointly by the woman and the clinician responsible for
treatment. The decision should be made after an informed discussion taking into account
the desired outcome of the treatment (such as reduced menstrual bleeding or complete
cessation of menstrual bleeding [amenorrhoea]), the relative benefits of all other
treatment options and the adverse events associated with them, as well as the clinical
condition, anatomical suitability and the individual preferences of the woman.
The Assessment Group's economic assessment utilized a Markov model, which
examined the progress of six hypothetical cohorts of women with HMB treated
separately by TBEA, MEA, TCRE, TCRE and RB, RB, or hysterectomy. Taking the
perspective of the NHS they calculated incremental cost utility between different
treatment options over a 10 year period. This model concluded that the second-
generation techniques (MEA and TBEA) are more cost effective than the first-
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generation techniques (TCRE and/or RB). Although base-case analysis showed that
TBEA dominated MEA, the overall differences in costs and utilities were negligible, and
moreover the results were sensitive to small changes in utility values.
In the NICE assessment they estimated that 26,000 hysterectomies are performed in the
UK each year for menorrhagia and a further 16,000 endometrial ablations are carried
out, of which about 2000 are performed using second-generation techniques. The
Assessment Group estimated that if all hysterectomies were replaced by EA, the annual
cost saving would be of the order of £29 million, (divided 50: 50, first generation: TBEA
/ MEA). Under a hypothetical scenario of all hysterectomies being replaced by second-
generation endometrial ablation techniques, the cost saving would be even greater at
more than £32 million per annum.
They commented on the lack of head to head comparisons between the two second
generation technologies. A Randomised Controlled Trial funded by the Chief Scientist
Office comparing the two technologies is in progress in Aberdeen and due to report in
2006/7.
1.4.11 Conclusion
The technology of Microwave Endometrial Ablation has solid evidence based in
pragmatically designed randomised controlled trial data. The treatment is approved of by
the National Institute for Clinical Effectiveness. The technology is suitable for the
majority ofwomen who present with the complaint of excessive menstrual bleeding. The
treatment is effective and acceptable to patients giving high levels of reported
satisfaction. It has long term follow-up data comparing it to the gold standard of TCRE
and has been proven in RCT's in a variety of clinical scenarios and situations under
general anaesthesia, local anaesthesia and post-menstrually in an outpatient environment
without loss of clinical or economic effectiveness
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Summary of Chapter 1
The published literature reviewed in chapter 1 demonstrates the body of knowledge thus
far as it relates to excessive menstrual bleeding, its epidemiology, aetiology and
treatment options -both medical and surgical.
There are a number of areas that require further assessment. The question of where
ablative procedures stand in the hierarchy medical and surgical treatment options for
menstrual problems remains to be answered. There is a complete lack of long term data
on the outcome of patients managed medically for their menstrual problems and this gap
in knowledge needs to be closed. These questions will be addressed in chapter 2 which
looks at the long term outcome ofwomen randomised to medical treatment or TCRE.
The established evidence for first generation ablative techniques has been presented.
MEA has been already been compared in a RCT to endometrial resection (TCRE).
TCRE is not the commonest ablative procedure world wide. In many countries and in
North America in particular rollerball (RBEA) remains the most popular method of
ablation. A randomised comparison ofMEA and RBEA is desirable and this is presented
in chapter 3.
Outpatient treatment was never feasible with 1st generation technologies however many
see it as a natural progression for many of the 2nd generation techniques with the
attendant benefits on precious healthcare resources. Before such treatment is established
it needs to be assessed in a RCT to assess outcome in a non biased and unselected
population. Patient centred outcome measures of acceptability and satisfaction with a
treatment require to be proved as does the economic impact. A randomised comparison
of MEA in both standard treatment under GA and treatment in a genuine outpatient
environment will be assessed in Chapter 4.
The impact of endometrial ablation on hysterectomy rates is often disputed. Some argue
that ablative procedure only delays the inevitable definitive surgery of hysterectomy and
as such 'interim operations' will only increase the health service costs in the long-term.
This impact is assessed both locally (Grampian) and nationally (Scotland) in chapter 5.
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CHAPTER 2
Five-year follow-up of women randomised to medical management or
transcervical resection of the endometrium for heavy menstrual loss;
clinical and quality of life outcomes.
2.1 Introduction
Twelve percent of all referrals to a gynaecologist are for the complaint of heavy
menstrual bleeding 313 whilst the estimated cost to the National Health Service of
medical treatment for the complaint in the UK in 1995 was £7 million 10°. There is
considerable uncertainty about how best to treat women suffering from excessive
menstrual loss with the numerous medical treatments available failing to control a high
and rising hysterectomy rate in the UK. Figures from an observational study by Coulter
et al 314 revealed that within five years of referral to a gynaecologist with menstrual
problems 60% of women will have a hysterectomy and only 12% are maintained on
medical treatment.
The majority of medical trials of treatments for menorrhagia take an explanatory rather
than pragmatic format. The trials are uniformly short in time scale (prior to the 2 year
follow up of this study there was no RCT trial data on medical treatment longer than 6
months).
The majority of trial data on medical treatment involves only 2 to 3 cycles of active
treatment before cross over to either placebo or an alternative medical
therapy53;124;134;135. These trials have inclusion criteria that restrict the trial data to
women with objective menorrhagia as estimated by either PBLAC or the Alkaline
Haematin Test. As a result generalising the trial results back to a clinical population
where up to 50% may have subjective menorrhagia is dubious.
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It is well established that excessive menstruation has a deleterious effect on a sufferer's
quality of life15;181. Coulter et al reported data from primary care.315 They performed a
prospective cohort study of patients consulting a general practitioners complaining of
excessive menstrual bleeding. Patients managed medically were significantly more
likely to be dissatisfied with their treatment than those in the surgical group (21% vs.
5%). Those with severe symptoms gained no benefit in quality of life if treated
medically whereas those in the surgical arm experienced significant improvement.
Despite the known deleterious effects on quality of life there is a paucity of data on the
long term effect of medical treatment on a patient's quality of life. Outcome measures
used in the existing medical trials focus on the reduction in measured blood loss, drug
associated side effects and subjective reduction in bleeding. This study will assess the
long-term satisfaction, acceptability and quality of life outcomes in both the medical and
surgical arms. Rates of subsequent surgery will be evaluated.
Endometrial ablation has been established as an effective alternative to
hysterectomy188;189;191;193. Two major national audits have confirmed the safety of the
technique 173;210 Long term data are available from one randomised trial assessing
hysteroscopic surgery 192, for women who were initially referred for hysterectomy.
Despite the many benefits of ablative procedures not everyone is convinced of the merits
of wide spread usage of the technology. Concerns that it may in actual fact increase the
hysterectomy rate rather than decrease it , possibly through an effect of lowering the
threshold for surgery316;3!7.
The purpose of this trial was to assess the long term follow up of the original trial
participants. Short ( 4 months) and medium term (two years) results comparing medical
management with TCRE have been published 15;181 . The results of the patient
preference arm have also been reported 187.
The five year results are now presented for this trial focusing on patient satisfaction,
acceptability, menstrual status, changes in health related quality of life, and rates of
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subsequent surgery. It is important to note that the Levonorgesterol intrauterine device (
Mirena) was not licensed as a treatment option at the time of the trial
2.2 Methods
Ethical approval was sought and obtained from the local area ethics committee. The trial
was designed to compare, in a RCT format medical management and TCRE for women
complaining of heavy menstrual loss. The women also had to have no preference for
either medical or hysteroscopic management (the patient preference trial analysed those
with an expressed preference). Eligible women were recruited from the general
gynaecology clinics of nine consultant gynaecologists between October 1994 and
September 1995. Women were eligible if they met the following entry criteria:
consulting a gynaecologist for the first time with a complaint of heavy menstrual loss;
family complete; a clinical diagnosis of dysfunctional uterine bleeding (uterus less than
ten weeks' pregnancy size and normal endometrial pathology); and had not been
referred specifically for surgery.
One hundred and eighty seven (69%) from 272 eligible women consented to
randomisation in a 1:1 ratio, 94 being allocated to medical treatment and 93 to
transcervical resection. Randomisation was by computer generated random numbers in
balanced blocks of twenty. Allocation was achieved by opening sealed, serially
numbered, opaque envelopes. The majority of those who refused randomisation had
expressed a preference for one or other treatment and were evaluated separately in a
patient preference trial l87.
In keeping with the pragmatic nature of the trial patients were not routinely scanned or
hysteroscoped prior to inclusion into the trial, nor was there any attempt made to
objectify or semi -objectify the menstrual loss.
Medical treatment was prescribed by the patient's own consultant and had to be a
recognised treatment for menorrhagia with which the patient had not previously been
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treated. The treatment was to be continued for at least three cycles. Treatments
prescribed were: Tranexamic Acid ( lgm four times a day) for the first five days for
women with regular periods with Mefenamic Acid ( 500mgs three times a day) added if
there was dysmenorrhoea ;Combined Oral Contraceptive Pill ( 30 micrograms second
generation pills); Danazol 200mgs continuous for 90 days; Progestogens were
prescribed for heavy irregular periods day 12 -25 ( day 5 -25 if associated
dysmenorrhoea) if they declined or were contra-indicated from receiving the COCP or
Danazol.
The majority of TCRE's were performed by the research registrar (Dr K G Cooper), the
remainder by three consultants. TCRE's were performed using a combined resection /
ablation technique. A 7mm 90 degree resection loop was used to resect the anterior,
posterior and lateral walls. Rollerball was used to ablate the fundal and comual regions.
The endometrium was pre-treated with a subcutaneous 3.6 mg gonadotrophin releasing
hormone analogue (Zoladex) 5 weeks prior to surgery. All procedures were performed
under general anaesthesia with urological glycine (1.5 %) as distension media. After
follow-up at four months, all recruits, irrespective of initial management, could request
further and /or different treatment. This policy reflected normal clinical practice in
keeping with the pragmatic 15'181 design of the trial.
Patients were in the initial trial results reviewed at 4 months by the research fellow with
postal follow up at two years as published 15'181.
Postal questionnaires were sent five years after initial treatment (with telephone follow-
up of non responders), assessing gynaecological symptoms, satisfaction with treatment,
and acceptability of management. Changes in health related quality of life were
measured using the Short Form-36 health survey (SF-36). Subsequent treatments were
also determined, both from the questionnaire and from the hospital surgical database.
As Aberdeen Royal Infirmary is the only hospital with a gynaecological service for the
district, we can be certain of further hospital treatment received for those who failed to
respond to the Grampian region of Scotland.
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2.2.1 Statistics
The original sample size calculations indicated that 180 randomised women would be
required for the study to have 80% power to detect an absolute difference in satisfaction
with treatment of 20% at the 5% level of significance19. Analysis was by intention to
treat with patients analysed according to initial treatment allocation. SPSS for Windows
(Version 8) was used for data entry and statistical analysis. Independent and paired t
tests were used to analyse continuous variables (independent and related) with a normal
distribution. The Mann Whitney U test was used for ordinal or continuous variables that
did not have a normal distribution. Independent nominal data were analysed using either
the Chi-squared test or Fisher's exact test, depending on sample size. McNemar's and
the Wilcoxon Signed Rank test were used for paired nominal data describing
dichotomous and related variables, respectively. 95% confidence intervals were
calculated for differences in means and proportions using the Confidence Interval
Analysis programme (version 1.1).
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2.3 Results
One hundred and eighty-seven women were originally randomised between October
1994 and November 1995, 94 to have medical treatment and 93 to TORE. Postal
follow-up questionnaires were sent five years (range 59 to 63 months) after initial
treatment and were completed by 144 (77%) women, 71 in the medical group and 73 in
the TORE group. Eleven of the forty-three not followed up were known to have left the
region. Operative details for the five years (from the hospital databases) on the other
thirty-two who failed to respond, but had not left the region, are included. The trial
profile is shown in figure 1.
2.3.1 Participants
Table 1 summarises the baseline characteristics of those successfully followed up: they
were very similar to the original trial group12. Baseline SF-36 scores were also
comparable for each group and globally reduced relative to women of the same age in
the general population 20(Table 2).
2.3.2 Subsequent treatment received by five years
Operative data were obtained from returned questionnaires and verified from the
hospital surgical database. Only 13 women had left the region by five years but any
operations they had received prior to their departure were recorded. Subsequent
management is summarised year on year in figure 2.
At five-year follow-up, 7/70 (10%) of those randomised to the medical arm were still
using medical treatment. Seventy-two of the 94 recruits (77%) had undergone surgery;
54 had a TORE, one a TORE with a further repeat ablation, 15 had undergone
hysterectomy, and two a TORE plus further hysterectomy. Twenty five (27%) women
allocated to TCRE had undergone further surgery; 7 repeat TCRE's, 15 hysterectomies
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and 3 repeat TCRE plus hysterectomy. Hysterectomy rates after five years were 18%
and 20% for medical and TCRE arms respectively. Over 70% of further surgical
procedures occur within two years ofhaving a TCRE.
2.3.4 Menstrual status at follow-up
Changes in menstrual symptoms at five years are shown in Table 3. Both trial groups
have a highly significant and comparable reduction in bleeding and pain scores.
Significantly fewer women in the medical arm were amenorrhoeic or had very light
periods (spotting / bleeding score from 1 to 5), than in the TCRE arm (66% compared
with 84%) whilst more women in the medical arm regarded their menstrual status as
unchanged or heavier (13% compared to 4%). Significant reductions were present in
three of the five pre-menstrual symptoms in the medical arm, as at two years.
Significant reductions occurred for all five pre-menstrual symptoms in the TCRE arm.
2.3.5 Satisfaction / Acceptability
These results are shown on table 4. Compared with the medical group, women allocated
TCRE were significantly more likely to be totally satisfied at five years. Those actually
dissatisfied with their treatment were low in both arms (10% medical, 5% TCRE).
Acceptability levels were very high in both groups at five years although only 20% of
women allocated to medical treatment would recommend this form of treatment,
compared with 79% in the surgical arm who would recommend TCRE (p<0.001,
difference -73% to -45%). Notably, of the 71 women in the medical arm who returned
questionnaires at five years, 45 had undergone TCRE and 36 (80%), of these would
recommend this form of treatment.
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2.3.6 Health related quality of life
The effect over time on QOL scores is shown in Figure 3.Baseline and five year SF-36
follow-up data are presented for those who completed both questionnaires (Table 2).
The changes in SF-36 scores were higher for all eight health scales at five years for
those allocated TCRE, and significantly so for three of them. Seven of the variables
were improved, four significantly, from baseline for those in the medical arm. In the
TCRE group, all eight health scales were significantly improved from baseline,




This study represents the longest follow-up of women participating in a randomised trial
of medical treatment for heavy menstrual loss and also of women undergoing TCRE
who were not initially referred for surgical treatment of their periods. As the randomised
cohorts are made up of women who were ambivalent to what treatment they received at
outset as those with a treatment preference were identified and studied separately 187.
Thus the potential for motivational bias to cloud the results has been removed and any
impact from allocation of the original trial of "resentful demoralisation" 318 is negated .
The treatment progression in both cohorts observed is a genuine response to that
treatment group allocation. This is the first time long term treatment data have been
presented for women with heavy menstrual loss in anything other than an observational
study. More importantly this trial demonstrates the impact that endometrial ablative
surgery can make on the high hysterectomy rates previously quoted314.
Follow-up questionnaires were not obtained from 45 women from the randomised
cohort, eleven of whom had left the region. Since this is the only hospital offering
gynaecological services in the area, information was available on operative procedures,
general practitioner correspondence, and subsequent clinic attendance for 34 of the 45
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women who remained in the region. The subsequent treatments received by these
women were comparable in type and number to those who returned questionnaires, for
each trial arm, and failure to obtain personal follow up should not affect the
generalisability of the results. We do acknowledge that the numbers required to fulfil
the initial power calculations have not been achieved. Nevertheless the difference
observed in those satisfied (22%), was of the size originally sought and the difference
was statistically significant at the 1% level.
2.4.1 Medical arm
Medical treatments allocated at baseline were all recommended treatments, and no
treatment proven to be ineffective was prescribed. Some may argue that optimal results
with medical treatment occurs if the original blood loss is objectively pathological,
which was not determined, but this also applies to endometrial ablation19. Only 10% of
women initially allocated to take medical treatment continued to take this at five years,
similar to the study by Coulter et al314 whilst 77% have undergone surgical treatment
for heavy menses by this time. Individual medical treatments used by women at follow-
up were not determined as the numbers were so small and it was the aim of the trial to
evaluate a medical policy rather than identify optimal medical treatment. We are unable
to address the numbers not using medical treatment because they are satisfied with their
menses. Such a number would be expected to be small as 87% are already accounted for
( 77% having surgical treatment and 10% continuing medical treatment). Those totally
satisfied with their treatment were significantly fewer than amongst those allocated to
TCRE, although bleeding and pain scores, and treatment acceptability were comparable
to the TCRE arm. Other menstrual parameters were also significantly improved whilst
pelvic pain remained low and equivalent in both arms. The results are generally similar
to those at two years, but much improved from the four-month results. This may be due
to the 77% of women in this arm who underwent TCRE or hysterectomy. The fact that
only 20% of those initially allocated medical treatment would recommend it, compared
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to 80% of those who subsequently had a TCRE from this group, who would recommend
TCRE, suggests that surgery has improved the medical arm results.
A significant fact is that the most effective medical treatment available the Mirena coil,
was not licensed for treatment of menstrual dysfunction when this trial was initiated.
Mirena offers an attractive medical alternative, particularly for those wishing to maintain
fertility. Barrington et al 183 have compared the Mirena IUS to Thermachoice
Endometrial Ablation in a small RCT. The trial has significant methodological failings
however they concluded that Mirena offers similar menstrual benefits to TBEA. These
conclusions remain to be proven in a well constructed randomised trial whether it is as
efficient and effective as endometrial ablation. An attempt to undertake a well
constructed trial in the UK had to be abandoned through failure to randomise women
due to strong preferences, particularly for endometrial resection, despite this being under
general anaesthesia 307.
2.4.2 Surgical arm
27% of women in the surgical arm have had further surgery by five years. Importantly,
few further procedures are performed after two years following TCRE, irrespective of
trial group. 20% of the TCRE cohort has had a hysterectomy, which is similar to the
proportion (18%), in the medical arm and can reassure us that a policy of early
endometrial ablation does not lead to an increase in hysterectomies. This rate is much
lower than the 60% hysterectomy rate reported after five years from observational study
undertaken before the widespread uptake of ablative surgery314.
Rates of satisfaction with, and acceptability of treatment, remain high, correlating well
with the numbers who would recommend TCRE (79%) as treatment for heavy menstrual
loss. Bleeding and pain scores and number of heavy days remained highly significantly
better than at recruitment, similar to short and medium term follow up, with only the
number of days heavy bleeding significantly less than amongst those in the medical arm.
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Pre-menstrual symptoms remain significantly reduced from baseline although the reason
for this remains unknown.
The fact that contraception is required post ablation has raised the question of
concomitant hormonal contraceptives adding to the menstrual effect of ablated patients.
This was not assessed in the trial given its pragmatic nature but previous studies form
Aberdeen confirm a large percentage ( 60- 65%) of couples in previous RCT of ablation
are sterilised (male or female) and thus not using or requiring any hormonal
contraceptive. 191;192;213
2.4.3 Health related quality of life
This trial represents the longest term evaluation of change in health related quality of life
for women with heavy menstrual loss managed medically or surgically. The effective
health care group100 recommended that measurement of changes in health related quality
of life should be performed when assessing treatments for menorrhagia. Heavy
menstrual loss is known to cause significant deterioration in general health and quality
of life15;319;320which has been overlooked when evaluating treatments for this condition,
particularly medical. At baseline SF-36 scores are globally and markedly reduced.
After five years in the TCRE arm SF-36 scores were returned to and maintained at near
normative levels321 and are all significantly improved from baseline. Women in the
medical arm also had improved SF-36 from baseline levels for seven of the eight
variables at five years, four of these significantly. The values achieved are lower than
those in the TCRE arm and also remain lower than normative values (Figure 3).
2.5 Conclusion
At five years, women allocated to TCRE remain in better health than those initially
managed medically. This clearly demonstrates that women treated immediately with
TCRE achieve higher rates of satisfaction, better menstrual symptom relief, and greater
improvements in health related quality of life than women initially allocated
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medication. Also of note those who received TCRE in the surgical arm had greater
health related quality of life scores even when compared to those in the medical arm
who subsequently received TCRE. Regarding medical treatment after five years few
women are still being maintained on medical treatment and the vast majority ofwomen,
around 80% in both arms have avoided a hysterectomy.
This study provides evidence that first line medical therapy may not be justified. It
would seem that a policy of early endometrial ablation using a proven technique to
women who are ambivalent about their treatment for heavy menstrual bleeding will
improve their outcome. Women managed by such a policy would be more likely to be
satisfied, have less menstrual loss and have no greater risk of hysterectomy than those
initially managed medically. A subsequent decrease in hysterectomies could be
expected.
The results therefore consolidate the conclusions drawn from the four-month and two
year data. The findings apply to women attending a gynaecologist for the first time for
treatment of heavy menstrual loss, who do not have a treatment preference. Early
recourse to endometrial ablative surgery will afford these women better relief of
symptoms and improvements in health related quality of life.
With more simple, but equally effective endometrial ablative options such as Microwave
ablation299 and the thermal balloon:219'220,322 now available, all hospitals offering a
gynaecological service should offer eligible patients a proven endometrial ablative
technique once referred to a gynaecologist for treatment ofheavy menstrual loss.
Crucially this trial allows the establishment of a hierarchy of treatment options for
excessive menstrual bleeding. Hysterectomy is superior to endometrial ablation offering
guaranteed amenorrhoea, the highest recorded satisfaction but at the greatest treatment
cost. Endometrial ablation in the form of TCRE is superior to medical treatment
(excluding the Mirena IUS). Eligible women referred from primary care can now be
offered effective treatment in the form of endometrial ablation without first having to
'earn it' by failing to respond to medical treatment.
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Figure 1 - Trial profile
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A Randomised Multicentre trial of Microwave Endometrial Ablation versus
Rollerball Endometrial Ablation in the treatment of menorrhagia.
3.1 Introduction
Excessive menstrual bleeding (menorrhagia) is a common complaint for which each year
1 in 20 ofwomen aged 30 -49 consults their general practitioner. Menorrhagia has been
defined from population based data as a blood loss of over 80 mis / cycle and is cited as
the reason for over one third of the 600,000 hysterectomies per annum performed in the
US236. In England approximately 52,000 hysterectomies and 16,000 endometrial
ablations are performed per annum in the public sector, almost half of these for heavy
menstrual bleeding 323. Whilst efficacious hysterectomy is associated with significant
morbidity, costs and prolonged recovery l97;214;324;325.
Endometrial Ablation emerged in the 1980's with first Endometrial Laser Ablation
pioneered by Goldrath in 1981170 in the United States ( US) and introduced into the UK
in 1986 by Davies I71and with the introduction of TCRE by Magos in 1989 172.These
first generation technologies established themselves as an effective and safe alternative
to hysterectomy 173;188;189;19l;210. It offered significantly faster recovery, shorter hospital
stays and fewer complications. In the hierarchy of treatments it proved superior over the
long term to medical treatments and only slightly inferior to
hysterectomy15; 19;181;182;189;19First generation Ablative techniques (combined loop
resection and rollerball ablation, rollerball endometrial ablation and endometrial laser
ablation) gave good results but were technically difficult to perform, with a long
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learning curve and new potentially serious procedure related complications such as fluid
overload1731326'327.
In the 1990's second generation techniques emerged that offered simple to leam, quick
procedures that avoided many first generation complications.
Microwave Endometrial Ablation ( Microsulis, Waterlooville, Hampshire, UK) a
second generation device, was first developed in Bath, England in 1993. It has a sound
evidence base. MEA has been compared in an RCT to the gold standard of TCRE
(combined loop resection and rollerball ablation) with follow up data to five
"777 •7QQ • 77R
years ' ' . Adequately powered methodologically sound RCT evidence of its
suitability under local anaesthesia is compelling and is expanding3291330.
We undertook a multicentre international investigation of MEA versus Rollerball
Endometrial Ablation ( RBEA) in the context of a phase III clinical trial.
3.2 Patients and Methods
3.2.1Study Design
Between April 2000 and September 2001, 322 women were enrolled in a clinical trial
comparing microwave endometrial ablation (MEA) with Rollerball Endometrial
Ablation (RBEA). Eight investigation sites were involved - 5 in the U.S, 2 in Canada
and 1 UK site (Table 1). All investigators were gynaecological surgeons who had
previous extensive experience of rollerball ablation and had been trained in MEA. A
MEA preceptor supervised all the early MEA treatments to monitor training issues
ensuring a standardised approve technique was utilised by all. The institutional review
board or local area ethics committee at each site approved the study. All patients were
fully counselled and gave written informed consent to participate in the trial prior to
screening and treatment. The study was not blinded. For the centres in the United States
the trial was performed under an investigational device exemption approved by the Food
and Drug Administration and was a phase III clinical trial.
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Women over 30 years were randomised only once they had satisfied the inclusion/
exclusion criteria of the study (see 3.2.4 Eligibility). Women were randomised in a 2:1
basis to MEA: REA. The reason for this unbalanced allocation was to maximise the
observations of the novel therapy ( MEA) .Randomisation was computer generated
random numbers accessed via the internet, stratification of women above and below 40
years was performed as this was felt to be a potential confounding factor with some
trials reporting better outcome in the over 40 year old age group210;331.
The primary end point was the reduction of pictorial blood loss assessment chart
(PBLAC) scores to less than or equal to 75 at 12 months post procedure ( PBLAC <75
being equivalent to normal period or eumenorrhoea). Secondary outcome measures were
amenorrhoea rate, satisfaction, acceptability, quality of life scores ( SF-36) , duration of
procedure, anaesthesia, device related complications, adverse incidents and
dysmenorrhoea.
After eligibility screening and consent all patients received a single injection of
endometrial preparation (leuprolide acetate depot [Lupron, Wyeth Pharmaceuticals,
UK], 3.75 mgms i.m.) 3-5 weeks prior to surgery. This preparation was chosen as it is
the most commonly utilised GnRH analogue in North America.
Post procedure PBLAC diaries were maintained prospectively each month for 12
months. Post procedure data collection including patient questionnaires, adverse events
and quality of life evaluations utilising Short Form 36 ( SF -36 332) were completed at 1
day, 14 days, 6 and 12 months. Patients were telephoned at 24 hours to assess
symptomatology and document any adverse events from the procedure, face to face
reviews with the research fellow were made at two weeks, 3, 6 and twelve months.
The incidence of further surgery was recorded. There were two hysterectomies (one in
each arm). In the MEA group one patient required a total abdominal hysterectomy and
right salping-oopherectomy for a benign ovarian mass, in the RBEA group there was
one hysterectomy for menstrual dissatisfaction despite PBLAC scores of 20. One
pregnancy occurred in the RBEA arm and subsequently miscarried.
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3.2.2 Statistics
The primary outcome measure was success of treatment as defined as reduction of the
PBLAC scores to less than 75 consistent with eumenorrhoea. Secondary outcome
measures were amenorrhoea rate, satisfaction, acceptability, quality of life scores ( SF-
36), duration of procedure, anaesthesia, device related complications, adverse incidents
and dysmenorrhoea.
The sample size required was based on the hypothesis that the two treatments of MEA
and RBEA would achieve equivalent results in the primary outcome measure based on
an estimate of 84.3% patients reporting a PBLAC of less than 75 at the 12 month follow-
up in the RBEA group. The planned sample size of 310 yielded a power of 80% to
detect equivalence at the 5% significance level.
Data based on intention to treat analysis (where all non responders or missing data is
recorded as a treatment failure) and evaluable population analysis (where only the data
recorded by responders is utilised) was recorded.
SPSS statistical software was used to create the database and perform statistical analysis.
Fishers Exact test was used to analyse nominal data. T tests were used to analyse
continuous variables that were normally distributed. Kruskal- Wallis tests were used to
analyse differences between the groups in apportionment across ordered PBLAC
outcome categories. 95% confidence intervals were used where appropriate.
3.2.3 Procedure
Patients were treated in their randomised groups.
Anaesthetic use (local [ plus or minus sedation] , regional, general anaesthesia) was left
up to the discretion of the operator, anaesthetist and the patients preference. All women
received Lupron (3.75 mg leuoprelin acetate) endometrial preparation 3 -5 weeks pre-
operatively.
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MEA was performed with the utilisation of pre-operative hysteroscopy in what is now
the recommended fashion. The cavity was sounded, the cervix dilated to 9mm diameter
and carbon dioxide hysteroscopy was performed to confirm the cavity as intact and
exclude false passage formation and / or uterine wall trauma. Carbon Dioxide is
preferable to saline as the distension medium as it prevents the potential cornual sparing
effect reported with saline hysteroscopy.301 The cavity length was rechecked and the
MEA probe (8.5 mm) in diameter was inserted. The treatment was commenced only if
the probe insertion depth equalled the established uterine cavity depth.
The initial temperature rise (recorded from the thermocouple at the tip of the probe and
displayed on screen) to 60 degrees is effectively gated. If as previously discussed in
Chapter 4 the profile moves out of the gated zone the device is inactivated, treatment
terminated and hysteroscopy suggested.
Once past the initial 60 degree point (approximately 5 seconds into treatment) the probe
is moved gently side to side to create a fundal warming effect. Once the 70 -80 degree
range is achieved the probe is gently displaced laterally to commence treatment of each
comual region in turn (no more than 5 seconds). The probe is then gently withdrawn in
0.5cm increments treating the walls of the uterus using a gentle side to side motion
whilst keeping the temperature display in the therapeutic range (70 - 80 degrees
Celsius). All operators in the trial were experienced with MEA and all initial treatments
were supervised by a Microsulis preceptor to ensure uniformity of treatment and exclude
any training issues.
The RBEA treatments were performed in a standard fashion commencing treatment at
the comual regions, extending over the fundal region and then treating the anterior,
posterior and lateral walls. Patients in the Rollerball Arm with fibroids / polyps were
resected first with a resection loop then rollerball performed. Urological Glycine
(1.5%) was used as the distension media.
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3.2.4 Eligibility
Patients were eligible for the trial if they were over 30 years of age, had completed their
family, failed or not tolerated standard medical treatment for heavy menstrual bleeding
and had demonstrable menorrhagia. Menstrual Blood loss was evaluated with PBLAC
charts. Scores greater than 185 correlate to menorrhagia using the charts designed by
Higham et al and modified by Janssen et al.23;333 In Janssen's study using a score of
185 as the cutoff point, the predictive values of positive and negative tests for
menorrhagia are high, 85.9 and 84.8%, respectively. All women eligible for the trial had
their PBLAC score measured prospectively prior to randomisation (over one cycle if
they previously received treatment for menorrhagia or as an average of 3 cycles if not
previously treated). Standardised sanitary ware was utilised and issued to all potential
trial participants to prevent errors in the scoring of the PBLAC diaries that can occur if
patients utilise their own preferred sanitary ware.
All women had a transvaginal ultrasound plus or minus hysteroscopy to evaluate the
uterine cavity regularity. Non obstructing fibroids and / or polyps up to 3 cm were
included. All women had demonstrable uterine wall thickness of 8 mm or more. Women
with previous endometrial ablation, previous classical section or myomectomy were
excluded. All women were required to have a normal endometrial biopsy (within the
last 6 months) with cavity lengths of 6 - 14 cm inclusive. A recent (within 6 months)
normal cervical screening smear was also required. All women were required to have an
internal examination, genital cultures for chlamydia and gonorrhoea and a negative
pregnancy test. Follicle Stimulating Hormone (FSH) level of <30 IU/ 1 was utilised to
exclude peri -menopausal women. Women with untreated cervical dsyplasia, untreated
pelvic infection, coagulation defects, a previous history of gynaecological malignancy in
the last 5 years and intrauterine contraceptive device wearers were excluded. Patients




A total of 322 women were randomised in the study (see Fig 1). 215 were randomised to
MEA and 107 to REA.
Six patients did not undergo MEA as they proved unsuitable for the procedure at the
time of surgery. Three women had obstructing sub-mucosal fibroids that had been
misdiagnosed on pre-randomisation ultrasound / hysteroscopy, one woman had cervical
stenosis and two suffered perforation during dilation.
One woman on the Rollerball group did not receive treatment as she had an obstructing
fibroid preventing access to the cavity.
3.3.1 Baseline Characteristics
The groups did not differ in baseline characteristics of age (note randomisation was
stratified into age greater or less than 40), body mass index, PBLAC scores at entry,
uterine cavity length, race, dysmenorrhoea and the presence of fibroids (see table 2). Of
note the Aberdeen cohort was 100% Caucasian, reflecting the limited ethnical diversity
in the population. Regarding the age stratification (less than or greater than 40 years),
44% in the MEA and 41% in the REA groups were patients under 40 years.
3.3.2 Clinical Outcomes
In the ITT analysis of success (as defined by PBLAC < 75) at twelve months there was
no statistically significant difference between the two groups. 187(87.0%) in the MEA
group and 89 (83.2%) in the REA group recorded treatment success (see Table 3). There
was no statistical significant difference in the numbers recording amenorrhoea (see table




A high Body Mass Index (BMI) has been implicated in improved outcomes. In this
trial there was a significant difference in outcomes in terms of success seen when the
data was stratified by BMI < 30 kg/m2 andBMI > 30 kg/m2 ( see table 4).
1.3.3 Fibroids
The effect of the presence or absence of non obstructing fibroids < 3cms was assessed.
In those with fibroids present there was a higher degree of reported success in the REA
group but this was not significant, also there was no significant difference in the
recorded amenorrhoea rates between the groups. The absence of fibroids was associated
with improved outcomes in terms of amenorrhoea rates and success for both treatment
groups ( see table 5).
1.3.4 Anaesthesia
Study data pertaining to type of anaesthesia (a non randomised outcome measure)
yielded a significantly lower number of MEA versus REA patients receiving general
anaesthesia, 45% and 78% respectively (p< 0.01). Of note the Aberdeen site utilised
only general anaesthesia due to a misunderstanding of protocol. Mean treatment times (
+ 2 standard deviations) were significantly shorter for the MEA group at 3.45 + 1.02
minutes versus 20.22 + 15.60 minutes for the REA group.
1.3.5 Quality of Life
Quality of life was measured utilising SF 36 at trial entry and to 12 months post
treatment were analysed in physical component scores and mental component scales.
Pre-treatment physical component scales for the MEA group were 47.1+ 9.22, and 54.1+
6.6 post-treatment. Pre-treatment physical component scales were 46.5 + 8.1 for the
REA group and 53.6 +6.9 post-treatment.
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Pre-treatment mental component scales for the MEA group were 46.5 + 11.5 and 52.2 +
9.1 post treatment. Pre-treatment mental component scales for the REA group were 46.6
+ 11.4 and 51.5 + 9.7 post treatment.
Pre-treatment dysmenorrhoea was reported by 81.8% (176 / 215) in the MEA group and
by 30.6% (66 /215) at 12 months. In the REA arm 80.4% (80 / 107) reported
dysmenorrhoea pre-operatively whilst 34% (36 / 107) reported it post -operatively.
1.3.6 Adverse Events
In keeping with the Phase III trial nature of the study adverse events were closely
monitored. All post operative adverse events were recorded by the women in the study
and assessed at 24 hrs (see table 6). There was a significantly higher incidence of post
operative vomiting and uterine cramping noted after MEA. There were no significant or
serious post operative events seen in either arm. There were no equipment failures or
device related adverse events. Four cervical lacerations (two in each group), one cervical
stenosis in the MEA arm, two cervical perforations pre- treatment in the MEA arm.
There were six cases of endometritis in the MEA arm, with none recorded in the REA
arm. All cases responded to antibiotic therapy. By one year there was no significant
difference in the incidence of adverse events reported in either trial arm. There was a
trend to higher reported uterine cramps in the MEA group versus the REA group (9%
and 3% respectively).
3.4 Discussion
As a technique MEA is easier and faster to leam than hysteroscopic techniques such as
REA and the gold standard of TCRE. It also requires considerably less technical skill.
The vast majority of gynaecologist after suitable training will be able to achieve
consistent results after 3 cases. 334 In comparison approximately ten times as many cases
are required before competency is achieved in the hysteroscopic surgical techniques.
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This study demonstrates a number of features ofMEA with regards to treatment times,
anaesthesia, menstrual outcomes and its efficacy with non - obstruction fibroids ( up to
3cms) . The significantly shorter duration of treatment with MEA when compared to
REA / TCRE is well demonstrated and has been confirmed in previous studies. 299 It is
also notable that the technique was able to perform under a combination of local
anaesthesia and intravenous sedation in a significantly greater percentage than was the
case for REA (62% of cases versus 18% respectively). The Aberdeen site deviated on
anaesthetic protocol due to a misunderstanding that all patients were to be treated under
general anaesthesia that was only identified at the data collection stage. This contributes
to the general data on MEA and lends support to its use as an outpatient technique,
however as this was left to individual patients and surgeons discretion its is prone to
biases that reduce the generalisability of these findings back to a general population.
Eumenorrhoea, Hypomenorrhoea or Amenorrhoea was achieved by 87% in the MEA
group by intention to treat analysis. Treatment success as defined as a PBLAC score of
75 or less was greater for MEA than REA, but not significantly so. Likewise
amenorrhoea rates were similarly higher in the MEA group but not significantly so.
Certain sub groups were studied that previous research had shown affects with respect to
outcome - those forty years of age and over, those with a BMI over 30 kg/m and the
presence of fibroids.
There was no significant difference seen in levels of success between those stratified by
age in either the MEA or REA groups. The previously identified effect of improved
outcome with age over 40 years 210 was not demonstrated in this trial.
Regarding the effect of BMI on treatment success rates there was a significantly greater
effect seen in the MEA group in those with a BMI of 30 kg / m2 or greater, confirming
previous work by Gannon.
The effect of the presence of fibroids was investigated as this is a known adverse
prognostic feature for both first and second generation ablative technologies.174;252;299;335
Many second generation endometrial ablative techniques require a small (10 cm or less)
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regular cavity. For others there is little data on the efficacy of the treatment in the
presence of fibroids. To increase the generalisability of the study fibroids up to and
including 3cm that and non -obstructing were included with the REA group albeit that
hey were augmented by a wire loop excision of the fibroid, a treatment that many would
argue would be the gold standard for hysteroscopic treatment of intra-cavity fibroids.
The analysis outlined in the previous chapter revealed MEA when compared to REA as
having a similar (68.3% versus 76.7%) success rate and a higher ( but not significantly
so) amenorrhoea rate with 46.3% in the MEA (fibroids present) arm reporting
amenorrhoea at 12 months. Thus from the trial data this suggest that MEA has
comparable and acceptable efficacy to combined REA and wire loop resection in the
treatment of intra-cavity non- obstructing fibroids. As identified in previous studies the
absence of fibroids was associated with higher reported success rates and amenorrhoea
rates in both arms.
Race was also assessed and found not to effect outcome. The Aberdeen site was 100%
Caucasian, reflecting the relative lack of racial diversity in the population in the North
East of Scotland versus that seen in the North American sites.
With regards to satisfaction, a key outcome measure in all endometrial ablation trials
comparable recorded levels of satisfaction were recorded in the MEA group and REA
group.
In keeping with the effect on QOL scores reported in other ablation studies ,81;223;299
there was a significant improvement in the SF 36 score for the physical and mental
scales for both MEA and REA at one year follow-up but no significant difference
between the techniques.
A previous concern with all new generation technologies is the reliability of the device.
Many studies including early MEA trials reported equipment failures. The Cochrane
Endometrial Ablation review group highlighted this as an area of interest and
encouraged all new device manufacturers to report such technical failures / problems.
There were no equipment failures in this trial. This represent a general improvement in
the robustness of the technology seen in the MEA (Version 2) and borne out in the more
139
recent MEA trial reported in the next chapter where again there were no technical
failures.
The multicentre, international RCT design increases generalisability, also the inclusion
and exclusion criteria of this trial (including a range of cavity lengths and the presence
of fibroids) was not restrictive again improving generalisability.
The fact that the trial was performed under the auspices of an FDA Phase III trial
deserves further discussion. The trial was paid for by Microsulis America PLC and as
previously discussed all trial funded by an interested party are subject to bias. That said
the regulatory function of the FDA, including data checks; site visits and interviews
provide protection against the undesirable effects of commercial pressure. The potential
for at best the introduction of bias and at worst scientific fraud entering into the
evaluation of a technology is always there when a product is applying for approval prior
to its launch into the most valuable free market in the world. In keeping with research
practices in North American these sites paid their patients to attend the follow-ups,
covering all travel and out of pocket expenses. In keeping with UK scientific regulations
none of the UK enrolled patients received any financial incentive. A financial incentive
may create an atmosphere of bias with the trial participants, however as both arms of the
trial were being paid this may not affect the outcomes.
3.5 Conclusion
This study further contributes to the already solid evidence base ofMEA. The MEA has
already been compared in a RCT with the gold standard TCRE and the data from this
trial. In terms of clinical outcome MEA in this study compares favourably with the
REA. The comparison to REA is valid as the population was predominately North
American and REA is the predominant ablation technique in North America.
MEA offers rapid treatment times, the possibility of local anaesthetic treatments and
high patient satisfaction. The low rates of further surgery at one year are also
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encouraging. The conclusion from this study is that treatment with MEA gives results as
good as and in many cases better than those seen in the REA arm. The technology is
dependable, easily learnt as a technique and within the confines of this trial would
appear safe.
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§ 1 Trial Design
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Age (years) 40.50 4.60 40.90 4.60 0.48
Body Mass Index
(BMI)
28.00 7.10 27.00 6.60 0.25
PBLAC Scores 451.80 356.60 524.60 429.50 0.11
Uterine Cavity
(cm)
8.09 0.98 8.14 0.77 0.61
N % N %
Race 0.92
Black 22.0 10.2 12.0 11.2
Caucasian 187.0 87.0 93.0 86.9
Other 6.0 2.8 2.0 1.9
Dysmenorrhoea 0.76
Present 176.0 81.9 86.0 80.4
Absent 39.0 18.1 21.0 19.6
Myomas 0.09
Present 41.0 19.1 30.0 28.0
Absent 174.0 80.9 77.0 72.0
SD = Standard Deviation
p = statistical significance (0.05)
Table 3 Menstrual Outcomes
Menstrual
Outcome





MEA 119 55.3 (48.4-62.1)
REA 49 45.8 (36.1-55.7)
p = statistical significance (0.05)
Table 4 Effect of BMI on Success
BMI ( kg / m2 ) N % (95% CI) P
< 30kg/m2 0.82
MEA 193 89.7 ( 83.3 -94.3)
REA 94 88.5 ( 79.2-94.6)
> 30kg / in2 0.05
MEA 184 85.3 (74.6-92.7)
REA 71 66.7 (46.0-83.5)
p = statistical significance (0.05)
Table 5 Effect of Fibroids on Success / Amenorrhoea (ITT Analysis)
Fibroids - Effect
on Success
N % (95% CI) P
Fibroid Present 0.59
MEA ( n=41) 28 68.3(51.9-81.9)
REA (n= 30) 23 76.7 (57.7-90.1)
Fibroid Absent 0.18
MEA(n=174) 159 91.4(86.2-95.1)
REA (n= 77) 66 85.7 (75.9-92.6)
Fibroid - Effect on
Amenorrhoea
Fibroid Present 0.33
MEA (n=41) 24 58.5 (49.8-64.9)
REA (n= 30) 15 50.0 (39.0- 62.2)
Fibroid Absent 0.34
MEA (n=174) 81 46.5 (30.7-62.6)
REA ( n= 77) 26 33.3 ( 17.3-52.8)
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Chills 19 8.8 7 6.5 0.52
Dysuria 17 7.9 11 10.2 0.53
Fever 2 0.9 0 0.0 0.55
Headache 6 2.8 4 3.7 0.74
Nausea 49 22.6 18 16.6 0.25
Vomiting 29 13.4 4 3.7 0.006
Urinary Tract Infection 1 0.5 1 0.9 1.00
Vaginal Discharge
Infection
1 0.5 0 0.0 1.00
Uterine Cramping 155 71.8 64 59.3 0.032
Abdominal Tenderness 11 5.1 9 8.3 0.33
Bloating 15 6.9 9 8.3 0.66
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Chapter 4
Microwave endometrial ablation without endometrial preparation in the
outpatient setting: patient acceptability, treatment outcome and costs. A
randomised controlled trial.
4.1 Introduction
Microwave endometrial ablation (MEA™) is a safe and effective conservative surgical
treatment for the treatment of excessive menstrual bleeding. 223;2";303;304;308;329 Unlike
traditional first generation endometrial ablative techniques MEA can be quickly leamt,
can treat most uterine cavities, and has been shown to be acceptable under local
anaesthetic.299;304;336
Traditionally, endometrial ablations are performed after thinning the endometrium,
usually with GnRH analogues or Danazol. This hormonal preparation results in better
visibility, reduces intra operative fluid absorption, shortens operative times and
improves outcomes. 337;338 These findings apply to first generation hysteroscopic based
ablative techniques such as rollerball and laser ablation, and may not apply to
microwave ablation. GnRH analogues increase cervical resistance, making dilatation
more difficult and potentially increasing the risk of cervical injury, uterine perforation
and false passage formation. 339 Danazol has therefore been used as endometrial
preparation for women undergoing MEA™ under local anaesthetic, to avoid the
discomfort associated with dilatation against increased cervical resistance. 340 Although
endometrial preparation allows predictable scheduling of operations four to six weeks
from commencement, treatment with Danazol or GnRH analogues is associated with
unpleasant side effects, and is expensive.
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Since microwave endometrial ablation requires neither cavity visualisation during the
treatment phase nor a fluid media to distend and irrigate the uterine cavity 303;304
endometrial preparation may not be necessary.
The aim of this study was to assess patient satisfaction with, and acceptability ofMEA
under local anaesthesia performed in an operating theatre, after five weeks of
endometrial preparation, compared to MEA on an unprepared endometrium performed
in a genuine outpatient setting.
4.2 Patients and Methods
4.2.1 Participants
The study was submitted and approved by the local area ethics committee. Primary
outcome measures were patient acceptability and satisfaction. Secondary outcome
measures were menstrual outcome and cost both to the health service and the patient and
their families (non-health service costs).
Eligible patients were those complaining of excessive menstrual loss who would
consider Microwave Endometrial Ablation under local anaesthesia and who fulfilled the
pragmatic inclusion criteria - normal endometrial pathology, finished family, uterine
size of 12 weeks or less. Non-obstructing submucous fibroids up to 3cm in size which
were included. To increase the generalisability of the study and in keeping with its
pragmatic nature patients were not routinely hysteroscoped or scanned prior to
recruitment. Patients were recruited from the dedicated Menstrual Clinic, General
Gynaecology clinics and surrounding peripheral clinics of the Aberdeen Royal
Infirmary.
Patients were counselled fully regarding the procedure, were given written information
on MEA procedure and the study. Fully informed written consent was gained. Patients
were randomised to either genuine outpatient treatment in the postmenstrual phase (
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performed in the treatment room of the gynaecological ward) or to standard treatment
after endometrial preparation (Danazol 200 mgs / bd. for 4-5weeks or one Zoladex
3.6mgms s/c 5 weeks pre-op) in the day case theatre. All MEA procedures were
performed under local anaesthesia with or without mild sedation. Sedations was
administered by the anaesthetist in those treated in day case theatre or by the treating
doctor in the outpatient treated arm. Rescue intravenous analgesia was used if required.
Patients who failed to tolerate the local anaesthesia regime were offered conversion to
general anaesthesia in the day case theatre arm or rescheduling treatment under general
anaesthesia in day case theatre at a later date with endometrial preparation in the
outpatient arm.
4.2.2 Procedures
Patients were randomised in a ratio of 1:1. Computer generated balanced random
number blocks were used and the sealed, opaque, sequentially numbered randomisation
envelopes kept at a separate site. Randomisation was gained by the research fellow
telephoning the gynaecology secretary who opened the next numbered opaque envelope.
Patients' randomised to post menstrual treatment telephoned the research fellow on the
first day of their period to arrange treatment appointments. These post menstrual phase
treatments were performed after naturally occurring menses, no hormonal manipulation
was used. Patients were treated in days 3-10 of their cycle. Day 1- 3 of a woman's cycle
are commonly the heaviest and represent the days when the majority of the endometrium
is shed, treatment was not performed in those days. After day 10 the endometrial
301*303thickness commonly exceeds 10mm which could compromise therapeutic effect.
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Patients completed pre-operative questionnaires to obtain baseline menstrual details,
quality of life parameters (Short Form 12) 341 and an assessment of anxiety and
depression (Hospital Anxiety and Depression Score). 342 Women's menstrual pain and
blood loss was assessed using a five-point scale of the severity of their symptoms (1-
mild, 5 severe). The scale gave a score from zero to fifty for bleeding and pain.
Operative details including endometrial thickness at operation measured by transvaginal
ultrasound scan were recorded. Procedure related pain was measured using the modified
McGill Pain Questionnaire.343
Clinical questionnaires were sent at two weeks. For women who had received the
hormone preparation treatment costing questionnaires were completed at treatment and 4
weeks to collect data on health service and non-health service resource use.
Acceptability of the procedure was assessed using a six-point Likert type scale and on a
10cm visual analogue scale (0cm = totally acceptable, 10cm = totally unacceptable).
Patients received a lOOmg Voltarol suppository 1 hour prior to treatment (patients
unsuitable for NSAID received lgm of Paracetamol). A venflon was sited prior to
commencing the treatment. Patients were offered i.v. sedation with Midazolam (2-4mgs
i.v. maximum), either from the outset or at their request intra -operatively. If
intraoperative analgesia was required, i.v. Fentanyl was used (25-50mcgms, i.v.
maximum). Patient's oxygen saturation and heart rate were monitored during the
procedure.
Post menstrual phase outpatient treatments were performed in the treatment room of
Ward 42 of Aberdeen Royal Infirmary. If required beds were available for recovery if
the patient suffered from nausea or pain. Treatment after endometrial preparation were
performed in the Day Case Theatre of Aberdeen Royal Infirmary on scheduled elective
lists.
All patients had a member of the nursing staff with them throughout the procedure for
reassurance and to provide 'verbal anaesthesia'. All received a four quadrant cervical
block using a 2.2ml ampoule of Citanest 3% , ( 3% Prilocaine with Felypressin 2.2mls)
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to each quadrant and a transvaginal ultrasound scan performed to establish endometrial
thickness. The cervix was then dilated to 9mm during which a gas (Carbon Dioxide)
hysteroscopy was performed to identify the cavity and to exclude false passages or
perforation. MEA treatment then proceeded in standard fashion. 303 Patients were
discharged with an information sheet and contact number once comfortable, voiding and
tolerating diet.
4.2.3 Stastistical Analysis
180 patients were required to achieve 80% power to detect a 20% difference in
satisfaction and a 10% difference in acceptability at the 5% significance level (Instat
2,Version 2). The baseline event rate for acceptability was derived from previous work
on MEA by Wallage et al 300 that reported 85% of women finding MEA under local
anaesthesia acceptable. This study was a randomised controlled trial ofMEA under local
anaesthesia versus general anaesthesia. In previous work from a randomised controlled
trial of MEA versus Transcervical Resection of the Endometrium by Cooper et al 223
77% ofwomen in the MEA arm reported themselves totally or generally satisfied.
In total 210 women were recruited to account for a 15% drop out rate post treatment.
Analysis was by intention to treat. SPSS for Windows (Version 9 .0) was used to create
the database and to perform statistical analysis. Independent and paired t tests were used
to analyse continuous variables that were normally distributed. Mann- Whitney test was
used for ordinal or continuous variables that were not normally distributed. Chi square
or Fishers Exact Test for independent nominal data. 95% confidence intervals (CI) were
calculated for normally distributed continuous variables and for differences in
proportions for categorical data.
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4.2.4 Economic Methods and Analysis
Health service costs consist of the costs prior to admission to hospital, during admission
for the MEA procedure and throughout the recovery period (4 weeks). The cost of the
hormone preparation treatment was estimated using the British National Formulary. 344
Anaesthetics, drugs and consumables were costed using local prices. Data from the
Health Technology Board of Scotland were used to compute staffing costs345 , Scottish
Health Service data were used to cost the overheads. 346 Equivalent annual costs (based
on replacement values) were computed to account for capital costs. 347 An average cost
• 348
per procedure for the MEA equipment was obtained from a previous study.
GP visits, clinic and hospital visits (including diagnostic tests, procedures and drugs)
were cross checked using hospital records and valued using costs from the published
literature.312;349
Data on non-health service costs were obtained using the two costing questionnaires
Information was collected on the time and transport costs associated with obtaining the
hormone preparation treatment and the hospital admission, companions accompanying
patients on the day of the procedure, the cost of caring for dependents and other costs
associated with the treatment. A standard cost per mile 312'350) and average wages for
Scotland 312 351 were used to value transportation and time of patients, companions and
dependent care givers. Values for other non-health service costs were directly obtained
from the questionnaires. All costs data were presented in 2002 pound sterling (£) and
exclude value added tax. The costing data was analysed using appropriate parametric
and non-parametric tests. Bootstrapping, a statistical technique was used to compute
limits around the estimates of total health and non-health service costs.
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4.3 Results
Study recruitment was commenced in April 2001 and the last treatments completed on
the 25th of July 2002.
210 women were randomised and 197 completed treatments- 97 were treated in the post
menses arm and 100 treated in the standard drug preparation arm (See Fig. 1). The
CONSORT scheme of study reporting was adhered to and Fig. 1 shows the flow of
patients through the trial.
Patient baseline characteristics are recorded in Table 1. There was no significant
difference in the number of patients with pathological anxiety or depression scores
between the groups (p=0823 and p=0.783 respectively).342
4.3.1 Operative Details
The Research Fellow was trained to do MEA and performed 95% of the procedures; the
Consultant in charge performed the remainder. Operating times and findings are
presented in table 2.
One patient in the drug preparation arm had severe cervical stenosis and a false passage
created, suspected and confirmed at hysteroscopy prior to MEA. She declined a further
attempt at ablation at 6 weeks. Two patients in the drug preparation arm required
general anaesthesia for pain (one during dilation, one during MEA treatment) no one in
the post menses arm required rescheduling under general anaesthesia for procedure
related pain or discomfort.
One patient required general anaesthesia in the post menses arm because of a significant
vaso-vagal reaction. This responded rapidly to 0.6 mgms I.V. Atropine and occurred half
way through the active MEA treatment itself. A Rollerball ablation under general
anaesthetic was required at a later date to visualise and ablate the untreated part of the
cavity.
154
One patient in each arm both who had had previous cone biopsies received cervical
lacerations at dilation. The MEA procedures were performed completed and the
lacerations sutured after the procedure under local anaesthesia.
4.3.2 Acceptability
In the six point Likert Scale categories of discomfort (none / mild / discomforting
/distressing / horrible / excruciating) there were no significant differences between the
groups (p= 0.614).
Greater levels of acceptability were recorded by women in the post menses group at two
weeks post operation (See Table 2).
Two women in the post drug arm recorded that their procedure was either totally or
generally unacceptable. All the women in the post menses arm recorded their procedure
as acceptable.
Procedure discomfort was assessed by a modified McGill pain questionnaire. Patients
were asked to compare the procedure to common experiences and rank them in order of
severity; MEA ranked a higher score than an internal examination or cervical smear but
was a lower score than worst head-ache, tooth-ache or stomach-ache. McGill Pain
Scores by group (un-weighted) showed no significant difference between groups
(p=0.944).
Intra-operative Midazolam usage was significantly higher in the post menstrual arm.
There was a low and almost identical requirement for intra-operative opiate analgesia in
both arms of the trial (Table 2).
Two women in the post drug arm required to be converted to general anaesthesia (GA)
because of unacceptable levels of pain and anxiety. No one in the post menses arm
required conversion.
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The likely side effects of the endometrial preparation were assessed in both groups for
the four weeks prior to their procedure. Comparing post menses group to the
endometrial preparation group respectively the incidence of Hot Flushes was 23.9% vs.
69.7%, (p=0.001), Nausea 15.9% vs. 33.7% (p=0.006), Rashes/ Itch 4.5% vs.
15.7%(p=0.014) and Weight gain 15.9% vs. 39.3% (p=0.001).
After their procedure patients were asked how they would prefer to have a repeat
operation. 91 (94.8%) in the post menses arm would arrange their treatment the same
way again, in the post menses phase, telephoning for a date, and 5 (5.2%) would change
to hormonal preparation.
In the drug prep arm 55 (56.1%) would arrange their operation the same way but 43
(43.9%) would prefer treatment after a period. In total if arranging their operation again
134 (69%, p= 0.001, 95%CI for difference in proportions 0.40, 0.61) opt for no
preparation post menstrual MEA™.
By 3 days post operatively significantly more women in the post menses arm were back
to normal activity 45 (46.4%) in the post menses arm and 28 (28%) in the post drug arm
(p=0.008). The groups did not differ in the characteristics of their normal daily activities.
4.3.3 Satisfaction
Satisfaction was assessed on a six-point scale (totally satisfied / generally satisfied /
fairly satisfied / fairly unsatisfied / generally unsatisfied / totally unsatisfied). There was
no significant difference seen in satisfaction at 6 or twelve months. 90 (97.8%) in the
post menses group and 91(93.8%) in the drug preparation group at 6 months reported
themselves as totally or generally satisfied (p=0.746). At twelve months 86 (92.5%) in
the post menses group and 84 (88.4%) in the drug preparation arm reported themselves
as totally or generally satisfied (p=0.297).
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4.3.4 Quality of Life
Quality of life scores (QOLS) were assessed. It is desirable to measure QOLS as they
are demonstrably poorer in women with menorrhagia and have been shown to improve
after ablative surgery.15 Two different quality of life instruments are available to use;
disease specific tool such as the Menstrual Distress Questionaire352 or generic tools such
as the SF 12 and SF36. The main benefit of disease specific instruments are that they
pickup condition specific issues that may be missed in generic QOL tools . An example
of this is the cyclical nature of menstrual problems which may reduce the validity of a
generic tools result if the questionnaire was performed between symptoms. A benefit of
the generic tools are that they allow a comparison between different and diverse disease
groups and that certain tools ( EUROQUOL) can be utilised in the calculation of
economic related data such as quality adjusted life years( QUALYS). In this trial we
utilised SF 12 ( Version 1) Previous trials in Aberdeen have used SF 36. SF12 was
chosen over SF 36 as it was shorter and less cumbersome. Unfortunately SF12 has not
been validated in menorraghia, it has however been validated against SF36 which is
valildated in menorraghia. The results for the Physical Component Summary and Mental
Component Summary scores are shown in Fig 3. The improvements in QOLS for both
categories from baseline to twelve months were significant (p<0.001) in both study
groups but no significant difference was seen between groups. The values in both study
groups were restored to normative values for an age matched healthy females.341
4.3.5 Menstrual Results
Menstrual data was available for 195 (99%) of the women at 6 months and 190 (96.4%)
at 12 months. At 12 months 52 (55.9%) in the post menses arm and 60(61.9%) in the
drug preparation arm were amenorrhoeic (p= 0.405). In those still menstruating 36
(87.8%) in the post menses arm and 33 (89.2%) in the drug preparation arm reported
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their periods as no longer heavy. The median bleeding scores (for those still
menstruating) and pain scores showed no statistically significant difference between the
groups (Table 4). Regards further surgery there was one rollerball ablation in the post
menses arm and one hysterectomy in the drug preparation arm by one year.
4.3.6 Economic Results
The main health services costs prior to admission are the prescription of the hormonal
preparation. Overheads, staffing costs, capital costs (buildings and equipment), and
consumables were the key items of resource during the hospital admission and
throughout recovery. Resource use data collected by the clinical research fellow
supplemented with information from the two-week clinical questionnaire.
The costing results are reported in Table 3. The mean cost for the total health service
costs including endometrial preparation treatment, clinician visits to the ward, drugs,
ward costs, costs of MEA procedure and GP visits post operative was £424 (95% CI
£421 - £433) for the patients in the post menses arm of the study and £526 [95%CI £514
- £533) in the drug arm of the study. This difference between both arms of the study was
statistically significant (p=0.001).
The mean cost for the total non-health service costs including patient travel costs, patient
time costs during admission, companion travel costs, costs of caring for dependants, and
other costs reported in the costing questionnaires was £146 (95%CI £119, £182) for




This study demonstrates that MEA™ performed under local anaesthetic, without
endometrial preparation; in an outpatient setting is both acceptable and results in high
levels of expressed satisfaction. MEA in the post menstrual phase results in comparable
menstrual outcomes to standard treatment with endometrial preparation. It is a suitable
technique for most women who wish to have an endometrial ablation as 69% of eligible
patients referred for MEA™ are willing to consider treatment under local anaesthetic
353whilst a normal cavity is not essential. It is reassuring that the effect on menstrual loss
of not preparing the endometrium is not compromised.301
Generalisability of the results are enhanced by the avoidance of entry criteria based on
menstrual bloods scores or predetermined uterine cavity regularity, a broad inclusion
criteria with minimal exclusion criteria in this pragmatic trial. In addition a junior
doctor taught microwave ablation just prior to the study commencing performed nearly
all the procedures. The equipment utilised and local anaesthetic regimens adopted are
available in the majority of health care facilities in the developed world. The results
achieved in this study should therefore be genuinely reproducible and attainable.
Methodologically one could argue that the post randomisation dropouts compromise the
results and that this does not represent a genuine intention to treat analysis in its purest
sense. However there are different interpretations of intention to treat. As the dropouts
did not receive treatment, no data collection was undertaken and the trial was not
unbalanced it can be argued that intention to treat analysis has been achieved. The 8 post
randomisation dropouts (5 in the post menstrual arm and 3 in endometrial preparation
arm) were all contacted at the end of the trial to ascertain why they had not attended for
treatment. They all reported that they no longer viewed their periods as a problem, had
been reassured by their investigations and no longer desired treatment.
In a recent study 69% (223 out of 322) women referred for MEA would consider
treatment under local anaesthesia. Women who expressed a preference for local
anaesthesia did particularly well, with the majority commencing and being completed
under local anaesthesia.354 The majority entering this trial wished to avoid hormonal
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endometrial preparation because of a desire to avoid the side effects of endometrial
preparations.
The actual active microwave time was significantly shorter in the drug preparation arm
reflecting the finding with first generation procedures of reduced operating times with
thinner endometrium. Endometrial thickness as expected was significantly different. The
post menses endometrium showed a considerable range compared to the predictable thin
endometrium under hormonal manipulation. The thicker endometrium and more
pronounced sub-endometrial vascular heat sink of an untreated cavity would
theoretically dissipate some of the microwave energy leading to the prolonged treatment
times seen. 30'. Whether this has an effect on long term clinical outcomes remains to be
seen. Overall total operative times showed no significant difference between both
groups.
The organisational issues ofMEA in the post menstrual phase needs addressing. Whilst
it was very easy for the dedicated research fellow to accommodate the 3 to 4 post
menstrual patients on a Friday morning each week there are real logistical issues in
providing a service that is dependant on patient's spontaneous onset of menstruation.
This practical issue of coordinating unpredictable events such as the onset ofmenses and
theatre lists or outpatient sessions is remedied by the use of timed withdrawal bleeds.
The use of Provera 10 mgs B.D. for 10 days stopped ten days prior to treatment date
allows the scheduling of treatments in the manipulated postmenstrual phase.
It is important to stress that the doses of sedative when used, were very small. There
were no adverse events from the sedation doses even when combined with the use of
intra -operative opiate analgesia with the vast majority of patients chatting through their
procedure. The sedation was performed in strict accordance with the Royal Colleges
Guidance document on the safe use of i.v. sedation.355
The difference in sedative use between the two arms of the trial is interesting. The
patients were all counselled pre-operatively in the same fashion by the research fellow.
It could be postulated that the knowledge that failure to tolerate the procedure in the post
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menstrual outpatient arm would require rescheduling under general anaesthesia in 6
weeks time biased this arm towards accepting the offer of sedation more readily.
Significantly more women reported treatment post menses as totally or generally
acceptable at two weeks (89%). A previous study randomising to MEA under general or
local anaesthesia reported 97% vs. 85% respectively describing treatment as totally or
generally acceptable.356 Health service costs are statistically significantly lower for care
provided in the outpatient setting. This modality could allow more patients to be treated
with the same financial resources, shortening waiting lists and freeing up theatre space
for other uses. The ability to move a traditionally theatre based treatment to an outpatient
setting with its reduced costs is attractive, particularly in a private / commercial set up.
The issue for the NHS is different. The financial irony is that the movement of any
traditional theatre based procedure to a 'cheaper' low cost outpatient environment results
in more work being done in different environments. Only if the vacated theatre or staffs
are not otherwise utilised are financial savings made.
Many second-generation ablation techniques now exist with the aim of bringing safe,
efficacious and simple to perform techniques to gynaecologist without specialist
hysteroscopic surgical skills - Novasure device™ (bipolar ablation device) 225, ELITT
™
(multifibre diode-laser) 242,Thermachoice ™ 219 / Cavatherm 357 / Menotreat ™
(thermal balloon) 224, Hydro Thermablator ™ (hot water instillation techniques)234, and
Her-Option Device ™ (cryoablation). 358 Most require some type of endometrial
preparation or have restrictions on cavity size /shape, or both. Some claim to be
amenable to treatment using local anaesthesia but have not demonstrated this as a
primary outcome measure in a randomised trial. Merely claiming the ability to
undertake a procedure in a particular way does not demonstrate its acceptability,
generalisability, effectiveness or efficiency. Good quality randomised control trials are
needed to fulfil these requirements.
Long term clinical parameters will be followed up to compare satisfaction, menstrual
outcomes and rates of further surgery in the two groups. Formal economic analysis over
the long-term will compare the two methods in terms of further treatment required.
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Menstrual outcome will be measured in the two groups up to one year. Clinical
outcomes and subsequent surgery have significant effects on economics. The majority of
repeat procedures and hysterectomies will take place within 18 months of surgery and
rarely after 3 years, follow-up will cover that period.182 The longer-term follow-up of
these groups will reveal the true cost.
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4.5 Conclusion
This trial demonstrates in the context of an adequately powered randomised controlled
trial that Microwave endometrial ablation performed under local anaesthetic in the
postmenstrual phase is an effective and efficient method of treating the majority of
women who wish conservative surgical treatment for heavy menstrual loss. Treatment
post menses avoids the side effects and significant costs of drug preparation. Treatment
post menses is more desirable to women than treatment after endometrial preparation
with the avoidance of preparation associated side effects being the main drive. The
technique is rapid, achieving both high satisfaction and acceptability rates, whilst also
achieving menstrual outcomes and rates of further surgery unmatched by other
endometrial ablative techniques. There are demonstrable cost savings and also the
potential benefit of releasing valuable operating theatre time and personnel for other
operations which require these facilities.
These results encourage the development of outpatient MEA by providing good quality
RCT based evidence of clinical efficacy and cost effectiveness. Outpatient treatment
remains the logical development of endometrial ablation. The results of this trial
establish the role of MEA in the outpatient setting and is timely given the recent
approval ofMEA ( and Thermal Balloon Treatment) for the treatment of menorrhagia
by NICE.311
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Figure 1 - Study recruitment diagram
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Table 1.







Mean Age (SD) 42.36 (4.78) 42.41 (5.35)
No. of Vaginal
deliveries





Previous caesareans 20 (20.6) 18( 18)
Clots and or Flooding 92 (94.8) 98 (98)
Double protection 85 (87.6) 85 (88.5)
Premenstrual
Dysmenorrhoea
62 (63.9) 59 (59.6)
Previous Cervical
Surgery
13 (13.4) 9 (9.0)
Median Menstrual Pain
Score* (IQR)
17 ( 10,21.5) 14(7,21)
Median Bleeding Score*
(IQR)
23 ( 19,29) 24 ( 19,31)
Cavity Length / cm (
range)
8.50 (5-11.5) 8.40 (6-13)
Regular cavity 81 (83.5) 86 (86.0)
* = Bleeding and pain scored from a minimum of zero to a maximum of 50.
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86 (89.5%) 76 ( 76%) P = 0.012





1.2 1.0 P= 0.735
Post Op Opiates 42 (42.4%) 22 (22%) P= -0.001
Discharge at 6 hrs 79(81.5%) 81 (81%) P= 0.937
Overnight Stay 12 ( 12.4%) 20 (20%) P= 0.147
Recommend to a
friend







Fig 2 Procedure Related Discomfort (Modified McGill's - Median Scores)
(1= none, 2= mild, 3= discomforting, 4- distressing, 5= horrible, 6= excruciating)
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Table 3 Procedure Data
Randomised to Randomised to Statistical
Post Menses Drug Preparation significance
Treatment (N=97) (N=100)
Procedure Time / 20(12-35) 20 (12-35) 0.841 a
minutes
Microwave time / 243 (105-475) 229(132-458)
~ ^ - a**
0.026 3
seconds




None 94 (96.9) 0(0)
Danazol 2(2.1) 85(85.0)
Zoladex 1 (1.0) 9 (9.0)
Both 0 (0.0) 6 (6.0)
a = Mann Whitney Test
** = Significant at the 5% level.
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52 ( 55.9) 60(61.9) P=0.405b














5(2, 8) 3(2,5) P=0.301a
Median Pain Scores
(IQR) (12 months)
4.5 (1.25,7.75) 3(2,6) P=0.357a
a = Mann Whitney Test
b = Differences in proportions yl test
c= Fishers Exact Test
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Chapter 5
Endometrial Ablation versus Hysterectomy - a review of rates of surgery
in the Grampian Region and Scotland 1998 - 2004.
5.1 Introduction
Hysterectomy remains a highly successful surgical procedure for the treatment of
menorrhagia, guaranteeing amenorrhoea and achieving high satisfaction rates. Benign
Hysterectomy rates vary both nationally and internationally, but are felt to be
unacceptably high in the Western world. Countries like the United States359 and Finland
287 have some of the highest reported rates of hysterectomy in the world ( 560 and 414
per 100,000 women respectively) in comparison other countries like Sweden and
Norway have much lower rates (145 and 164 per 100,000 respectively).
It has been demonstrated that a number of factors may alter hysterectomy rates. Coulter
et al reported that hysterectomy rates varied enormously (up to three fold difference)
between different general practices.314 . If referral per se is a risk factor for hysterectomy
then factors that reduce referral may reduce hysterectomy. Work by Fender et al
revealed that active education of 'good menorrhagia management' in primary care
halved the numbers referred but doubled the risk of surgery in those referred 36°. Vessey
361
reported that lower social class , higher parity and older age were associated with
increased likelihood of hysterectomy. However, the latter study was conducted amongst
a selected population from the Oxford region that consisted of Caucasian, married
women, aged 25-39 who were all willing to co-operate with follow up.
UK data from the early 1990's revealed that after 5 years of being referred to a
gynaecologist with heavy menstrual bleeding, 60% of women have had a
hysterectomy.302 Furthermore, 20% of UK women have undergone a hysterectomy by
the time they are 55 years old 3I4;362. These figures precede the introduction and general
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uptake of endometrial ablation and more recently the Levonorgestrel IUS. As 80% of
women having hysterectomy had no demonstrable pathology the vast majority of
hysterectomies could, it was predicted be replaced by ablations. A resulting reduction in
hysterectomy was thus expected. Many felt the widespread use of ablation technology
would result in a decrease in hysterectomies. Others remained to be convinced. They
argued that hysterectomy rates would be unaffected in the long term. Arguments
followed that the majority of endometrial ablations would require a hysterectomy in the
future with patients merely temporising their ultimate definitive surgery.
Bridgman and Dunn 363 analysed hospital admissions data for women who underwent a
hysterectomy or endometrial ablation for dysfunctional uterine bleeding in England and
Wales between 1989 and 1996. They reported an initial rise in operation rates for
endometrial ablation until 1992/3 following which the rates fell. They commented on the
fact that hysterectomy rates have remained relatively steady since the introduction of
endometrial ablation. They reported the total operation rates (hysterectomy and ablation
combined) for dysfunctional uterine bleeding initially increased but then tended to fall
after 1992/3. The ratios of hysterectomy to endometrial ablation for dysfunctional
uterine bleeding troughing at 3:1 in 1992/3, but by 1995/6 had increased to 4:1. They
concluded that rather than, as many had predicted, ablations replacing hysterectomy in
the treatment of dysfunctional uterine bleeding, endometrial ablation appeared to have
added an alternative operative technique. The knock on effect of this being an increase
in the total number of operations for this condition and thus instead of reducing NHS
expenditure it was actually increasing costs. They suggested a hypothesis that the less
invasive nature of the ablative techniques would encourage women who would never
consider a hysterectomy to seek a surgical procedure for their menorrhagia through a
lowering of the threshold for intervention.
Reid et al have recently reviewed the trends in the numbers of hysterectomies and
ablations in England for menorrhagia between 1989 and 2002-3. 364 NHS hospital
episode statistics were analysed for the years 1989 -1990 and 2002 -2003. An average of
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23,056 hysterectomies was performed per annum in England for menorrhagia in the
period 1989 -1990 to 1994-1995. Since 1995-6 they demonstrated a progressive decline
with 8332 hysterectomies performed in 2002-2003. Analysis of the number of ablations
revealed that the shortfall in hysterectomies was not being made up in an increased
number of ablations. The total number of operations for menorrhagia was seen to
decrease. In total a 64% decrease in the number of hysterectomies and a 43% reduction
in the total number of operations for menorrhagia were observed (23,284 vs. 13,252).
Reid's data would suggest that the reduction in hysterectomy numbers is not explained
by a concomitant increase in ablations. One potential explanation that has been proffered
has been that the increasing use of the Levonorgestrel Intrauterine System (IUS) for
treatment of menorrhagia has reduced the demand for hysterectomy. Licensed in 2001
for the treatment of menorrhagia the IUS has, it is assumed, been used extensively off
license prior to this date. The device has been available as a contraceptive since 1995
coinciding with the decline in hysterectomies for menorrhagia. An ongoing RCT study
to determine the 'Effectiveness and Cost-effectiveness of Levonorgestrel containing
intrauterine system in Primary care against Standard treatment for menorrhagia'
(ECLIPSE study) is being conducted by the NHS Health Technology Assessment
Programme, which may determine whether indeed the IUS has had an effect on
hysterectomy rates in England & Wales. The trial commenced in January 2004 with the
aim of recruiting 1000 women aged 25-50 years presenting to their General Practitioners
with menorrhagia, and not intending to become pregnant in the next 5 years. Subjects
are randomly allocated to the Levonorgestrel-releasing intrauterine systems or standard
medical treatment (combined oral contraceptive pill, tranexamic acid or mefenamic
acid), based on the Royal College of Obstetricians and Gynaecologists (RCOG)
guidelines. Outcome measures are effect on quality of life, patient satisfaction,
hysterectomy rates and a cost effectiveness analysis. Follow up is intended for 6 months,
1, 2, 5 and 10 years.
Analysis of hysterectomy and endometrial ablation rates from Australia (New South
Wales) from 1981 to 1994-1995 have been published.365 The hysterectomy rate declined
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by about 16% during 1981-1991 rising since; the endometrial ablation rate increased by
28% between 1991 and 1994-1995. They reported a trend towards older mean age at
operation, a swing to vaginal hysterectomy with or without laparoscopy, a shift to
private hospitals, and a dramatic decline in length of hospital stay. They concluded that
the introduction of endometrial ablation techniques has had a major impact on
hysterectomy rates.
The aim of the study reported in this chapter was to analyse the relationship of ablation
to hysterectomy for menorrhagia in the Grampian Region (served by Aberdeen Royal
Infirmary) and also the comparable Scottish national data.
5.2 Methods
With the assistance of the Information Management and Technology Department (IMT)
of Aberdeen Royal Infirmary (Grampian figures) and NHS Scotland Information and
Statistics Division (ISD) data (Scottish National Figures) on the numbers of endometrial
ablations and benign hysterectomy were collected and analysed for women aged 20-55
years, both at Aberdeen Royal Infirmary and in Scotland between Jan 1998 and Dec
2004.
The ICD 10 (1996 onwards) codes were used. As there is no specific code for
menorrhagia a number of different codes were used. The codes for endometrial ablation
were -Microwave Endometrial Ablation - Q17.4 + Y11.4, Trans Cervical Resection of
the Endometrium - Q 17.1, Thermal Balloon Ablation - Q 17.4 + Y11.8, Hysteroscopic
Endometrial Ablation - Q 17.4 + Y08.8.
For Hysterectomy the codes used were Total Abdominal Hysterectomy - Q07.( all) ,
Vaginal Hysterectomy - Q 08.2, Laparoscopically Assisted Vaginal Hysterectomy ( any
route)- Q 08.2 + Y50.8 plus diagnostic codes - N92 ( = menstrual) / D 25.9 ( = fibroid)




The Scottish National Data was collected with the assistance of the ISD department of
NHS Scotland using SMOR1 data. The data is represented in Table 1.
Table 1 Scottish Benign Hysterectomy and Ablation 1998- 2004.
Operation /
Year
1998 1999 2000 2001 2002 2003 2004
Benign
Hysterectomy
















5:1 3.6:1 2.6:1 2.5:1 2.3:1 1.8:1 1.7:1
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0 1 1 1 1 1 1
1998 1999 2000 2001 2002 2003 2004
Year of Surgery
—♦—Benign Hysterectomy —•—1st Gen Ablation —*—2nd Gen. Ablation
Figure 1 Hysterectomy and Endometrial Ablations in Scotland 1998-2004 (
women aged 25-55years)
The number of ablations (first and second generation) performed in Scotland increased
by 65 % over the time frame from 1319 per annum in 1998 to 2181 in 2004. A drop of
11% in the number of first generation ablations and an increase of 65% in the number of
second generation ablations was reported. The total number of surgical procedures for
menorrhagia (ablation plus hysterectomy) fell from 7928 in 1998 to 5973 in 2004 (25%
reduction). (Table 8.1). The ratio of hysterectomy to ablation fell from 5: 1 in 1998 in
1998 to 1.7: 1 in 2004.
Sub analysis of the operative route for hysterectomy was performed. The number of
abdominal hysterectomies for menorrhagia fell from 5637 in 1998 to 3264 in 2004 (a
drop of 42%). The number of vaginal hysterectomies for menorrhagia fell from 799 in
1998 to 545 in 2004 (a fall of 31%) also the number of Laparoscopically Assisted
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Vaginal Hysterectomy ( LAVH) for menorrhagia fell from 173 in 1998 to 74 in 2004 , (a
drop of 57%) over the seven year period.
Table 2 Grampian Benign Hysterectomy and Ablation 1998 -2004
Operation/
Year 1998 1999 2000 2001 2002 2003 2004
Benign
Hysterectomies 205 146 146 137 165 122 136
Endometrial
Ablation 221 277 335 285 256 305 347
Total Number of
Procedures 426 423 481 422 421 427 483
Ratio
Hysterectomies to
Ablations 0.9: 1 0.5:1 0.4:1 0.5:1 0.6:1 0.4:1 0.4:1
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Nos. of Ablations and Hysterectomies Grampian 1998-2004
1997 1998 1999 2000 2001 2002 2003 2004 2005
Operations per year
Figure 2 Numbers of Endometrial Ablations and Hysterectomies in Grampian 1998-2004.
Between 1998 and 2004 in Grampian Region a 34% reduction in hysterectomy rates was
observed. Endometrial ablation increased by 57% in the same time period. Comparing
the figures for the total number of procedures there was a 13% increase in the total
number of procedures performed. Looking at the ratio of ablation to hysterectomy
reveals a move from a ratio of almost equivalence with 0.9:1 ratio of ablations to
hysterectomy to a ratio in 2004 of 0.4: 1.
5.4 Discussion
Looking at the National data first there has been a smaller drop in the number of
hysterectomies performed in Scotland than reported in the Reid paper for England.364 A
43% drop in the number of hysterectomies performed in Scotland between 1998 and
2004 can be compared to the 64% decrease reported by Reid & Mukri for period 1989-
2003. The time scales are different but the overall trend is the same. Looking at the
hysterectomy data for the more comparable period 1998 -2003 in Reid's paper shows a
fall from 15 hysterectomies per 1000 to 8 per 1000, a 46% drop which is very similar to
the 43% drop in the Scottish data. An overall reduction of 25 % in procedures performed
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for menorrhagia is noted less than the 43% reduction reported by Reid et al.364 The ratio
ofHysterectomy to Ablation in Scotland fell from 5: 1 in 1998 to 1.7:1 in 2004.
Looking at the decrease in the numbers of hysterectomy by route is revealing. Why the
drop in LAVH is more marked when compared to abdominal and vaginal hysterectomy
is difficult to say but may relate to a wearing off of the 'honeymoon effect' associated
with any new technology or treatment modality. The higher complication rate reported
in the Evaluate trial may also be an important factor.277;324;325 The drop in vaginal
hysterectomies is on balance more concerning. The vaginal route when compared to the
abdominal route has much in its favour including more rapid recovery, reduced post
operative ileus, reduced postoperative complications, reduced analgesia use, reduced
inpatient days and faster return to normal activity.325 Many feel that more hysterectomies
should be performed vaginally. The question ofwhether more women would be suitable
for vaginal hysterectomy was asked by the group from the Endoscopy Training Centre at
the Royal Free Hospital who analysed a group of 500 women who underwent
hysterectomy to assess their suitability for vaginal surgery.366 In this population 96
(19.2%) women underwent vaginal hysterectomy whereas the group estimated that 382
(76.4%) women could have had the procedure vaginally. Lack of uterine prolapse
(76.4%), uterine fibroids (44.5%), and a need for oopherectomy (43.2%) were the three
most common reasons for choosing the abdominal route. The group suggested an
increased familiarity in the surgical techniques for dealing with non-prolapsed uteri,
uterine fibroids, and vaginal oopherectomy would increase the vaginal hysterectomy
rate. Training issues may be in part to blame. Shortened career paths, reduced operative
exposure and opportunities may impact on the favored routes of vaginal surgery. A UK
National Survey of experience and attitudes to vaginal hysterectomy revealed that that
senior trainees' (SpR 4 and 5) experience in vaginal as opposed to abdominal
hysterectomy was relatively poor. However, despite this, trainees believed that the
majority of hysterectomies should be done vaginally, and only a minority,
abdominally.367
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Looking at the ablation data for Scotland the 65 % increase over the time frame is
notable and goes against Reid's observation of a fall in the number of ablations
performed. A drop of 11% in the number of first generation ablations and an increase of
65% in the number of second generation ablations was reported in Scotland. The total
number of surgical procedures for menorrhagia (ablation plus hysterectomy) fell from
7928 in 1998 to 5973 in 2004. (Table 8.1). The ratio of hysterectomy to ablation fell
from 5 : 1 in 1998 ( similar to Bridgeman and Dunn's figures363 ) to 1.7: 1 in 2004 .
A 25% reduction in the total number of procedures performed in Scotland in thel998 -
2004 time frame is reported, this is less than the 43 % reduction seen in England
between 1989 and 2003. The Grampian region population is predominantly Caucasian,
static and served by one major teaching hospital, thus making it perhaps
unrepresentative of the larger Scottish population.
The numbers of hysterectomies in Grampian dropped by 34% over the time scale 1998 -
2004. This is less than that reported by Reid et al 364 in England in an equivalent time
scale and that recorded in the Scottish data. The Grampian Ablation data is slightly at
odds with that seen in Scottish data, a 57% increase in Ablations is reported in
comparison with to the 65% increase in Scotland. This may represent the fact that the
Grampian Consultants had already adopted ablation techniques in 1998 and thus
proportionally, the increase in the number of ablations in 2004 is less evident than in the
rest of Scotland. Grampian region has a very pro-ablation consultant body with a
number of internationally recognised ablationists practicing at Aberdeen Royal
Infirmary. If the Scottish figure for reduction in surgery for menorrhagia is less than for
England & Wales (25% versus 43%) then the reduction in Grampian is even less marked
with a reduction of 13% noted. The ratio of Hysterectomy to Ablation in Grampian is
also strikingly different with a ratio of 5:1 reducing to a ratio of 1.7:1 seen in the
Scottish data over the time period 1998 to 2004 compared to a ratio of 0.9 :1( almost
equality) reducing to 0.5:1 in the Grampian data. This data is at odds with the English
ratios produced by Bridgeman and Dunn which reported a 3:1 ratio of hysterectomy to
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ablation in 1992/3 increasing to a 4:1 ratio in 1995/6. Looking at the Grampian data the
smaller reduction in rates of surgery for menorrhagia and the greater rates of ablation
compared to hysterectomy may represent the strong preference to ablations in Aberdeen.
It is also notable that the number of ablations in Grampian has remained relatively static
whilst the hysterectomy figures have continued to decrease. This might suggest that
perhaps the use of Mirena has had an effect on the number of operations for
menorrhagia. It is difficult to estimate the effect of the Levonorgestrel IUS Mirena on
the Grampian and Scottish surgical figures. The launch of IUS as a contraceptive in
1995 coincides with the start of the drop off in English hysterectomy and a cause and
effect is postulated.364 A significant amount of off license use is assumed to have taken
place before it was finally licensed for menorrhagia in 2001, but unfortunately, we have
no hard data to back this hypothesis up. The ECLIPSE trial should help unravel the
epidemiological issues around the role Levonorgestrel IUS has in menorrhagia.
5.5 Conclusion
Rates of surgery do not remain static but show dynamic changes over time. A variety of
influences on the rates of surgery exist and some are easier to assess than others.
Hysterectomy will always remain an effective and definitive procedure that offers cure
of menorrhagia but at a price. The optimal route of hysterectomy is vaginal and it is
concerning that the preferred route of surgery is still abdominal in Scotland (3264 versus
545). The role of endometrial ablation is established and long-term data is encouraging
that the rates of further surgery remain low. A shift from the more operator dependant
technically difficult 1st generation ablative techniques to the second generation ablative
techniques is seen in the Scottish figures. How much the procedure of ablation replaces
hysterectomy is more difficult to say. Hysterectomy rates have fallen as ablation rates
increase but whether this is pure cause and effect and how much of an impact is brought
with the Levonorgestrel IUS is more difficult to untie, hopefully further studies in the
pipeline will reveal this.
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The lowering of the threshold for surgery suggested by Bridgeman and Dunn is
interesting and such an effect may be expected in a pro-ablation region like Grampian.
Ablation in Grampian is almost now twice as common ( 2004 data) as hysterectomy
and contrast markedly to the national ratios for hysterectomy to ablation which fell from
5 : 1 in 1998 in 1998 to 1.7: 1 in 2004. Which ratio is optimal is difficult to say. The
small (13%) reduction in operative procedures in Grampian may represent a lower
overall impact on total operative procedures caused by patients who would never
consider hysterectomy opting for ablation. Whether this is an undesirable effect is
debatable. This potential switching of patients who would never consider hysterectomy
and therefore be managed medically to ablation would increase operative rates and
theatre usage. However, as observed in the study of long-term follow up after ablation
reported in chapter 2 of this thesis, patients that were randomised to surgical (ablation)
had superior outcomes in terms of higher satisfaction scores and quality of life when
compared to those randomised to medical treatment. Thus, perhaps better patient
outcomes in the long-term may be realised with greater uptake of endometrial ablation




Conclusions arising from the work presented in this thesis and suggested
areas for future research.
This thesis has centred on excessive menstrual bleeding and in particular the role and
evidence base of endometrial ablative surgery.
In chapter one the aetiology, epidemiology and treatment options were reviewed. As a
condition excessive menstruation exerts a significant health care burden with an
estimated cost to the country of 7 million pounds per annum in medical treatments and a
similar amount on surgery.100
Rates of surgery vary significantly both nationally and internationally with data from the
1990's reporting 60% ofwomen referred to a gynaecologist being hysterectomised
within 5 years.314 Ablations rates also vary with conflicting views on the long-term
effect of ablations on hysterectomy rates.
Medical treatments can be effective and to some are the only acceptable treatment but
most RCT evidence is poor. The trial evidence suffers from small numbers, with short
term follow up and a cross over design with patients acting as their own control group.
In chapter two I reported on a five year follow up of a RCT offering women referred
with menorrhagia either current best practice medical therapy or ablative surgery. This
represents the longest follow up of patients treated medically. The numbers persisting
with medical treatment long term was minimal, with 77% in the medical arm undergoing
surgery (18% a hysterectomy). Interestingly the hysterectomy rate in the ablated arm
was almost identical (17%) to that in the medical arm. The QOL scores in the ablation
arm were superior to those in the medically treated arm with all eight scales of the SF36
health survey scores restored to normative values and only 4 being restored in those
treated medically despite the majority receiving ablation over the trial interval. This trial
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establishes the hierarchy of treatment (with the comment that the trial predates the use of
the Mirena Levonorgestrel IUS). Medical treatment in this trial resulted in poorer QOL
outcomes, patient satisfaction with smaller numbers who would recommend it to a
friend. This trial establishes medical treatment as inferior to ablative surgical treatment
which in turn is inferior to hysterectomy. The trial also addressed the potential effects of
early ablation, a policy many are concerned will have a negative impact on overall rates
of surgery. The policy of offering early ablative surgery in those referred to a
gynaecologist with excessive menstrual bleeding did not increase the hysterectomy rate
in this trial and more over was associated with improved outcomes. These results are
highly generalisable into the wider clinical population with the limited inclusion criteria
and pragmatic study design.
In chapter three I report on a RCT ofMEA versus RBEA. Worldwide RBEA is a
common ablative procedure. In North American especially RBEA is the commonest first
generation ablative procedure. The trial establishes MEA to be as effective as RBEA in
the measured outcome variables.
The trial design has certain features. The unbalance randomisation ratio (2:1, MEA:
RBEA) was designed to maximise the numbers in the experimental treatment arm. Some
negative exist. The strict inclusion criteria and objectification of menorrhagia decrease
generalisability of the trial and may result in exaggerated outcomes compared to those
seen in a general clinical population. The influence of a competing commercial interest
must also be bome in mind as a potential for bias. Overall the trial can be seen to give
RCT evidence that MEA gives comparable outcomes to RBEA.
In chapter four MEA outpatient ablation in the post menstrual phase was assessed. Many
would argue that outpatient therapy is the natural progression of the second generation
ablative procedures. The simplicity of technique and short operative times lend these
procedures to use in this setting. Transferring out of a high cost labour intensive theatre
environment into a low cost environment has many advantages. Many ablative
technologies claim acceptability as outpatient techniques. Looking at the quality of the
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data however reveals little evidence of this being assessed as a primary outcome
measure in adequately powered RCT. The evidence base for the majority of technologies
claim of suitability for outpatient treatment is derived from small non randomised and
inherently biased case series.
The reported trial reveals the economic benefits of outpatient ablative surgery with a
significant financial saving, a mean of £ 124 less than standard treatment. The treatment
was also highly acceptable to the trial participants with significantly more women
finding post menses outpatient treatment acceptable compared to treatment in an
operating theatre as a day case (89.5% versus 76.0%). The numbers in each arm
reporting themselves as totally or generally satisfied with their treatment were similar.
Importantly menstrual outcomes were unaffected by the avoidance of endometrial
preparation with similar menstrual outcomes in each arm. This is reassuring as there was
concern about the possibility of reduced efficacy in the absence of endometrial
preparation. Thus this trial established outpatient MEA in the postmenstrual phase as a
feasible proposition, that endometrial preparation was not essential and that post
menstrual treatment was not only acceptable but indeed more acceptable than standard
drug preparation.
Overall the feasibility of post menstrual outpatient treatment remains unfortunately
slightly questionable. Whilst it is undoubtedly possible in the context of a RCT with a
dedicated research fellow and well motivated support staff certain aspects may make it
more difficult to introduce into routine care. The logistics of scheduling patients into
treatment slots on the basis of their menses is a problem in its self. Also for those who
are intolerant of the procedure there is the question of rescheduling under general
anaesthesia. These practical issues are in conflict with the desirability of the procedure
as an outpatient. At present treatments in Aberdeen Royal Infirmary are scheduled after
an artificially induced withdrawal bleed (Provera lOmgs is taken twice daily for 10 days
and stopped 10 days prior to surgery). This result in the patient being in the early
postmenstrual phase at the time of surgery. This allows patients to be scheduled into
standard operating lists. A second issue is post operative pain and nausea. Unfortunately
whilst a well tried pre / intra-operative regime of analgesia plus or minus conscious
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sedation exist there remains the issue of post operative pain. Post operative pain is
unpredictable and may necessitate admission. Certainly in Aberdeen with many patients
living over 30 miles away this is a real problem which would prevent the use of ablation
as an outpatient therapy off site. Analgesia use post operatively was high with 43.3%(
post menses) and 22% (post endometrial preparation) requiring opiates and similar
numbers around 81% being fit for discharge at 6 hours the majority of the remainder
requiring overnight stay.
Overall the trial establishes MEA as feasible, economically advantageous and successful
as a post menstrual outpatient treatment.
In chapter five rates of ablative surgery and hysterectomy were assessed. An over view
of the Scottish and Grampian data was made with comparison to comparable English
data. The 1990's figure of 60% hysterectomy rates at 5 year are now compared to the
more recent figures after the general uptake of ablation of 18%. The pro - ablation
stance ofAberdeen may well infact result in a reduction in hysterectomy but at a cost of
an increase in the total number of procedures (ablation + hysterectomy). In Scotland the
ratio of ablation to hysterectomy is in the order of approximately 2 to 1 whilst the
Grampian data suggest almost the opposite ratio of 2 ablations for every hysterectomy.
Certain trends in the national figures give cause for concern with the numbers of vaginal
hysterectomies remaining disproportionably small. Training issues may have a role to
play in this. The drop in laparoscopically assisted vaginal hysterectomies is also a
concern, training issues again may again be in part responsible for this.
6.1 Suggestions for Future Research
Major inroads into the management ofmenorrahagia have been achieved; however
significant deficiencies in our knowledge still exist. New and promising treatment
modalities require further evaluation. Adequately powered, randomsied controlled trials
with adequate periods of follow up would make a significant and effective contribution
to the medical knowledge base.A pragmatic design utilising both economic outcomes
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and health related quality of life as a outcome would be highly desirable. Quality of life
tools should ideally include both generic and disease specific tools.
6.1.1 Genetics
Further work is required into the genetic basis of endometrial dysfunction. Human
genomics and proteonomics may well hold the key to unlock the label of dysfunctional
uterine bleeding. The basis of the disease is likely to lie in abnormal gene expression.
Borthwick et al have established the transcript profile for human endometrium in normal
endometrium of the secretory and proliferative phases of the menstrual cycle.368 Work
reported form Cambridge in the late nineties established the feasibility of in vivo gene
transfer in murine endometrium and in vitro gene transfer in human endometrial
preparations.165 This work using DNA - lipososme complexes described by Charnock -
Jones et al 165 is highly significant and may be the first step along a road away from
steroid agonists and antagonists and towards a directed gene therapy.
6.1.2 Medical Treatments
The epidemiology ofMirena use in menorrhagia needs to be addressed. The long term
outcome ofMirena users needs to be defined. The exact numbers persisting with the
device over a 10-15 year interval is unknown.
Mirena has been compared to hysterectomy and limited ablation data is available but has
been hard to come by. Now that evidence is accruing of the feasibility and acceptability
of outpatient ablation the comparison with IUS is even more valid. The recruitment
difficulties experienced by the previous RCT ofMirena verus ablation need to be
overcome either through different study design or larger multicentre trials.
Further research into the mechanism and treatment of irregular bleeding seen with the
IUS is required. These side effects are commonly sited as a reason for discontinuation
and premature removal. Endometrial Hyperplasia ( with or without atypia) as a
pathological group are often treated with Mirena especially in patients who are
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unattractive for surgery ( e.g. severe medical problems / morbid obesity). There is little
evidence however as to the safety of this treatment versus standard oral progestagen
regimes and this represents an area for research.
The management of fibroids remains surgically dominated. The longterm outcome of
Uterine Artery Fibroid Embolisation require further evaluation especialliy as many
studies only involved a 6 - 12 mth follow-up period.How many women will still retain
their uterus at 5 years remains to be established. The role of repeat embolisation also
remains to be clarified.
The suitability of Mirena in irregular or large cavities ( e.g. fibroid cavities) is unknown
, studies into the use in such cavities would aid in patient counselling and management.
New oral medical treatments exist that may offer a treatment option for fibroid
associated menorraghia. These may offer potentially a longterm (unlike GnRHa) fertility
sparing medical option.
Progesterone receptor anatagonists have been used. Mifepristone has proved useful in
the management of unwanted pregnancy and miscarriage and in the induction of labour.
A systematic review of 3 studies of the use ofMifepristone in the medical treatment of
fibroids revealed promising menstrual symptom relief, reduction of fibroid volume and
pressure symptoms but a rather worrying level of hyperplastic change.369
Asoprisinil is a SPRM ( Selective Progesterone Receptor Modulator) that shows some
early promise in the medical treatment ofboth menorraghia and fibroids. Dose
dependant suppression of menstrual blood loss, reduction in fibroid volume and pressure
effects have been demonstrated with preservation of ovulation and the basal oestrogen
levels remaining unchanged. No adverse effect on the endomeruim was reported. Further
research is highly desirable.370;371
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6.1.3 Education
The taboos and misconceptions surrounding menstruation are unhelpful. The
development of educational programmes to educate and empower women may, over the
long term reduce hospital referrals. Qualitative research into exactly why women seek
referral performed without the constraints and censorship implicit in a questionnaire
would prove illuminating.
6.1.4 Endometrial Ablation
The acceptability of ablation under local anaesthesia needs to be assessed in adequately
powered randomised control trials for each method that claims to be suitable as an
outpatient treatment. Long term safety and outcome data of all second generation
ablative treatments are required, a 'MISTLTOE 2 'study is long overdue. Safety issues
must remain at the forefront of our minds. Whilst the newer techniques may not lend
themselves so easily to a Mistletoe style audit this should not deter us from being
vigilant. The usefulness of device specific data collection by national bodies such as the
US FDA MAUDE Database is to be bourn in mind.
Long term concerns regarding the effect on the incidence, presentation and prognosis of
endometrial cancer need to be addressed through epidemiological studies.
Further head to head RCT of different ablation modalities require to be performed
especially in the context of outpatient treatment. The role of ambulatory or ' one stop'
menstrual clinics (including the uses of see and treat ablation clinics) requires to be
defined. Their usefulness, safety, cost effectiveness and acceptability to patients require
evaluation.
6.1.5 Diagnostic Tests
The role and ideal combination of diagnostic tests in the investigation ofmenstrual
disturbance requires evaluation. Th exact combination of history taking, clinical
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examination, endometrial evaluation and medical imaging that would provide efficient,
cost effective and acceptable ( from a patients perspective) investigation requires to be
defined. 372 Further investigation into the role bleeding disorders have to play in the
presentation and management of menstrual disorders is desirable. Von Willibrands
disease is common but no easy test exists that could be applied effectively to the
population with menstrual problems. Further scientific developments into rapid,
effective and cheap tests of coagulation are desirable.
6.2 Conclusion
The work highlighted in this thesis represents my clinical interest in menstrual disorders
and their treatment. I wish to thank the women who agreed to take part in the research
that this thesis is based upon and the assistance and support ofDrs Cooper and Cameron.
The evolution through medical and surgical treatments and their development represents
a body ofwork that has taken a number of years to complete and longer to evolve into a
literary piece. A family has been started and completed in the same time frame.
My interest continues to evolve as the treatment ofmenstrual disorders improves
immeasurably from the days when all roads led to hysterectomy.
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Appendix 1. Study Questionnaires
l.lChapter 5 TCRE versus Medical: Five year follow-up questionnaire.
Study No Original treatment Medical / T.C.R.E.
The study you took part in about five years ago for treatment of heavy periods is
now finishing and the questionnaire enclosed is the final part of the project. You were
allocated the above treatment originally, although we realise that you may have had
other treatments since then. We would be grateful if you could take some time to
complete the questionnaire as best you can and return it in the pre-paid envelope. If you
feel that you are still having problems with your periods and would like to be seen again
then please say so at the end.
Thank you for your help and time





* if stopped, then go straight to question 8* continued but heavier 4
2/ How many days are there from the first day of
one period to the first day of the next ?
less than 21
21 to 35 2
more than 35 3
totally unpredictable 4
3/ On average, for how many days does your less than 3 days
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period last ? between 3 and 7 days
between 8 and 10 days
more than 10 days
4/ On average, for how many days is the bleeding heavy ? □




6/What is an average period like for you now ? For each day please show how severe
your
bleeding and pain are by giving each day a score from 1 to 5












Bleeding score Pain score
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7/ Do your periods stop you from carrying out no, not at all
your work, housework or other daily activities ? no, but work suffers
yes, but only one day
yes, more than one day
8/ What further treatment have you had for your tablets (name below)
periods since the original treatment that you T.C.R.E.
were given in the study? repeat / second T.C.R.E.
hysterectomy
other (explain below)
91 Do you get any of the following symptoms just before or during a period, or on a
cyclical basis if you are not having periods?
Yes No





10/ Is sexual intercourse painful for you ? no
yes, but less than before
yes, the same as before
yes, worse than before
11/Since your treatment are you experiencing any no



















12/ Overall, what effect has your treatment so far had on your period symptoms ?
No effect
improved, but not sufficiently
improved to an acceptable level
cured completely
13/ Have you found your treatment acceptable ? Yes
No





15/ Please indicate how you would rate your overall satisfaction with your treatment.
(please circle the number that is closest for you)
1 2 3 4 5 6
totally generally fairly fairly generally totally
satisfied satisfied satisfied dissatisfied dissatisfied dissatisfied
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The following questions ask for your views regarding your health and how you feel
about life in general. Answer all the questions, if you are unsure then think about
your overall health and give the best answer you can.







2/ Compared to a year ago, how would you rate your general health now ? (circle one)
much better 1
somewhat better 2




3/ The following questions are about activities you might do during a typical day. Does
your health limit you in these activities ? If so, how much ?(circle one number for each
question)
YES. YES. NO.
ACTIVITIES LIMITED LIMITED NOT
A LOT A LITTLE LIMITE
D AT
ALL
a/ vigorous activities, such as running,
lifting heavy objects or 1 2 3
strenuous sports ?
b/ moderate activities such as moving a
table, hoovering ,bowling or golf ? 1 2 3
c/ lifting or carrying groceries ? 1 2 3
d/ climbing several flights of stairs ? 1 2 3
e/ climbing one flight of stairs ? 1 2 3
f/ bending, kneeling or stooping ? 1 2 3
g/ walking more than a mile ? 1 2 3
h/ walking half a mile ? 1 2 3
1/ walking 100 yards 1 2 3
j/ bathing or dressing yourself 1 2 3
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4/ During the past 4 weeks , have you had any of the following problems with your work
or other regular daily activities as a result of your physical health ?
(circle one number for each
question)
YES NO
a/ cut down on the amount of time you spent
on work or other activities ? 1 2
b/ accomplished less than you would have
liked ?
1 2
c/ were limited in the kind of work or
activities ?
1 2
d/ had difficulty performing the work or
other activities (e.g it took extra effort)? 1 2
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5/ During the past 4 weeks , have you had any of the following problems with your work
or other regular daily activities as a result of any emotional problems ( such as feeling
depressed or anxious)?
a/ cut down on the amount of time you spent
on work or other activities ?
b/ accomplished less than you would have
liked ?
c/ didn't do work or other activities as
carefully as usual ?
6/ During the past 4 weeks, to what extent has your physical health or emotional
problems interfered with your normal social activities with friends, family or groups ?
(circle one)



















8/ During the past 4 weeks, how much did pain interfere with your normal work (
including both work outside the home and housework) ?
(circle one) not at all 1
a little bit 2
moderately 3
quite a bit 4
extremely 5
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91 These questions are about how you feel and how things have been with you during the
past 4 weeks.
For each question, please give the one answer that comes closest to the way you have
been feeling, (circle one number for each question)
HOW MUCH TIME ALL OF MOST OF A GOOD SOME A NONE
IN THE LAST 4 THE THE BIT OF OF LITTLE OF
WEEKS TIME TIME THE THE OF THE THE
TIME TIME TIME TIME
a/ did you feel full of 1 2 3 4 5 6
life?
b/ have you been 1 2 3 4 5 6
nervous ?
c/ have you felt so
down in the dumps that 1 2 3 4 5 6
nothing could cheer
you up ?
d/ have you felt calm 1 2 3 4 5 6
and peaceful ?
e/ did you have a lot of 1 2 3 4 5 6
energy ?
f7 have you felt 1 2 3 4 5 6
downhearted and low ?
g/ did you feel worn 1 2 3 4 5 6
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out ?
h/ have you been happy
?
1/ did you feel tired ?
j / Has your health
limited your social
activities?
10/ How TRUE or FALSE is each of the following statements for you
(circle one number for each
question)
a/ I seem to get ill more
easily than other people
b/ I am as healthy as
anybody I know
c/ I expect my health to
get worse

















1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
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1.2 Chapter 6 MEA versus REA Trial Questionnaire
A COMPARISON BETWEEN ROLLERBALL ENDOMETRIAL ABLATION
AND MICROWAVE ENDOMETRIAL ABLATION
Rollerball endometrium ablation (REA) versus microwave endometrial ablation
(MEA.)
We would like to invite you to participate in a study comparing two methods of treating
the lining of your womb (endometrial ablation) as treatment for heavy periods. The
study is part of a research project to promote medical knowledge in this area of
gynaecology, but may be of no benefit to you personally.
The following information should give you more of an understanding of what the study
is trying to find out, but if you have any further questions then please ask. Please be
aware that there is absolutely no obligation to participate in the study. Even if you did
decide to take part, you can change your mind and withdraw from the study at any time,
for any reason, without explanation, and your care will not be affected.
Each month a lining (endometrium ) forms inside the womb and is shed as your period.
Sometimes this bleeding can become heavy and even unpredictable. Removing this
lining can result in periods stopping altogether or becoming lighter. It has been decided
that this is the most appropriate treatment for your heavy periods. There are many
different ways of destroying the endometrium. Passing an instrument up through the
neck of the womb (cervix) usually when you are asleep performs them all. The
commonest method world-wide at present is to perform a rollerball ablation, which
involves destroying the lining using a small electric ball.
Another newer way of destroying the womb lining to a predictable depth is to use a
microwave probe. Both techniques are proven to be safe, successful and acceptable
treatments and are performed in exactly the same way. Indeed you would not know
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which technique you had received unless you were told. Both REA and MEA are used in
Aberdeen and have been for some time.
REA and MEA have never been compared with each other to determine whether there
are any advantages of one technique over the other .
To find out how useful treatments are doctors need to do a study. If you were to take part
in this study comparing MEA and REA you would be allocated to having one or other
operation by chance. You would have a two out of three chance ( 66% ) of having a
MEA and a one in three chance (33%) of a REA. We would ask you to complete
questionnaires before the operation and at two weeks, three, six, twelve and twenty-four
months afterwards. These would allow us to find out how effective each technique is at
treating heavy periods, but particularly how acceptable each operation is and whether
MEA is quicker and easier to perform.
In addition we would want to take a blood sample to measure two female hormones,
FSH and oestradiol (5 teaspoonfuls / 10 mis of blood). These blood tests are taken at the
beginning and repeated six months and one year after your operation to tell us whether
you are close to the menopause
It is important to add that neither operation guarantees that you cannot fall pregnant in
the future, although it is unlikely. If you wish, a sterilisation can be performed at the
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This questionnaire Is completely confidential. When completing, please read the Instructions care¬
fully. take your time and be honeet. If you cannot answer a particular question, leave it out and we
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fectiveness of Microwave Endo¬
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PATIENT NO: j | |
Please specify answer by checking the appropriate box fa the right
1. How long have you suffered from heavy periods? Less than one year
One to three years
1
1
More than 3 years




Z. On average for how many days does your period last? Less than 3 days
Betvrcen 3 and 7 days
Between 8 and 10 days
More than todays
A. On average, for howmany days is the bleeding heavy? Mot heavy
1 to 3 days
4 to 6 days
7 Ormore days
5. Imagine an average period for you: for each day ptaase show how severe Day of Period Bleedng Pain
your bleeding and pair were by grving each day a score from 0 to 3

















Plaaae apatffy en*war by checking the appropriata box to the right
«. Do your periods stop you from carrying out your work outstda the home? No, not at alt
No, but work suffers
Ym. but onlyone day
Yaa. mom than ©na day





At any time in the last three month*, heve you naadad to u*« mora than oral
form of protection at tha tame time? No
Tampon and pads
Tampon and two pads
Mom than this (a.g taws 1)
*. On your haaviast day, how many tampons «mlA>r pad* do you use? Numbac of tampons
Nomber of pad*
10. Do your panada occur at regular intervals (*, The same time ovarymonth)? Ya*
No
11 On avarsga, howmany days am there between the start of one period and




Controlled Trial to Aaaeu the Ef-i
fectivdnaaa of Miciowava Endo¬
metrial Ablation (MEA) Versus
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{Controlled Trial to Assess the Ef-!
fectiveness of Microwave Endo- j
metrial Ablation (MEA) Versus j
Rollerball Endometrial Ablation













' INCLUSION CRITERIA (All questions must be answered YES)
Please specify by checking the appropriate box to the right.
i
Yea No
1. SELECT ONI COLUMN TO THE RIGHT & CHECK THE APPROPRIATE CATEGORY BELOW
Previous Documentation of menorrhagla - Imonth PBLAC
Previous diaonosis failed medical therapy
Pt. refused medical therapy (document on source doc.)
Pt was unable to tolerate medical theraov (document on source doc.l
PBLAC score >A= 185 (RECORD SCORE)
t. No previous documentation of menonhagla - 3month PBLAC
PBLAC scores (average! >/= 185 (RECORD SCORES1
». FSH measurement ml U/ml < 3D
4. Negative pregnancy test
! G. Negative endometrial sampling
I. Uterine cavltv lencrth cm < 14
I 7.
I AgeW= 30 years
a. Patient agrees not to use hormonal contraception or other interventions for
abnormal uterine bleeding for the duration of the study
SPECIAL PRECAUTIONS
1. Long term steroid use
2. Connective tissue disorder
2. Bicomuate uteri s




Controlled Trlak to Assess the Ef¬
fectiveness of Microwave Endo¬
metrial Ablation (MEA) Versus
RoHertaii Endometrial Ablation












EXCLUSION CRITERIA (All questions must be answered NO )
Please specify by checking the appropriate box to the right. Yes No
1. SELECT ONE COLUMN TO THE RIGHT AND COMPLETE INFO BELOW IF APPLICABLE
Does the patient have submucosal fibroids, polyps, or fibroids that
obstruct treatment access to any part of the uterine
cavity (as determined by hysteroscopy or U/S)?
Fibroids Size Number Tvoe
Polvps Obstruction Cavitv Location
2. Previous endometrial ablative surgery?
3. Previous classical cesarean section
4. Presence of IIJD?
S. Patient who is pregnant or still desires to conceive?
E. Presence of atypical endometrial hyperplasia {i.e. adenomatous) or
Endometrial carcinoma on preoperative endometrial sampling?
7. Presence of active endometritis?
8. History of gynecological malignancy within past five years?
9. Active Pelvic Inflammatory Disease (PID)?
10. Known clotting defeclaor bleeding disorders?
11. Untreated/unevaluated cervical dysplasia?
12. Thickness of uterine wall < 8mm \














I'ADENT INITIALS: | [ | j
PATIENT NO.
t. Date of Birth: X
bey ~4r








CODE: 1'Normal (Conditio or Function) STATUS: 1'Resolved
g'Abnormai 2-Existing
Body System Code Specify Abnormality Status
1. Skin n n
2. Eyes, Ears, Nose 4 Throat n n
3. Respiratory n n
4. Cardiovascular n n
5. Musculoskeletal n n
6. Gastrointestinal □ □
7. Genito-Urinery n n
8. Endocrine & Metabolic n n
9. Neurological n n
10 Psychological n n
11 Hematopoietsc/Lymphatic n n
12, Allergies □ n















PATIENT INITIALS: | |
PATIENT NO:
Doe* the patient have a history of prior surgical procedures? (1=Yes"; 2=No)




























tatiekt initials: [J j
patient no.
VITAL SIGNS, HEIGHT AND WEIGHT
Oral Temperature 1 1 1 Resoiralion Rate,ill/ minute
Pulse Rate I 1 / minute Blood Pressure: | ] | | / 1 1 mmHg






1. Head, Neck & Thyroid n
2. Ears, Nose & Throat n
3. Eyes n
4. Chest (including breasts) i i
S. Lungs □
6. Heart □
7. lymph Nodes □
8. Abdomen □
9. Anorectal □









Ccriirotled Trial to Assets trie Ef¬
fectiveness of Microwave Endo¬
metrial Ablation (MEA) Versus
Rollerball Endometrial Ablation
(REA) (or the Treatment of Menor-
rtwjw
PASE: 9
PHYSICAL EXAM: INDICATE IN RIGHT COLUMN WWVBt»
OOCUNOttAnON
PEHFOMIEO
Pap smear (if net within last 6 mo )
Endometrial biopsy (if not within last 6 mo.)
Uterine eourrdina cm
U/S
Uterine wall thickness mm
Hysteroscopy
Is the uterine cavity within normal limits? YES
NO
Are fibroids present? YES
NO









Controlled 1 rial to Assess the El- j
feotivsness ot Microwave Endo-|
metnal Ablation (MEA) Versus'
Koliertwiil Endometrial Ablation









DATE: [ ! ! I j
'v»
USB DIAGRAM TO INDICATE POSITION AND SIZE OF R8ROIDS AND/OR POLYPS:
Are polyps present? YES
NO








Controlled Trial to Aasess tn« Et-
jf«e<Sveness ol Microwave Ercio-
ImeWal Ablation (MEA) V#r*us
Rollerball Endometrial Ablation






PATIENT NO: 1 1 1 1
IDATE: n
FiB in the blanks tmtfor mark the appropriate box to th# right




Were there any intraoperative complications?























Long term steroid therapy
Blcomuate uteri
Acute retroverted uterus
How iong wes tr>e operative i«ne? _Seoonda (M£A)
JWtiMtom (REA)




Controlled Trial to Assess the Ef¬
fectiveness of Microwave Endo-
Imetriet AolaSon (MEA) Versus
'
RoHerbatt Endometrial Ablation










"1* | I || M
Fill in the thanks aiwtformark the appropriate box to tha right
* Recovery room hme (observation) Minutes







A. it \hm uterine cavity within normal femes? Cavity length vet
No
B< Art ftofOJd* present? Yea
No




Conuoted Trial to Assess the Ef¬
fectiveness of Microwave Enao-
metiiat Ablation (MEA) Versus
RoilerbaJI Endometrial Ablation,











Fill to the blanks and/or mark the appropriate bo* to the right !
1B. Nytteroeeopy {continued)
P. Arc polypi present* Yet
No




11 Was post op pain relief required In recovery? Yet
* No
iZ Wat readmnMion required? (If YES. document) Yet
1 No111.
1
What type ot anesmesia was used* General Anttiheela
IV Sedation
Regional
14, For REA. fluid deficit post procedure . . mis







Controlled Tnei to Assess the £(■
: fectiveness of Microwave Endo-;
'
metrijl Ablation (MEA) Versus
RoOcrbal! Endometrial Ablation








PAT IENT INITIALS; n
PATIENT NO: I I I
DATE: I I I I I
PLEASE USE THIS FORM TO DETAIL ANY INTRAOPERATIVE COMPLICATION.





*•—' 'Controlled Trial to Aeaess the Ef-
■ lecthreneM of Microwave Endo¬
metrial ABIatw (MEA) Venus
RoBertMll Endometrial Ablation







PATIENT INITIALS: | | j 1
PAT1ENTNO: Mill
DATE: I I I 1 I I




i Controlled Tnal to Assess the £f- i
. fectiveness of Microwave Enoo-i
melrial Ablation (MEA) Versus i
Rosierball Endometrial Ablation I









PATIENT INITIALS; [ | | j '
PATIENT NO: | | | | j
DATE: 1' I I I I I i
Pleas,® cbecK the appropriate box to the right YES NO
1. Have you experienced any nausea or vomiting?
2. Have you experienced a fever *101?
3. Have you experienced chills?
4. Have you experienced difficulty or pain with urination?
S. Have you experienced difficulty or pain with BM?
6. Are you experiencing excessive abdominal bloating?
7. Have you experienced uterine cramping unrelieved by pain medication?
8. Have you experienced any vaginal bleeding greater than 1 pad/hour?




RTO (2 WEEKS FROM PROCEDURE -»/- 2 DAYS):
COORDINATOR'S SIGNATURE DATE:
INVESTIGATOR'S SIGNATURE DATE: j
CONFIDENTIAL
PROTOCOL: ftendomwKl
W> ! Controlled Trial tc Assess tne B-1
lectivoness of Microwave £nd»
metnai Ablation (M£A) Versus
RoBerbal! Endometrial Ablation









■Piease answer by risking tmly em feo* to th* right
1. Hew long after the procedurem ftm fee! that yne had completely recovered? t have not recovered yet I
less than 2 weeks
2 to 4 weeks,
2, When were you able to return to you? norma! everyday actrvrtres (housework,
work., etc.)
leoc man 2 week*
2 to 4 weeks





4, DKS yov fcmf the operated acceptable? Ye*
Ho I
£. DH you require actional pain relief after going home? Yes
HO






! have not stepped yet,
CONFIDENTIAL Pi umm & Date
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i i PROTOCOL: Randomized
ConlfoUcd Trial lo Assass the Ef¬
fectiveness ol Microwave Endo¬
metrial Ablation (MEA) Versus
Roilcrbaft Endometrial Ablation









r-1' I K t" I
PATIENT NO: | I J I I










More men adc hmea/day
9. hew much medtcabOT! era/ware you uking at each dotung? (Please aptcrfy




More than three ta&tets




CONFIDENTIAL Pt. Initiate I Data
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PROTOCOL: R«r,aomized j
; Controlled Thai to Assess the Et-i
jf«cliv«oe»» of Microwave Entto-j
i medial Ablation (MEA) Versus j
Rolle/ftaH Endometrial Ablation
<REA) for the Treatment of Menor.
mag la









Pleas* amwor by chocking only one box to the right
1. What date was the procedure performed? i i
MONTH OA* V&AK




3, Has the patieftt used any med»c*b©r» since the pfooedure?
(if YES, record on Concomitant MediationCftf)
YES
NO
4. Has the patient experienced any adverse events Since the procedure?
(II YES, record on the Adverse Event* CRF)
YES
NO
'5. Were them any post~cp complications? (if YES, document below) YES
NO
6, Wat the pelvic axam at today's visitwithin normalmU2 (If HO. detail below
And record on the Adverse Event* CRf)
YES
NO
7. Detail action taken if the 2 week pelvic examwas not within norm* limits:
;
i
SIGNATURE OF INVESTIGATOR: DATE:
CONFIDENTIAL
I PROTOCOL: P»ndorruz«d,| Controlled Tnel to Asse&c the £t-
• teMtvtenei* of Microwave Endo-
mcinal Ablation (MEA) Vrnus
RallwtMil Endometrial Ablation









PATIENT NO" | j | | | '
Pleaee answer by chocking only ONE box to the right. !
1. How long after the procedure did you fee? thai you had completely recovered? 1 have not recovered yet !
a"
Less thaan 2 week*
2 to A week*
4 to 8 week*
2 to 2 months
2. When were you abfo to return to your normal everyday acbvtbe* <housewofX,
work. etc.>
Left* than 2 weeks
7 to 4 wMrs
4 to 5 weeks J
2 to 3 months
Stli unable
3. Have yoot periods Stopped
Continued bu* lighter
Continued as before
j Continued Cut heavier






!& Do your periods stop you from carrying out your work outside the home? No, not at all
No, but work suffer*
Yes, bid only one day
Yes, more then one day
CONFIDENTIAL Pt. Initial* & Date
PROTOCOL: Randomized
i Controlled Trial to Assess the El-
I fearveness o( Microwave Endo-
imetrial Ablation (MEA) Venus
RoHerba* Endometrial Ablation






















it. Dip you ftftd the operation •cceptaote'? Yea
No





CONFIDENTIAL Pt & Date
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PROTOCOL: Randomued
S Controlled Trial to Assess the Ef¬
fectiveness of Microwave Endo¬
metrial Afclation (MEAj Versus
RoHerball Endometrial Ahiatkm











Please answer fey choking only GN£ box to IM right
I1- How Umg after the procedure <*M you t**i thai you baa completely recovered? i have not recovered yet
""
lass than 2 weeks
I
2 to 4 weeks
4 to 6 weeks !
2 to 3 months
3 to 6month* I
%. When were you able to return to your normal everyday ectMttos {hoosewo*k«
work, etc >
Less than 2 weeks
2 to 4 weeks
4 to 8 week*
2 to 3 month*
3 to €• month*




: 4, Do you have pam with your period? No
| less mm before
SonetM before
Worn* than before
it. 00 your periods stop you from carrying out you? work outside the homo? No, not at a it
No, but work suffers
Y#s„ but only one day
Yes, more than or# day
CONFIDENTIAL iH. tn&ais & Dm
| PROTOCOL: Randomized
I Controlled Trial to Asses* ttie Ef¬
fectiveness of Microwave Endo¬
metrial Ablation <MEA) Versus
i Rollerball Endometrial Ablation



















8. Did you find the operation acceptable? Yes
No
9. Please indicate how you would rate your overall satisfaction with your treat- Very satisfied
Satisfied
Dissatisfied
CONFIDENTIAL Pi. Initials & Date
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PATIENT INITIALS; | | |
PATIENT NO'
Pleat* *n»w*r by only GN£ bo* to the right.
1, Hm long after the procedure did you feel that you had ccmptetsty recovered? 1 have not recovered yet
Less than 2 weeks
i
2 to 4 weefcs
*
4 to 8 week*
2 to 3 month*
3 to 6 month*
6 to 12 monite





4 to 8 week*
2 to 3 month®
3 to ft months
6to !2mootfe*








is. Do your period* *tep you from carrying out yourwo* ouUude the home? Mo. net at an
No, but worn suffers
Ye*, but only one day
Yes, more then one day
i PROTOCOLS Remand
'
Controlled Trial to Assess the Ef-
tectrveoeM ol Microwave Endo¬
metrial Ablation (MEA) Vcrsui
: Aol'crbaii Endometrial Ablation










| Controttad Trial lo Assets the Ef-j !«ctiv»ness of Mtorowava Endo-
-matna! Ablation (MEA) V.nua
Rofiarfcall Endomatriai Ablation









PATJENT INITIALS: j | | |
PATIENT NO: | | j | |










3 Did you find the operation accapUDte"* Yea
No
- t









CONFIDENTIAL Pt Ir.bals A Data
1.3 Information Sheet and Questionnaire Outpatient Trial
INFORMATION SHEET FOR WOMEN HAVING M.E.A. UNDER LOCAL
ANAESTHETIC
STUDY TO ASSESS THE VALUE OF HORMONAL MEDICATION BEFORE M.E.A
(MICROWAVE ENDOMETRIAL ABLATION) TREATMENT
You have been referred for microwave endometrial ablation ( M.E.A. ) to treat your period
problems.Traditionally women having endometrial ablation operations have been
prescribed hormone treatment, either tablets or an injection, to thin the endometrium,(
womb lining) before surgery.
Some surgeons have not used hormone treatment but have operated just after the woman's
period instead.
For technical reasons it may be less important to use the hormones before M.E.A. than before
the original types of endometrial ablation called T.C.R.E. ( transcervical resection of the
endometrium) or laser ablation.
There could be definite advantages for patients if the hormone treatment could be avoided.
However, before changing our advice for everyone, it is important that we know whether
M.E.A is just as successful without hormones as it is when they are used.
To do this we need to do a study where some women receive hormones before M.E.A. and
some women don't.
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We can only offer this to women having their M.E.A. under local anaesthetic.
You are invited to take part in the study. If you took part you would be allocated either M.E.A
after hormone treatment or M.E.A. after a period. The allocation would be made randomly,
like "rolling a dice". There would be a 50:50 chance of receiving hormone treatment or of
having treatment after a natural period.
Women having hormone treatment would be given an operation date for the end of their 5
weeks treatment. Women having M.E.A. after a period would be asked to phone in when they
get a period to arrange the operation for a date within the next 10 days.
If you took part in the study you would be asked to fill in a questionnaire before your
treatment and again at 2 weeks, 4 months and 1 year after treatment.
It is completely up to you whether you take part in the study and you could withdraw from the
study at any time without giving a reason and without any effect on your future medical care.
If you did not want to take part in the study you would receive standard hormone preparation
and have your operation planned for 5 weeks after starting this.
All information collected as part of the study is confidential.
Please contact me on the number below to confirm whether or not you would like to take part
in the study
and to make arrangements for your M.E.A. operation. I will be happy to answer any questions
you may have.
Dr Stuart Jack, Clinical Research Fellow in Gynaecology.







WARD 43, ABERDEEN ROYAL INFIRMARY
ABERDEEN AB25 2ZN
Tel: 01224 681818 ext. 53429 OR Bleep 3195
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PATIENT STUDY CONSENT FORM.
MICROWAVE ENDOMETRIAL ABLATION (M.E.A.I
STUDY TO COMPARE TREATMENT AFTER HORMONE PREPARATION
OR AFTER A PERIOD
ABERDEEN ROYAL INFIRMARY, DEPARTMENT OF GYNAECOLOGY
PR COOPER PR PARKIN, PR JACK
Patient Name
Hospital Number Study Number
I have read the patient information sheet on the above study and have had the
opportunity to discuss the details and ask questions.
The doctor has explained to me the nature and purpose of the study and I fully
understand what is proposed to be done.
I understand that this study is part of a research project designed to promote medical
knowledge and has been approved by the Joint Ethical Committee. The studymay be of
no benefit to me personally.
I understand that I can withdraw from the study at any time if I wish and that this will
not affect my continuing medical care.
The information obtained from the study is confidential but my General Practitioner may
be informed that I have taken part in it.
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I consent to taking part in the study by completing questionnaires and also consent
to being allocated either hormone treatment or treatment after a period, at random
for my microwave endometrial ablation M.E.A. treatment.
Signed Date




IF YOU WOULD HAVE HAD A STRONG PREFERANCE TO HAVING YOUR
TREATMENT WITH OR WITHOUT DRUGS PLEASE STATE WHICH YOU
WOULD HAVE PREFERED AND WHY.
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The questionnaires are completely confidential.
When completing a questionnaire, please take your time and read the instructions
carefully.
If you cannot answer a particular question leave it out and we will go through it with you
later.
Please could you complete the following information to ensure we have up to date








Patient Questionnaire for Before the Treatment
Thank you for completing this questionnaire while you are waiting for your M.E.A.
Please take your time and ask for help if any questions are not clear.
All the information is confidential and your answers will not affect your treatment
in any way.
1/ How long have you had trouble with your periods?
less than 1 year
1 to 3 years









3/ Would you describe your periods as
moderate
heavy with clots





4/ On average, how many days does your period last?
less than 7 days
more than 7 days
□
□
5/ On average for how many days is the bleeding heavy?
not heavy




6/ Are your periods usually painful?
4 to 6 days \Z1
7 or more days I I
Yes O
No □
7/ Do you often get period pain more than a day before the bleeding starts?
Yes □
No □
8/ Imagine an average period for you; for each day of a period please show how
severe your bleeding and pain were by giving each day a score from 1 to 5. Only fill in
for the usual number of days your period lasts.
(1 is mild bleeding/pain, 5 is the worst bleeding/pain you can think of)
Day ofperiod bleeding score pain score
Day 1 □ □
Day 2 □ □
Day 3 □ □
Day 4 □ □
Day 5 □ □
Day 6 □ □
Day 7 □ □
Day 8 □ □
Day 9 □ □
Day 10 □ □
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10 / At any time in the last three months have you needed to use
more than one form of sanitary protection at a time?
no □
tampon and pad I I
two pads I I
tampon and two pads I I
more than this, e.g. bath towel Q
1 la/ Have you had any of the following symptoms in the last 4 weeks.
Hot Flushes Q Headaches I I
Feeling Sick O Abdominal pain or bloating Q
Skin Rashes or itching Q Backache I I
Leg Cramps Q Weight Gain [ I
Feeling tearful or anxious or irritable Q Swelling of fingers or face I I
Difficulty getting a good nights sleep Q Feeling very tired ! j
Heavier bleeding than usual Q Bleeding for longer than usual I I
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lib/ Have these symptoms affected your lifestyle ?
No, I have not had any of these symptoms EH
Yes, I've not been my usual self but I've carried on EH
Yes, I have had to change planned work, household or social activities EH
12/ Do you do paid work outside the home?
Yes full time EH
Yes part time EH
No □
13/ Have you needed to arrange care for dependent children or elderly / disabled
relatives
until you are back to normal after your treatment?
No □ Yes □
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14/ The following questions are about how you feel in yourself at the moment.
Tick the box which comes closest to how you have been feeling in the past week.
Don't take too long over your replies: your immediate reaction to each item will
probably be most accurate.
I feel tense or wound-up:
most of the time Q
a lot of the time O
occasionally Q
not at all Q
I feel as if I am slowed down:
nearly all the time Q
very often I I
sometimes Q
not at all |
I still enjoy the things I used to enjoy:
definitely as much Q
not quite so much I I
only a little I I
hardly at all Q
I get a sort of frightened feeling like
"butterflies" in my stomach:




I get a sort of frightened feeling as ill
something awful is about to happen:
very definitely and quite badly Q
yes, but not too badly Q
a little but it doesn't worry me Q
lost interest in my appearance:
definitely Q
I don't take as much care as I [ I
should
I may not take quite as much carel I
not at all Q I take as much care as ever jJ
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I can laugh and see the funny side
of things:
as much as I always could Q
not quite so much now Q
definitely not so much now [
not at all O
I feel restless as if I have to be on
the move:
very much indeed Q
quite a lot CH
not very much O
not at all M
Worrying thoughts go through my mind: I look forward with enjoyment to
things:
a great deal of the time Q
a lot of the time | J
time to time but not too often O
only occasionally Q
as much as I ever did I 1
rather less than I used to Q
definitely less than I used too I I





most of the time
I get sudden feelings of panic:
I I very often indeed \Z1
I I quite often Q
I I not very often \Z1
I I not at all [H




















15/ In general, would you say your health is ?
excellent Q




16/ Does your health limit you when you do the following activities?
Yes No
Moderate activities such as moving a table, Q I I
hoovering, bowling or golf
Climbing several flights of stairs Q Q
17/ In the past 4 weeks have you had any of the following problems with work or other
daily
activities as a result of your physical health?
Yes No
Accomplished less than you would have liked Q Q
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Were limited in the kind ofwork or activities you did Q Q
18/ In the past 4 weeks have you had any of the following problems with work or other
daily activities as a result of any emotional problems ( such as feeling depressed or
anxious)?
Yes No
Accomplished less than you would have liked Q Q
Did not do work or other activities as carefully as Q I I
usual
19/ In the past 4 weeks how much has pain interfered with your normal activities?
Not at all O
A little bit I I
Moderately Q
Quite a bit I I
Extremely Q
20/ In the last 4 weeks for how much time did you have a lot of energy?
All of the time Q
Most of the time Q
A good bit of the time O
Some of the time O
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A little of the timel I
None of the time Q
21/ In the last 4 weeks for how much time did you feel calm and peaceful?
All of the time Q
Most of the time Q
A good bit of the timel I
Some of the time Q
A little of the time Q
None of the time LJ
22/ In the last 4 weeks for how much time did you feel downhearted and low?
All of the time I I
Most of the time Q
A good bit of the time Q
Some of the time O
A little of the time Q
None of the time Q
23/ In the last 4 weeks how much of the time have your physical health or emotional
problems
interfered with your social activities ( like visiting friends or relatives)
All of the time Q
Most of the time Q
A good bit of the time Q
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Some of the time [j
A little of the time I I
None of the time [j
Thank you for filling in this questionnaire
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Patient Questionnaire for After the Treatment
Please fill in a short while before you go home
We would like to find out how you feel about the treatment you have just had. It would
be helpful if you could complete the following questions for us. Please be honest and
answer as best you can. If you are having any difficulties please ask for assistance.
1/ The 20 groups of words below can be used to describe pain. Some of the words
below may describe any pain you may have had during and after your treatment.
Please read all the words. Then circle ONE word in each group, the one that best
describes the pain. If no words in a group are like your pain leave that group out.
1 2 3 4
Flickering Jumping Pricking Sharp
Quivering Flashing Boring Cutting
















































































2/ People agree that the following six words represent pain / discomfort of
increasing intensity:-
1 2 3 4 5 6
none mild discomforting distressing horrible excruciating
Answer each question below, writing the number of the most appropriate word in
the space beside the question.
a/ which number best describes the discomfort of the procedure you have just had?
b/ which number describes the discomfort of a cervical smear test?
c/ which number describes the discomfort of an internal (vaginal) examination?
d/ which number describes the worst toothache you ever had?
e/ which number describes the worst headache you ever had?
f1 which number describes the worst stomach ache you ever had?
3/ Please circle the number in the following list which you feel is closest to how
acceptable your treatment was for you.
1 2 3 4 5 6
totally generally fairly fairly generally totally
acceptable acceptable acceptableunacceptableunacceptableunacceptable
4/ Would you be prepared to have a procedure in the same way in the future? Yesl I
NoD
If no, please state reason why below, e.g. discomfort, embarrassing, time-consuming
etc.
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6/ Have you felt sick after the procedure?
No □
Yes □
Yes, and I have actually vomited O
7/ From your experience so far would you arrange to come in for your treatment in the




8/ The line below represents the range from totally unacceptable to totally
acceptable.
Please put a cross on the line below at the position between the two extremes which
you feel shows how acceptable your experience in theatre was today.
Totally Totally
ACCEPTABLE UNACCEPTABLE
9/ How soon after the treatment did you feel ready to go home? (Please record the
earliest time when you felt well enough to leave hospital rather than when you were
actually collected)
less than 1 hour i_J
between 1-2 hours l_J
between 2-4 hours [J
between 4-8 hours [_J
longer than 8 hours
10/ If you chose whether to have hormones and arrange your operation in advance or to
call when you got your period please write down any reasons below.
11/ Please note down any comments you have about your experiences today and the
information you were given before coming to hospital.
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Thank you very much for filling in this questionnaire. All the information is
entirely confidential and is not filed in your hospital notes.
I will be sending you another questionnaire in 2 weeks time to see how you are
getting on.
You will receive an information sheet with advice about recovery after M.E.A.







Previous cervical surgery (L.L.E.T.Z. / laser cone) Yes [H
No □
Endometrial preparation none I I
Danazol I I
Zoladex □




Maximum force cervical dilation
Cavity length cm
Hysteroscopy
Active Microwave time taken








(From start iv site to leave room)
minutes
Needed IV midazolam?






yes pre la Q
yes for dilation 1~~1
hegar size
yes forMEA I~1




no, failed instrumentation Q
no, uterine perforation blunt Q
no, uterine perforation with active probe O











When was patient fit to leave hospital? (i.e. drinking & comfortable)
<2 hours post op
by 4 hours post op
by 6 hours post op
by 8 hours post op
following day
If overnight stay give reason:
pain
nausea/vomit





FOR TWO WEEKS AFTER M.E.A.
DR Stuart Jack
DUGALD BAIRD CENTRE, ABERDEEN ROYAL INFIRMARY
ABERDEEN AB25 2ZN
Tel: 01224 681818 ext. 53429 OR Bleep 3195
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It is now 2 weeks after your M.E.A. operation. I hope you are recovering well.
I would be grateful if you could complete the following questionnaire about how you are getting on.
Please contact me if you have any questions about your operation or recovery.
1/ Did you have discomfort after you went home?
Not really [H
Yes, like my usual period pain I I
Yes, worse than period pain but relieved by painkillers □
Yes very severe pain but relieved by painkillers EH
Yes very severe pain which kept me awake despite painkillers EH
2/ Did you need any painkillers after you went home?
No □
Yes, day of operation only EH
Yes, for 1 day after I I
Yes, for 2-3 days after EH
Yes, for more than 3 days EH
3/ Did you have any feelings of sickness after you went home?
No □
Yes, 1 felt sick the day I went home I I
Yes, I felt sick and actually vomited the day I went home EH
Yes, I felt sick for more than 1 day I I
Yes, I felt sick and actually vomited for more than 1 day EH
4/ Did you see your G.P. in the first 2 weeks after the operation?
No □
Yes EH
5/ If yes what was the reason? (tick all that apply)
pain EH
fever EH
vaginal bleeding / discharge EH
other, unrelated to the operation EH
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6/ If you saw your G.P. within 2 weeks of surgery what was the outcome?
(tick all that apply)
painkiller prescription EH
antibiotic prescription EH
seen at hospital as emergency □
7/ Please circle the number in the following list which you feel is closest to how acceptable the
procedure was to you.
1 2 3 4 5 6
totally generally fairly fairly generally totally
acceptable acceptable acceptable unacceptable unacceptable unacceptable
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8/ It is too soon to see any effects of the operation on your periods, but from your experience so far,
would you recommend this procedure to a friend with period problems?
Yes CH
No □
9/ If you needed the operation again would you want to arrange it in the same way?
Yes, I would prefer to have the hormones and know the date 5 weeks ahead Q
Yes, I would prefer to wait for my period and phone in for a date that week Q]
No, I would prefer to have hormones and know the date 5 weeks ahead
No, I would prefer to wait for a period and phone in for a date that week Q
10/ What would you have been doing if you had not been in hospital that day?
(tick all that apply)
paid work O
housework Q
care of child/ relative/ friend □
education O
11/ How physically demanding is the type ofwork you do?
sedentary work e.g. office O
involves prolonged standing O
light physical work e.g. driving Q
heavy physical work O
care of pre-school children /
physically dependent adult O







more than 2 weeks
13/ Did anyone need to take time off from their normal activity to look after you or your
children/relatives while you were in hospital or recovering?
No
Yes
If yes, please write down how many days:
days
Thank you for completing this questionnaire. All the information is confidential.





FOR SIX MONTHS AFTER M.E.A.
Dr STUART JACK
DUGALD BAIRD CENTRE, ABERDEEN ROYAL INFIRMARY
ABERDEEN AB25 2ZN
Tel 01224 681818 bleep 3195
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PART A
It is now 6 months since your MEA.
You may be noticing some effects of the treatment already.
I would be very grateful if you could complete the following questionnaire and return it in the enclosed
prepaid envelope.
1/ How soon after treatment did you return to normal everyday activities?
Within 2 weeks Q
2-4 weeks O
more than 4 weeks Q
2/ How long did the vaginal bleeding / discharge last after the treatment?
(enough to need a pad)
Less than 3 weeks [J
3-5 weeks [J
more than 5 weeks [J





4/ If you had these problems how soon did they settle down?
Within 2 weeks □
In 2-4 weeks Q
More than 4weeks O
5/ Since the postoperative bleeding/discharge settled after the MEA your periods may have changed from
the way they were before the treatment. Have they:
stopped altogether □
become lighter □
stayed the same □
become heavier □
6/ If you are still having periods how long do they last?
Less than 3 days O
3-7 days I~1
more than 7 days HH
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7/ If you are still having periods how long is the bleeding heavy?
Not heavy Q
Less than 3 days Q
3-7 days 1 I
more than 7 days Q
8/ Are you having any abdominal pain?
No □
Yes with periods n
Yes at period time even though
there is little/no bleeding Q
Yes, most weeks of the month Q
9/ Imagine an average period for you since the treatment; for each day of a period
please show how severe your bleeding and pain were by giving each day a score
from 1 to 5. Only fill in for the number of days your period lasts.
(1 is mild bleeding/pain, 5 is the worst bleeding/pain you can think of)
Day of periodbleeding score pain score
Day 1 □ □
Day 2 □ □
Day 3 □ □
Day 4 □ □
Day 5 □ □
Day 6 □ □











10/ Since the bleeding stopped after the MEA treatment have you needed to use more than 1 type of
sanitary protection at a time?
No □
Yes 2pads d
Pad and tampon □
Other e.g bath towel □





12/ Please circle the number in the following list which you feel is closest to how
satisfied you are with the MEA treatment.
1 2 3 4 5 6
totally generally fairly fairly generally totally
satisfied satisfied satisfied unsatisfied unsatisfied unsatisfied









14/ Does your health limit you when you do the following activities?
Yes
Moderate activities such as moving a table, hoovering,
bowling or golf Q
Climbing several flights of stairs Tj
15/ In the past 4 weeks have you had any of the following problems with work or
other daily activities as a result of your physical health?
Yes No
Accomplished less than you would have liked Q O
Were limited in the kind ofwork or activities you didQ Q
16/ In the past 4 weeks have you had any of the following problems with work or other daily
activities as a result of any emotional problems ( such as feeling depressed or anxious)?
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Accomplished less than you would have liked
Yes
□
Did not do work or other activities as carefully as usual Q






18/ In the last 4 weeks for how much time did you have a lot of energy?
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
19/ In the last 4 weeks for how much time did you feel calm and peaceful?
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
20/ In the last 4 weeks for how much time did you feel downhearted and low?
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
21/ In the last 4 weeks how much of the time have your physical health or emotional
problems interfered with your social activities (like visiting friends or relatives)
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
PART B
The purpose of the remaining questions are to find out:
1. Whether you have visited either your General Practitioner (GP) or Aberdeen Royal
Infirmary in relation to your menstrual problems in the last 5 months (i.e. since you last
completed a costing questionnaire).
2. Any costs to you and your family associated with these visits. These costs may include
costs of travelling to the GP or hospital, time off work and costs of someone accompanying
you to this appointment.
3. Additional time taken off paid work and usual activities due to menstrual problems in the
last 5 months.
Qla/ Over the last 5 months how many times have you visited your GP for your menstrual
problems? Please write the number of times in the box below. (Put zero if you have not visited
your GP over the last 5 months for your menstrual problems).
Number of visits
If you answered 1 or more to the question above please continue with Question lb. Otherwise, GO
TO QUESTION 5a.
Qlb/ If you saw your GP in relation to your menstrual problems, what was the outcome? Please circle.
Painkiller prescription 1
Antibiotic prescription 2
Referral to Aberdeen Royal Infirmary 3
Tests (please specify) 4
Other (please specify) 5
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Q2a/ When you visited the GP, how did you normally travel? Please circle one number which
describes the main way you travelled.
Walked 1
Cycled 2
Public transport (eg bus, train or taxi) 3
Private car/motorbike 4
Other (please specify) 5
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Q2b/ If you normally travelled by public transport (e.g. bus, train or taxi) for part or the whole
journey, what was the cost of the (return) fare?
Cost of (return) fare (£) Pence
Q2c/ If you normally travelled by private car or motorbike for part or the whole journey, about how
many miles did you travel (return)?
Number ofmiles (return)
Q2d/ If you normally travelled by private car or motorbike for part, or all of the journey and had to
pay parking fees how much did these amount to?
Cost of parking fees (£) Pence
Q3a/ When you visited the GP, how long did it normally take you? Please include travel time,
waiting time and time taken to see the doctor in your answer.
Number of hours Minutes
Q3b/ What would you normally have otherwise been doing as your main activity if you had not had
to attend the GP? Please circle one number that best describes this.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
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On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
Q4a/ Did anyone normally accompany you to the GP? Please circle.
Yes 1
No 2 GO TO QUESTION 5a
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Q4b/ Who was the main person who normally accompanied you to the GP? Please circle.
Partner/spouse 1
Child/children under 16 years 2
Other relative 3
Paid caregiver 4
Other (please specify) 5
Q4c/ What would your main companion normally otherwise have been doing as their main activity if
they had not accompanied you to the GP? Please circle.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
Q5a/ Over the last 5 months how many times have you visited Aberdeen Royal Infirmary for your
menstrual problems? Please write the number of times in the box below. (Put zero if you have
not visited the hospital over the last 5 months for your menstrual problems).
Number of visits
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If you answered 1 or more to the question above please continue with Question 5b. Otherwise, GO
TO QUESTION 9.
Q5b/ Please indicate the nature of your visit/s at Aberdeen Royal Infirmary. Please circle.
An appointment at the Menstrual Clinic 1
An appointment with Dr Stuart Jack on Ward 42/43 2
Admitted for a menstrual related operation (please specify) 3
Other (please specify) 4
Q6a/ When you visited Aberdeen Royal Infirmary, how long did you normally spend at the
hospital? Please include waiting time and time taken to see the doctor in your answer.
Number of hours Minutes
Q6b/ What would you have otherwise been normally doing as your main activity if you had not had
to attend the hospital? Please circle one number that best describes this.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
Q7a/ Did anyone normally accompany you to the hospital? Please circle.
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Yes 1
No 2 GO TO QUESTION 8a
Q7b/ Who was the main person who normally accompanied you to the hospital? Please circle.
Partner/spouse 1
Child/children under 16 years 2
Other relative 3
Paid caregiver 4
Other (please specify,) 5
Q7c/ What would your main companion otherwise have been normally doing as their main activity if
they had not accompanied you to the hospital? Please circle.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify 9
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The following questions ask whether you required any additional assistance to look after your
dependants for example, children, elderly relatives etc. when you visited the hospital or during your
recovery in the last 5 months. We are only interested in assistance, which was in addition to your usual
care arrangements.
Q8a/ Did you get someone to look after your dependants? Please circle.
Yes 1
No 2
Not applicable 8 J GO TO QUESTION}
Q8b/ How many hours in total did they spend looking after your dependants while you were in hospital
and when you were recovering in the last 5 months?
Number of hours Minutes
Q8c/ Please think about the main caregiver, that is the person who you consider most needed to be
with your dependants. Did you pay that person to look after your dependants? Please circle.
Yes 1 GO TO QUESTION 9
No 2
Q8d/ If they were not paid, what would that person have been doing as their main activity if they had
not been looking after your dependants? Please circle.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
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On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
Q9/ In the last 5 months, how many days or weeks have you taken off paid work as a result of your
menstrual problems (excluding the time taken to visit the GP and Aberdeen Royal
Infirmary)?
Number of weeks Days
Q10/ We are interested in whether your normal activities have been affected by your menstrual
problems in the last 5 months. Could you please indicate whether any of the normal activities
have been affected in the last 5 months and if so, how they have been affected?
Normal activities Please circle
If YES, please explain
Paid work Yes/No
Housework Yes/No
Childcare Yes / No














FOR 1 YEAR AFTER M.E.A.
Dr Stuart Jack
DUGALD BAIRD CENTRE, ABERDEEN ROYAL INFIRMARY
ABERDEEN AB25 2ZN
Tel 01224 681818 bleep 3195 ext 53429
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It is now a year since your MEA treatment and we would like to hear how you are getting on, even if you
have been back to the gynaecology department for an appointment or treatment meanwhile.
I would be very grateful if you could complete the following questionnaire and return it in the enclosed
prepaid envelope.
Please get in contact if there is anything related to your treatment that you would like to discuss further.
1/ Compared with the way things were before the MEA treatment have your periods:
stopped altogether Q
become lighter □
stayed the same □
become heavier Q
2/ If you are still having periods how long do they last? Less than 3 days i J
3-7 days Q
more than 7 days Q
3/ If you are still having periods how long is the bleeding heavy?
Not heavy □
Less than 3 days □
3-7 days []]
more than 7 days Q
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4/ Are you having any abdominal pain?
No □
Yes with periods d
Yes at period time even though
there is little/no bleeding d
Yes, most weeks of the month [I]
5/ Compared with the way things were before the MEA treatment, is the pain:
worse, it only started since MEA d
worse than before I I
unchanged I I
improved but still a problem I I
improved, not a problem now I I
I've had no problems with pain
before or since the MEA d
6/ Since the bleeding stopped after the MEA treatment have you needed to use more than one type of
sanitary protection at a time?
No □
Yes 2 pads d
Pad and tampon d
Other e.g. bath towel [J
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7/ Imagine an average period for you in the last 4 months. For each day of a period please show how
severe your bleeding and pain were by giving each day a score from 1 to 5. Only fill in for the number of
days your period lasts.
(1 is mild bleeding/pain, 5 is the worst bleeding/pain you can think of)
Day of period bleeding score pain score
Day 1 □ □
Day 2 □ □
Day 3 □ □
Day 4 □ □
Day 5 □ □
Day 6 □ □
Day 7 □ □
Day 8 □ □
Day 9 □ □
Day 10 □ □
8/ From your experience so far would you recommend this treatment to a friend with period problems?
Yes O
No □
9/ Please circle the number in the following list which you feel is closest to how satisfied you are with the




















10/ Have you been back to the gynaecology department since your treatment?
No □
Yes to do with my periods ED
Yes for another reason ED
11/ Have you had, or are you on the waiting list to have more gynaecological surgery?
No □
Yes ED
12/ The following questions are about how you feel in yourself at the moment.
Tick the box which comes closest to how you have been feeling in the past week.
Don't take too long over your replies: your immediate reaction to each item will probably be most
accurate.
I feel tense or wound-up:
most of the time
a lot of the time
occasionally
not at all
I feel as if I am slowed down:
I I nearly all the time
□ very often
I I sometimes
I I not at all
I still enjoy the things I used to enjoy:
definitely as much ED
not quite so much ED
only a little ED
hardly at all ED
I get a sort of frightened feeling like





I get a sort of frightened feeling as if
something awful is about to happen:
very definitely and quite badly L.J
yes, but not too badly ED
a little but it doesn't worry me ED
not at all ED
I have lost interest in my appearance:
definitely
1 don't take as much care as I shoul
I may not take quite as much care
I take as much care as ever
I can laugh and see the funny side
of things:
as much as I always could
not quite so much now
definitely not so much now
not at all
Worrying thoughts go through my mind:
a great deal of the time
a lot of the time






most of the time






I feel restless as if I have to be on
the move:
I I very much indeed
I I quite a lot
I I not very much
I I not at all
I look forward with enjoyment to things:
I I as much as I ever did
I I rather less than I used to
L i definitely less than I used too
I I hardly at all
I get sudden feelings of panic:
I I very often indeed
I I quite often
I I not very often
I I not at all
I can enjoy a good book or radio or T.V.
I I often
□ sometimes
I I not often
I I very seldom






14/ Does your health limit you when you do the following activities?
Yes No
Moderate activities such as moving a table, hoovering,
bowling or golf □ Q
Climbing several flights of stairs Q Q
15/ In the past 4 weeks have you had any of the following problems with work or other daily activities as a
result of your physical health?
Yes No
Accomplished less than you would have liked Q I I
Were limited in the kind ofwork or activities you did O Q
16/ In the past 4 weeks have you had any of the following problems with work or other daily activities as a
result of any emotional problems (such as feeling depressed or anxious)?
Yes No
Accomplished less than you would have liked Q □
Did not do work or other activities as carefully as usual Q Q
282






18/ In the last 4 weeks for how much time did you have a lot of energy?
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
19/ In the last 4 weeks for how much time did you feel calm and peaceful?
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
20/ In the last 4 weeks for how much time did you feel downhearted and low?
All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time
21/ In the last 4 weeks how much of the time have your physical health or emotional problems interfered
with your social activities (like visiting friends or relatives)
All of the time □
Most of the time □
A good bit of the time □
Some of the time □
A little of the time □
None of the time □
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PART B
The purpose of the remaining questions are to find out:
4. Whether you have visited either your General Practitioner (GP) or Aberdeen Royal
Infirmary in relation to your menstrual problems in the last 6 months (i.e. since you last
completed a costing questionnaire).
5. Any costs to you and your family associated with these visits. These costs may include
costs of travelling to the GP or hospital, time off work and costs of someone accompanying
you to this appointment.
6. Additional time taken off paid work and usual activities due to menstrual problems in the
last 6 months.
Qla. Over the last 6 months how many times have you visited your GP for your menstrual problems?
Please write the number of times in the box below. (Put zero if you have not visited your GP over the last
6 months for your menstrual problems).
Number of visits
If you answered 1 or more to the question above please continue with Question lb. Otherwise, GO
TO QUESTION 5a.
Qlb. If you saw your GP in relation to your menstrual problems, what was the outcome? Please circle.
Pain killer prescription 1
Antibiotic prescription 2
Referral to Aberdeen Royal Infirmary 3
285
Tests (please specify) 4
Other (please specify) 5
Q2a. When you visited the GP, how did you normally travel? Please circle one number which describes
the main way you travelled.
Walked 1
Cycled




}GO TO QUESTION 3a
4
5
Q2b. If you normally travelled by public transport (e.g. bus, train or taxi) for part or the whole journey,
what was the cost of the (return) fare?
Cost of (return) fare (£) Pence
Q2c. If you normally travelled by private car or motorbike for part or the whole journey, about how
many miles did you travel (return)?
Number ofmiles (return)
Q2d. If you normally travelled by private car or motorbike for part or all of the journey and had to pay
parking fees how much did these amount to?
Cost of parking fees (£) Pence
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Q3a. When you visited the GP, how long did it normally take you? Please include travel time, waiting
time and time taken to see the doctor in your answer.
Number of hours Minutes
Q3b. What would you normally have otherwise been doing as your main activity if you had not had to
attend the GP? Please circle one number that best describes this.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
Q4a. Did anyone normally accompany you to the GP? Please circle.
Yes 1
No 2 GO TO QUESTION
5a
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Q4b. Who was the main person who normally accompanied you to the GP? Please circle.
Partner/spouse 1
Child/children under 16 years 2
Other relative 3
Paid caregiver 4
Other (please specify) 5
Q4c. What would your main companion normally otherwise have been doing as their main activity if
they had not accompanied you to the GP? Please circle.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
Q5a. Over the last 6 months, since your last MEA questionnaire, how many times have you visited
Aberdeen Royal Infirmary for your menstrual problems? Please write the number of times in the box
below. (Put zero if you have not visited the hospital over the last 6 months for your menstrual problems).
Number of visits
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If you answered 1 or more to the question above please continue with Question 5b. Otherwise, GO
TO QUESTION 9.
Q5b. Please indicate the nature of your visit/s at Aberdeen Royal Infirmary. Please circle.
An appointment at the Menstrual Clinic 1
An appointment with Dr Stuart Jack on Ward 42/43 2
Admitted for a menstrual related operation (please specify) 3
Other (please specify) 4
Q6a. When you visited Aberdeen Royal Infirmary, how long did you normally spend at the hospital?
Please include waiting time and time taken to see the doctor in your answer.
Number of hours Minutes
Q6b. What would you have otherwise been normally doing as your main activity if you had not had to
attend the hospital? Please circle one number that best describes this.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
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Q7a. Did anyone normally accompany you to the hospital? Please circle.
Yes 1
No 2 GO TO QUESTION 8a
Q7b. Who was the main person who normally accompanied you to the hospital? Please circle.
Partner/spouse 1
Child/children under 16 years 2
Other relative 3
Paid caregiver 4
Other (please specify) 5
Q7c. What would your main companion otherwise have been normally doing as their main activity if
they had not accompanied you to the hospital? Please circle.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
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The following questions ask whether you required any additional assistance to look after your
dependents for example, children, elderly relatives etc when you visited the hospital and/or during your
recovery in the last 6 months. We are only interested in assistance which was in addition to your usual
care arrangements.
Q8a. Did you get someone to look after your dependents? Please circle.
Yes
No
Not applicable. } GO TO QUESTIONJ 9
Q8b. How many hours in total did they spend looking after your dependents while you were in hospital
and/or when you were recovering in the last 6 months?
Number of hours Minutes
Q8c. Please think about the main caregiver, that is the person who you consider most needed to be with
your dependents. Did you pay that person to look after your dependents? Please circle.
Yes 1
No 2 GO TO QUESTION9
,Q8d. If they were not paid, what would that person have been doing as their main activity if they had not
been looking after your dependents? Please circle.
Housework 1
Childcare 2
Caring for a relative or friend 3
Voluntary work 4
Leisure activities 5
Attending school or university 6
On sick leave 7
Paid work (employed/self employed) 8
Other (please specify) 9
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Q9. In the last 6 months, how many days or weeks have you taken off paid work as a result of your
menstrual problems (excluding the time taken to visit the GP and Aberdeen Royal Infirmary)?
Number of weeks Days
Q10. We are interested in whether your normal activities have been affected by your menstrual problems
in the last 6 months. Could you please indicate whether any of the normal activities have been affected in
the last 6 months and if so, how they have been affected?
Normal activities Please circle
If YES, please explain
Paid work Yes / No
Housework Yes / No
Childcare Yes / No
Caring for a relative/
friend
Yes / No
Voluntary work Yes / No




Thank you for filling in this questionnaire
Your answers are essential to help us plan treatment for women having MEA in the future.
Please get in contact if you have any questions about your treatment or recovery.
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